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Abstract 
Approximately 50% of medications are not used as prescribed, this phenomenon is known 
as non-adherence. The literature concerning this phenomenon focuses on reasons 
medicines are not taken, dissecting experiences to identify mechanisms that act as barriers 
and facilitators to using medicines as prescribed. Theoretical frameworks and models have 
been developed that conceptualise the phenomenon, enabling interventions to be 
established to improve medicines use. However these interventions have yet to 
demonstrate sustainable improvements in adherence. A novel perspective of the 
adherence phenomenon may direct future intervention development that will lead to 
improved adherence.  
This project evaluated current literature concerning the adherence phenomenon; 
concluding that a largely ‘biomedical perspective’ had been taken to understanding 
patients’ medicines use and that further work was needed that approached the 
phenomenon from with a novel outlook. A systematic review and thematic synthesis was 
conducted of evidence that, through phenomenological methods, rejected previously held 
beliefs and concluded that adherence was experienced by patients as an interaction 
between the patient’s and the medicine’s identity. The systematic review identified a gap 
in the literature that described adherence from patients’ lived experiences across different 
disease states.  
Using phenomenology, empirical research included forty-one interviews that explored 
patients’ experiences of medicines use across five disease areas, namely cardiovascular 
disease, gout, chronic obstructive pulmonary disease, cancer and diabetes. This uncovered 
a novel description of the phenomenon as a construct of social interaction between the 
patient, their product and wider society (embodied as family and friends, healthcare 
professionals, the media and policy). Three focus groups were conducted to validate these 
findings and locate patients’ perspectives of interventions within this novel description. 
Analyses from these focus groups identified that current adherence interventions 
represented micro-social interactions between the patient and the product, with few 
interventions developed that utilise patients’ interactions with wider society. These works 
are synthesised to present new directions for future intervention development that might 
seek to utilise patients’ interactions with friends, family, healthcare professionals and 
policy to improve adherence.  
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Chapter 1: Introduction and Literature Review 
What is adherence? 
Adherence describes a phenomenon concerned with how patients use prescribed 
medicine. As such, the phenomenon can be argued to be as old as medicines themselves 
and has been reported as going back to the time of Hippocrates (Osterberg and Blaschke, 
2005). Since then the concept of medicines adherence has been defined, re-defined; 
identified and re-identified (Ahmed and Aslani, 2014). There is often misunderstanding 
when defining ‘medicines adherence’ with ‘medication compliance’ and ‘medicines 
concordance’.  
Compliance has been said to infer that the patient is simply ‘following orders’ and 
complying with the wishes of their doctor. This implies a paternalistic relationship in which 
the patient’s autonomy, choice and shared decision-making rights are not acknowledged 
(Cribb, 2011).  As a result some healthcare professionals have avoided using this term and 
in 1997, the Royal Pharmaceutical Society of Great Britain (as was) suggested a discursive 
shift from ‘compliance’ to ‘concordance’ (Mullen, 1997, Royal Pharmaceutical Society of 
Great Britain, 1997). Concordance was preferred, as this term implies that there is an 
agreement between the patient and the practitioner about how prescribed medicines will 
be used.  
Despite semantic difficulties, current estimates indicate that between 30-70% of medicines 
are not used as prescribed, however this figure varies greatly depending on the context and 
the measure used (Haynes et al., 2008, World Health Organisation, 2003). A wide variety of 
methods exist for measuring adherence, including self-report techniques, electronic 
monitoring of adherence, pharmacy administrative data, observing clinical effectiveness, 
measuring blood concentrations of medication and newer techniques that utilise tracking 
technology and health apps (Haynes, 2001, Proteus Digital Health Inc, 2015). Whilst many 
methods of measurement exist, policymakers accept that non-adherence is common, 
demonstrated here by The National Institute for Health and Clinical Excellence (2009) that 
argued that in order to support adherence ‘healthcare professionals must recognise that 
non-adherence is common and that most patients are non-adherent sometimes’ - although 
the precise meaning of ‘sometimes’ in this context is ambiguous.  
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Non-adherence is common across disease groups, with adherence reported as low in 
diabetes (Asghari et al., 2010), in cardiovascular disease (Banik and Ray, 2012, Bane et al., 
2006, Hagström et al., 2005) and to inhaled therapies (Cecere et al., 2012).  
Defining adherence: a case of semantics or ontology? 
The definition of adherence can be interpreted as an area of contention within the 
literature. Many professional bodies and healthcare organisations have contributed to the 
medicines adherence debate in defining the phenomenon (Cribb, 2011, National Institute 
for Health and Clinical Excellence, 2009, Royal Pharmaceutical Society of Great Britain, 
1997, World Health Organisation, 2003, Nunes et al., 2009, The Audit Commission for Local 
Authorities and the National Health Service in England and Wales, 2001). Health reform 
across the globe, centering on improved patient outcomes rather than traditional models 
of healthcare delivery, have made defining, measuring and improving medicines adherence 
a focus of academic and clinical discussion (Rosenbaum and Shrank, 2013). Yet this 
relatively modern interest is underpinned by an historical context – reportedly going back 
to the time of Hippocrates (Osterberg and Blaschke, 2005). Since then defining the concept 
of medicine adherence has been a subject of academic interest (Ahmed and Aslani, 2014). 
Within the literature, there is often overlap when defining ‘medicines adherence’ with 
‘medication compliance’ and ‘medicines concordance’. As outlined above, compliance is 
considered to give prescribers more ‘power’ than patients, implying a paternalistic 
relationship in which the patient’s autonomy, choice and shared decision-making are not 
fully acknowledged (Cribb, 2011). As a result some healthcare professionals have been 
directed to avoid using this term, preferring to use the terms ‘concordance’ or ‘adherence’ 
(Mullen, 1997, Royal Pharmaceutical Society of Great Britain, 1997). Concordance is argued 
to imply that there is an agreement between the patient and the practitioner about how 
their prescribed medication will be used. However, work by Dingwall and Pilnick (2011) 
argue that asymmetry in knowledge and power prevents patients from adopting the role of 
an equal decision maker. This suggests the term concordance might not appropriately 
reflect the reality of the prescribing process or adherence phenomenon. Adherence, as a 
term, has grown popular over the last decade in an attempt to avoid subjective 
assumptions of patients’ behaviour, emphasising how closely medicines use ‘sticks’ to the 
prescription. Variation in semantics appears to be further compounded by variation in the 
ontological basis of what adherence is. 
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Definition, dissection, quantification   
Changes in ontology can be inferred across the literature over time and between 
publications. Authors writing about medicines adherence typically begin by defining their 
interpretation of the phenomenon. For example, Osterberg and Blaschke (2005), describe 
medication adherence as ‘the extent to which patients take medications as prescribed by 
their health care providers.’ The World Health Organisation defines adherence differently, 
adding more complexity to the phenomenon, as ‘the extent to which a person’s behaviour 
– taking medication, following a diet, and/or executing lifestyle changes, corresponds with 
agreed recommendations from a health care provider’ (World Health Organisation, 2003). 
A Cochrane Review uses another variation, defining adherence as ‘the extent to which 
patients follow the instructions they are given for prescribed treatments’ and adding to the 
definition by attaching a numerical value to the concept, adding ‘thus, if a person is 
prescribed an antibiotic to be taken as one tablet four times a day for a week for an 
infection, but takes only two tablets a day for five days, his /her adherence would be 
(10/28=) 36%’ (Haynes et al., 2008). The addition of a calculable, numerical value to the 
description may have represented a shift in the ontology of the phenomenon – rather than 
being concerned with beliefs or a set of behaviours, there is greater focus on objective 
measures of a task.   
The objective measurement of adherence presents further ontological issues. For example, 
is non-adherence identified after missing just one dose or many? What counts as missing a 
dose – missing it by five minutes, fifteen minutes or fifty? Further objectification appeared 
in the literature as a reconceptualization of the phenomenon, giving rise to terms such as 
‘persistence’ and ‘discontinuation’. These concepts pertain to the duration of treatment 
whereas previous definitions appeared to describe the day-to-day process of medicines use 
(Cramer et al., 2008, Cramer et al., 2007). Others argue that adherence can be dissected 
further into ‘initiation’, ‘implementation’ and ‘discontinuation’ (Vrijeans et al., 2012), 
enabling adherence to be calculated discretely across time. The deviation and separation of 
different components of the phenomenon in the literature represents a dissection of the 
ontology of adherence, adopting a scientific, and almost biomedical approach, to the 
phenomenon by identifying component parts to understand the whole.  
A common dissection in the literature is intentional or unintentional adherence (Clifford et 
al., 2008), further stratification can be made, not only into adherent and non-adherent, but 
also in terms of poor, satisfactory, good, very good and excellent. In this sense, intentional 
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and unintentional adherence engenders patients as active decision makers, choosing to 
adhere or not (Simpson et al., 2006). Attaching numerical values to these labels enables 
adherence behaviours to be quantified, which can then be used to position the patient 
within pre-defined categories of adherence thresholds. As patients move up and down an 
ordinal scale, adherence can be stratified as a range from poor to perfect, however due to 
the pre-determined (and sometimes arbitrary) thresholds, in some instances patients can 
be classified as non-adherent by one classification system and poor adherers by another 
(Haynes et al., 2008). This dissection and classification is argued to enable the phenomenon 
to be considering scientifically, as an objective representation of the experience.   
The phenomenon as a whole however, appears to be confused by these dissections and 
reclassifications, with some, as in the case of ‘compliance’ and ‘concordance’, shifting 
power from the prescriber to the patient. These shifts are also evident in the literature. In 
2009 NICE reported that in order to support adherence, healthcare professionals must 
‘recognise that non-adherence is common and that most patients are non-adherent 
sometimes’ (National Institute for Health and Clinical Excellence, 2009). Controversially for 
some, these guidelines direct responsibility for non-adherence towards professionals, ‘non-
adherence is a large problem, but it should not be seen as the patient’s problem. Rather, it 
represents a limitation in the delivery of healthcare.’ This generates a paternalistic 
ontological position, where patients are passive (as opposed to active) medicines users.  
Other guidelines recommend and advocate patient involvement in decision-making about 
using medicines, further confusing the ontology of adherence in terms of responsibility and 
accountability.  Indeed other positions state ‘patients should not be blamed for the 
problems they experience in medicines taking’ (York Health Economics Consortium and 
School of Pharmacy, 2011). Apportioning blame and responsibility to the phenomenon, 
pulls the definition of adherence away from an objective numerical value and towards a 
moralistic or social perspective.  
Positivist definitions 
Rather than consider this more moralistic perspective however, accepted definitions within 
the literature remain focused on objectification of adherence and dissection of the 
phenomenon. Much of the research base has focused on identifying general barriers or 
facilitators to individuals’ adherence. The proposition is that by removing the barriers or 
increasing the facilitators, adherence can be improved. This approach is not-too-dissimilar 
to biomedical conceptualisations of disease progression. For example, as patients move 
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through different stages of a disease, they have different experiences and physiologically 
different processes are happening. Pathophysiology is increasingly understood through 
research that dissects tissue, with biological processes or targets identified and treatments 
developed. Adherence appears to have been approached in a similar way, dissecting the 
phenomenon metaphorically, with different social, psychological, biological, and economic 
constructs identified as barriers and facilitators of adherence and non-adherence. From this 
almost wholly biomedical perspective, adherence is posited as an ideal or an ‘ideal truth’, 
which can be worked towards and achieved, like a measure of blood pressure or 
temperature, through manipulation of barriers or facilitators. This ontological position in 
the literature is underpinned by biomedical or psychological ‘stimulus – response’ 
paradigm. A syllogistic view of a directly observable response in medicines taking is 
commonplace yet deductive reasoning of this kind appears to have failed to deliver 
interventions that improve long-term adherence. 
Epistemological positions that identify ‘ways of knowing’ have underpinned the 
development of multiple methods of measuring adherence (Bauer et al., 2013, Weinstein 
et al., 2011, Asche et al., 2011). Methods of measurement have included assessing the 
different levels of dosing irregularities or measuring gaps in treatment from a range of 
measures, including: pharmacy-claims data, reviewing administrative claims; pill counts; 
calculating medication possession ratios; administering Morisky Medication Adherence 
Scale (MMAS); calculating Proportion of Days Covered (PDC); self-management profiles; 
administering Brief Medication Questionnaire; electronic packaging to record when a 
medication is opened; five-item Medication Adherence Report Scare (MARS-5); electronic 
diaries and dose-counters; pill-cap monitoring or Medication Event Monitoring Systems 
(MEMS); Real Time Medication Monitoring; self-reported levels of adherence or a mixture 
of multiple methods.  
Whilst variation is often favoured in research, providing methods of triangulation and 
validation, a downside is that such variation may impact the underlying conceptualisation 
of the phenomenon, particular when findings are transferred or generalised. For example 
when adherence is measured using prescription refill data, the phenomenon of adherence, 
might be understood only as the supply or collection of medicines, a symbol perhaps of the 
intent to adhere, rather than of the act of adherence. Another example may be a self-
reported questionnaire, here adherence might be ontologically positioned as a construct of 
the patients belief or memory, rather than a physical act of collecting or taking a 
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prescription medicine. These epistemological differences further compound and confuse 
the literature as to the ontological nature of adherence.  
In addition to the definitions reported by academics, professionals and policy makers, what 
is conspicuous by its absence in the literature is the definition used by patient groups. Very 
few patient groups appear to have been involved in constructing definitions of adherence 
to medication and a ‘man on the street’ [sic] test may show that few patients are actually 
familiar with the concepts or terms of ‘medicines adherence’, ‘medicines compliance’ and 
‘medicines concordance’. This lack of a patient voice in the ontology of this area may mean 
that patients have not been involved in the development of understanding adherence or 
the development of interventions to improve adherence. This suggests that the adherence 
literature is continually framed from the perspective of those doing the research, typically 
healthcare professionals, psychologists, and scientists. This highlights a gap in the literature 
for work that defines or describes the phenomenon from a perspective that is separated 
from the previously held presuppositions and beliefs of adherence researchers.   
Reasons for non-adherence  
Ontological underpinnings of adherence have fed into models of adherence that locate a 
number of various constructs as key facilitators or barriers to adherence. Interpretation of 
the broad literature here infers that much research has been conducted within 
paradigmatic silos that have focused on the phenomenon from a narrow perspective, such 
as a specific disease group or specific barrier or facilitator. This disintegration of the 
phenomenon could be argued to have drawn attention away from understanding of the 
phenomenon as whole. As a consequence many reasons for non-adherence that are 
reported in the literature are within specific social, economic or disease contexts, arguably 
limiting their transferability to an individual patient in practice. Reasons for non-adherence 
that appeared in the literature are evaluated below.   
Ethnicity, age and gender 
A systematic review found similar reasons for non-adherence in different countries, 
however concluded that ethnic minorities were less adherent (Gebregziabher et al., 2011), 
suggesting interventions to be culturally adapted. On evaluation, ethnicity does not lend 
itself well to a dissection of the phenomenon through statistical modelling. Quantitative 
research cannot consider all of the factors associated with ethnicity and thus patients 
become categorised as simply ‘white’ or ‘black’ or ‘other’. Ethnicity can be described as 
more than the colour of a person’s skin, as it is often stratified in quantitative studies, and 
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rather embodies language, culture, family, neighbourhood, poverty, housing, literacy and 
religion, which all come to bear within a person’s ethnic identity. The social factors that 
intersect ethnicity appear to be subsumed within categorical values, enabling statistical 
analysis of ethnic subgroups, which show statistical differences in levels of adherence. 
However often the underlying cause of the difference, as addressed by qualitative 
research, shows similarities in barriers and facilitators to adherence across ethnicities and 
cultures (Marshall et al., 2012). Any difference that does occur in the literature seems to be 
mediated by the relationship with the healthcare provider; i.e. if the provider is ethnically 
concordant with the patient (Traylor et al., 2010) or mediated by health literacy. A 
systematic review in 2011 was unable to determine if ethnicity does influence adherence 
due to the heterogeneity of the data selected for inclusion (Peeters et al., 2011). 
Age is often reported to influence adherence. Older (>70 years) and younger (<50 years) 
ages are associated with lower adherence, compared with middle-aged patients (50-69 
years) (Mann et al., 2010). Younger age has been associated with poor adherence in type 
one diabetes, but good adherence in hypertension and dyslipidemia. Whilst specifically to 
thienopyridines, such as clopidogrel, in cardiovascular disease, younger age correlated with 
poorer adherence (Nigam et al., 2012). However older-age has been shown to reduce the 
effect of good adherence on positive clinical outcomes, but has also been shown to 
positively correlate with adherence in a number of studies (Rolnick et al., 2013). Within this 
literature, the influence of age on adherence does not appear to appreciate the 
complexities involved in ageing and natural disease progression, often over simplifying 
poor adherence as a symptom of old age or morbidity. This demonstrates the 
disintegration of the literature, in that whilst providing evidence for specific groups of 
medicines or patients, the role of age within the experience of adherence remains difficult 
to determine. 
The role gender plays in adherence is also conflicting; arguably females are more adherent 
after retirement in certain areas however a number of studies argue men are more 
adherent prior to and after retirement (Hertz et al., 2005, Davies et al., 2013, Khanna et al., 
2012). Evidence framed by disease state (namely hypertension, COPD and diabetes) shows 
that gender was not found to result in statistically significant differences between genders 
(Matsumura et al., 2013) although other authors argue females are more likely to be 
intentionally non-adherent to their COPD medication, how this can be translated to other 
disease areas remains unknown. Other work argues that males may have their own issues 
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with adherence, due to difficulty in the integration of illness with their masculine identity, 
leading to difficulties in taking medicines as prescribed (Hagström et al., 2005). In these 
studies gender is situated biologically, as male or female, without considering gender as a 
psycho-social construct, it is considered as a biological proxy. Here too, as in ethnicity and 
age, the literature is conflicting and limiting the ability to understand the adherence 
phenomenon across different contexts.    
Similarly, socioeconomic factors differ regarding their influence over adherence with some 
studies suggesting they have an impact - usually a positive correlation between adherence, 
education and income (Mann et al., 2010) and others suggesting no difference (Kivimaki et 
al., 2013). Some argue the social constructs that enable age, gender and ethnicity to be 
identified and understood are the reasons any difference in adherence is seen, rather than 
being due to biological classifications of age, gender and ethnicity (Tantikosoom et al., 
2011).  Arguably these constructs may have an influence on adherence, however this 
influence has thus far failed to be demonstrated consistently in the literature. At best, this 
literature informs how practitioners might predict adherence behaviours, at worst it 
generates prejudices that might damage practitioner and patient relationships.  
The patient, their medication and their disease 
Adherence was often described as a negotiation between the patient, their medication and 
their disease. This literature often considered patients’ understanding of the purpose of 
their medication (Horne and Weinman, 1999) and as above, often research was conducted 
within a specific patient group, to a particular medication or medication class and within 
certain disease contexts. For example in patients with cancer, the specific medication used 
was shown to influence adherence (Streeter et al., 2011), however this is likely to be linked 
to the tolerability of chemotherapy, and might not be easily applied to medication in other 
disease contexts, such as differences between adherence to ibuprofen and paracetmol.  
Patients’ sense of satisfaction was shown to be a significant predictor of adherence to 
COPD medications in Spain and the UK, but satisfaction only had a moderate impact on 
adherence in France, Italy and Germany – generating questions about patient expectations, 
culture, and access to treatment more than answering questions about patients’ medicines 
use in COPD. For patients with diabetes injection-related discomfort was considered a 
source of patient-reported anxiety that may contribute to non-adherence (Fu et al., 2009) 
without considering anxiety that may be experienced due to negative health and 
socioeconomic outcomes of a diagnosis. For example, barriers to adherence in 
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hypertensive patients in the United Arab Emirates included health beliefs rooted in a lack 
of information about their disease, in cultural practices and in relationships with family, 
friends and the health system (Alqasem et al., 2010). Further research highlights the 
positive impact newer methods of insulin delivery, including inhalation, can have on 
adherence (Baser et al., 2010) and healthcare costs – however this research does not 
appear to adequately consider how such technological innovations might be applicable to 
other disease or patient contexts.  
Literature investigating patients’ perspectives of medicines use report dynamic and varied 
findings. Here too the literature demonstrates work carried out in disease specific settings 
(Jin et al., 2008, De Vera et al., 2013, Farooqui et al., 2011, Gordon et al., 2007) although in 
many instances patients’ perspectives appear transferable across disease groups, for 
example Gordon et al.  (2007) report patients’ concerns of side effects in cardiovascular 
disease, which are mirrored in Farooqui et al.’s (2011) and Jin et al.’s (2008) work on cancer 
and gout respectively.   
A minority of literature considered facilitators and barriers to adherence from more than 
one perspective, for example the duration of the prescription appeared to influence 
adherence to oral anticancer treatment (increased duration, decreases adherence) as well 
as in other diseases areas (Partridge et al., 2003, Cheah et al., 2013). Patients have been 
shown to be more adherent to medication for pre-existing conditions (hypertension and 
diabetes) than to medication prescribed for more recently prescribed conditions although 
the mechanism or mechanisms underpinning these findings are unclear. In the study 
investigating views about co-morbid diabetes and cardiovascular disease, authors 
concluded that patients were sceptical about the addition of new medicines, with more 
importance given to diabetes medication rather than medications for cardiovascular 
disease, with lipid-lowering agents given the least importance (An and Nichol, 2013). 
Further research confirms that patients are at higher risk of non-adherence with statins 
compared to anti-hyperglyceamic agents, suggesting variation between medications within 
the context of multiple disease states (Zhang et al., 2011).  
Whilst a minority of work was conducted in patients with multiple diagnoses, the majority 
of studies were conducted in disease specific groups, highlighting a gap in the literature of 
studies that consider adherence across disease groups. What is unclear from this literature 
is if barriers and facilitators to adherence that have been identified within these patient-
specific, medication-specific and disease-specific contexts are transferable to other 
   
 
Page 25 of 261  
contexts to support patients’ medicines taking across different settings. Work identifying 
the transcendental structures of the experience, which are essential to the experience of 
adherence, across different disease contexts and in different patient groups, using different 
medication, have not yet been identified. 
The prescriber, the pharmacist and cost 
The influence the prescriber has on adherence is well documented in the literature (Gault 
et al., 2013, Traylor et al., 2010), ranging from the prescriber’s education (Cooper, 2002) to 
some patients comparing their prescribers’ instructions to those from God (Stewart et al., 
2013). Interventions that are pharmacist-led showed significant promise in improving 
adherence although why this occurred remains unclear (Ryan et al., 2011, Hung, 2013, 
Mehuys et al., 2011, Khdour et al., 2009). A Cochrane review concluded that pharmacist-led 
interventions could improve adherence (Lindenmeyer et al., 2006) however further 
research is needed to understand how this interaction is located within broader 
perspectives of the adherence experience. Other research has shown that some pharmacy 
services, namely the ‘repeat prescription service’, were reported to confuse patients and 
make patients less likely to engage in treatment (Beattie, 2007). By removing patients from 
the ordering process of medicines, it could be argued that their responsibility and 
investment in the medicines taking process has been reduced, making them less likely to 
engage with treatment.  
The financial cost of picking up prescriptions or paying for prescription medicines at the 
point of collection appeared to influence the way medicines are used; the higher the 
medicines cost, the less likely patients are to collect their medicines however in some cases 
an increased cost, and perception of cost, improved medicines adherence (Bowry et al., 
2011, Dunlay et al., 2011, Castaldi et al., 2010, Dolce JJ et al., 1991) – highlighting disparity 
between research in specific contexts. In one study, patients reported cost-related non-
adherence to cholesterol-lowering agents compared to symptom-relief medication and 
another study has demonstrated that the influence of cost is mediated by the number of 
co-morbidities a patient has (Wang et al., 2011) suggesting work that considers adherence 
within the specific context of cost may miss broader experiences of adherence. This 
conflicting body of literature highlights the importance of the context of medicines taking 
as a high-cost drug may improve adherence in one setting and reduce adherence in 
another. Indeed cost must be considered carefully in light of the varying payment 
structures for medicines across the world. 
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Whilst many reasons for non-adherence exist within the literature, there was unified 
approach that appeared to bring facilitators and barriers together. Rather the literature 
suggests a dynamic interaction between multiple factors, barriers and facilitators across 
biological, psychosocial and economic platforms within a multitude of different contexts. 
Further empirical work is needed to describe how these constructs sit together within 
interactions of daily life, such as interaction with family, friends, the media and the Internet 
as well as interactions with specific products, disease states and patients. A reductionist 
approach has led to the dissection of the phenomenon into facilitators and barriers and the 
construction of theoretical models that describe the whole by synthesising constitutive 
parts.  
 
What happens when patients are non-adherent?  
Patients who do not use medicines according to a prescription are at increased risk of 
mortality, hospitalisation, disease progression and wastage of medicines and associated 
resource. However, increased adherence to prescription medication can also lead to 
increase healthcare expenditure and increase patient experiences of side effects. 
Increased morbidity and mortality 
A study from 2012 reported that more than 125,000 people die in America each year due 
to medication use that deviated from the prescription (Banik and Ray, 2012). Lower 
medication adherence increases hospitalisation, with up to 20% of acute care hospital visits 
in the United States associated with non-adherence (Davis et al., 2012, Heaton et al., 2013, 
Simoni-Wastila et al., 2012, Stuart et al., 2010). Mortality is significantly increased in 
diabetes, cancer and a range of other diseases including COPD - with almost double the 
number of patients defined as poor adherers dying in one randomised control trial (Currie 
et al., 2013, Han, 2009, Simpson et al., 2006, McCowan et al., 2008). Studies have also 
shown that adherence to medication produces statistically better clinical outcomes, 
contributing to reduced mortality rates, across a range of diseases, including cardiovascular 
disease (Matsumura et al., 2013), diabetes (Al-Qazaz et al., 2011, Hong and Kang, 2011, 
Currie et al., 2013, Evans et al., 2011).; chronic obstructive pulmonary disease (Vestbo et 
al., 2009, Han, 2009); cancer (Geynisman and Wickersham, 2013, Marin et al., 2010, 
McCowan et al., 2008); and in meta-analyses across disease groups (Simpson et al., 2006). 
Indeed other work locates non-adherence as leading to increased severity of illness and 
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impact on a person’s quality of life (York Health Economics Consortium and School of 
Pharmacy, 2011, National Institute for Health and Clinical Excellence, 2009) 
Additionally, there is a growing body of evidence to support the concept of a ‘healthy 
adherer’, with clinical trials reporting improved outcomes in patients who adhere to both 
placebo and the test drug (Han, 2009), some studies now control for ‘healthy adherer’ bias. 
Despite this, the link between mortality and adherence is not considered tenuous and is 
best described in a quote from the US’s Surgeon General, “medicines don’t work in 
patient’s who don’t take them,” (Osterberg and Blaschke, 2005). 
Increased financial waste 
Many professional bodies and healthcare organisations have identified poor adherence as a 
global cause of negative health outcomes and financial waste (National Institute for Health 
and Clinical Excellence, 2009, Royal Pharmaceutical Society of Great Britain, 1997, World 
Health Organisation, 2003, Nunes et al., 2009, The Audit Commission for Local Authorities 
and the National Health Service in England and Wales, 2001). Despite some studies 
reporting correlation between adherence and increased health expenditure by consumers 
and governments (Breitscheidel et al., 2009), poor adherence is most commonly reported 
to lead to financial waste (Carls et al., 2012, Stuart et al., 2012, Balkrishnan et al., 2003).  
Wasted medication in the National Health Service in England account for approximately 
£300 million annually (York Health Economics Consortium and School of Pharmacy, 2011), 
tying this into adherence, Carls et al. (2012) showed that adherence is also linked to 
significant economic loss. The authors argue that adherence lowers healthcare costs as it 
prevents more serious and expensive treatments later on in the patient’s life (Lee et al., 
2006, Hong and Kang, 2011, Balkrishnan et al., 2003, Egede et al., 2012, Jha et al., 2012, 
Salas et al., 2009, Simoni-Wastila et al., 2012, Stuart et al., 2011, Wild, 2012, Zhao et al., 
2011). However other researchers argue that increased adherence increases expenditure, 
as more medication needs to be purchased for patients to consume (Asche et al., 2011, 
Breitscheidel et al., 2009, Cheng et al., 2013, Hansen et al., 2010, Stuart et al., 2013).  A 
literature review by Foley et al. (2012) concluded that 81% of studies assessing cost and 
adherence found a statistically significant reduction in healthcare costs for increased 
adherence, suggesting increased expenditure may be outweighed by costs saved from 
preventing illnesses. 
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Although not all attributable to poor adherence, a joint report by the York Health 
Economics Consortium and the School of Pharmacy, University of London concluded, in 
England waste medicine represents £90 million of unused prescriptions medicines retained 
in homes at any one time, an additional £50 million of medicines is wasted by care homes 
and £110 million of medicines are returned to pharmacies annually.  The authors state this 
is an underestimate due to methodological flaws of the research method used to obtain 
the figures and go on to say that ‘cost effective waste reduction techniques’ may only 
deliver marginal cost reduction due to the multiple causes of non-adherence (York Health 
Economics Consortium and School of Pharmacy, 2011). Considering that improved 
adherence may lead to the improved health of a population, it stands to reason that 
improving non-adherence will result in an overall economic saving as the population 
remains healthier for longer or recovers from illness sooner – potentially improving 
productivity through reducing absenteeism and improving productivity. Understanding this 
phenomenon such that interventions can be developed, which support adherence, 
therefore has significant economic value. 
Given the opportunity cost of improving medicines adherence is likely to be in excess of 
£500 million per year (York Health Economics Consortium and School of Pharmacy, 2011), 
representing a considerable sum, governments and health organisations have been keen to 
identify common patterns and reasons for non-adherence. 
Many reasons for adherence and non-adherence have been identified. This makes it 
difficult to delineate clear constructs that are important to the experience of adherence. 
Literature, both qualitative and quantitative, that describes reasons for adherence and 
non-adherence are often contextualised within a specific setting – such as patient group or 
disease (Munro et al., 2007, DiMatteo, 2004). Despite work often being conducted in 
context specific silos, adherence is understood as a construct of patients’ physical ability to 
consume medicines and patients’ beliefs about medicines. 
The predominant framework describing adherence is known as the Necessity-Concerns 
Framework (Horne, 2005). This framework posits medicines use as an individual risk-
benefit appraisal of medicines used based on constructed perceptions about medicines and 
disease as part of the Beliefs about Medicines Questionnaire. When patients perceive 
medicines as more dangerous than beneficial, non-adherence is predicted.  Conversely 
when medicines per se are considered more by the patient to be more beneficial than they 
are dangerous, adherence is predicted. The National Institute of Health and Care Excellence 
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(NICE) describes reasons for non-adherence that are underpinned by a distinction of the 
phenomenon into domains of intentional non-adherence, where the patient’s beliefs about 
medicines or their disease direct them to avoid using medicines as prescribed, and 
unintentional non-adherence, where patients’ beliefs about a medicine or their disease 
direct them to take medicines as prescribed however due to external factors they are 
unable to (Nunes et al., 2009). Here external factors describe practical problems associated 
with the physical enactment of taking medicines, such as forgetfulness, being physically 
unable to open containers, and accessing medicines due to shortages or healthcare 
structures. Whilst reasons for non-adherence can be stratified into two broad themes, 
much of the research that has investigated adherence is underpinned by biomedicalism, 
whereby phenomenon are dissected and understood as constituent parts of the whole. For 
example some research is targeted to patients in specific disease groups, making it difficult 
to transfer these findings to patients in other disease groups and develop interventions 
that might benefit broader populations.    
Whilst interventions may represent a paternalistic construct of the biomedical sphere, 
many interventions promoting adherence exist and these are often developed based on a 
particular conceptual or theoretical perspective that describes reasons for non-adherence. 
For example, interventions that attempt to educate patients about medicines might be 
based on frameworks that posit medicines use as a construct of patients’ beliefs. 
Alternatively interventions that attempt to remind patients to use medicines might be 
underpinned by approaches that locate medicines use as a function of memory. Whilst 
there appears to be theoretical congruency between current interventions and 
philosophical understanding of adherence, only a limited number of interventions have 
demonstrated improvements in adherence or patient outcomes. For example an intensive 
intervention included supplying participants with pill containers, reminders, counselling, 
and feedback by a dedicated team of staff improved adherence in uncontrolled 
hypertension (Haynes et al., 1976). Equally in patients with diabetes, bi-weekly telephone 
calls and educational follow-up interventions improved medicines adherence (Piette et al., 
2000). Whilst these interventions demonstrated improvements in specific disease contexts, 
meta-analyses across disease groups has yet to demonstrate sustainable improvements in 
adherence (Haynes, 2001, Nieuwlaat et al., 2014) – suggesting that further work is needed 
to understand the phenomenon and direct the future development of interventions across 
disease groups.   
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That adherence interventions have been developed within specific disease contexts 
(Vervloet et al., 2012), may demonstrate the dissection of the adherence phenomenon to 
reflect variation in somatic experiences of illness across disease states. For example 
patients with cardiovascular disease and type two diabetes may be unaware of their illness 
for many years, where as patients in more acutely symptomatic contexts, such as gout or 
chronic obstructive pulmonary disease, may be more aware of their illnesses. In other 
disease contexts, such as cancer, pharmacotherapy may generate adverse events that are 
more severe than initial symptoms of the disease. These differences between disease 
settings have directed intervention development to specific patient groups, as evidenced 
above. However a preliminary evaluation of an intervention that focuses on the initiation of 
medicines, the New Medicines Service, that is theoretically underpinned by a model of 
adherence based on individual patient’s beliefs about their medicines and disease, 
delivered on a societal scale (i.e. it is commissioned nationally) is reported to improve 
adherence significantly (Barber et al., 2004, Clifford et al., 2006, Elliot et al., 2014). Whilst 
this more recent work still represents a one-to-one interaction between the pharmacist 
and the patient the commission approach suggests that future interventions may need to 
transcend diagnosis, focusing less on disease context and rather on approaches to 
medicines use at a societal level.  Further work is therefore needed to present a novel 
perspective of adherence that describes patients’ lived experiences of adherence across 
disease states that might direct future intervention development.  
Theoretically framing adherence 
Whilst varied definitions appear to have driven the research of barriers and facilitators to 
adherence, constructing the reasons for non-adherence outlined above, conceptual 
modelling of the phenomenon also appears in the extant literature. Reasons for non-
adherence have been synthesised, condensed and moulded into theoretical frameworks or 
conceptual approaches. Here the dissected parts of the phenomenon are reconstituted to 
represent the whole, in a way that enables adherence behaviours to be predicted within a 
positivist paradigm. Reconstructing a representation of the whole however has led to the 
construction of theoretical framings that characterise adherence from specific, rather than 
general, ontological perspectives. For example. one model outlined by Dowell and Hudson 
(1997) classifies patients as passive acceptors, active users or all-together rejecters with 
adherence influenced by multiple constructed facilitators such as ‘faith in the prescriber’, 
‘knowledge’ and ‘acceptance of the disease’ with practical issues of physically taking 
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medicines given lesser emphasis. This further clouds the ontology of adherence, raising 
question as to the underpinning essence of the phenomenon within constructed models.  
Models of adherence are varied and only a handful of key models are discussed below to 
demonstrate the broader perspectives of understanding medicines adherence. These 
models are tabulated in Appendix A, but for completeness other models that have been 
used to investigate adherence include Self-Determination Theory (Li, 2010, Williams et al., 
2009), Peer-Crowd Peer-Support Model (Fleischman, 2013), Social Action Theory (Gore-
Felton et al., 2005), Information-Motivation-Behavioural Skills Model (Zarani et al., 2010), 
Coping Theory (Garay-Sevilla et al., 2011), The Self-Efficacy Model (an adjunct to The Health 
Belief Model) (Girdwood, 2008), Klieinmann’s Explanatory Model (Lai et al., 2007), The 
Trans-theoretical Model (outlined by Donyai, 2012) , The Self-Regulation Model (Leventhal 
et al., 1992a), Integrated Model of Behaviour Prediction (Ruppar, 2010), The Ecological 
Health Systems Model (Ruppar, 2012) and Cognitive Orientation Theory (Nurymberg et al., 
1996). As demonstrated by this extensive but not exhaustive list there is current debate 
about how adherence, and health behaviour encompassing adherence, should be modelled 
and conceptualised. 
The Theory of Planned Behaviour models behaviour on intentions (Manning and 
Bettencourt, 2011). Patients who had long-term plans had better levels of adherence, using 
constructs such as ‘locus of control’, ‘financial instability’, and ‘trust in the provider’ as keys 
to achieving adherence outcomes (Atkins and Fallowfield, 2006, Edwards, 2011, Kohlmann 
et al., 1993). This defines adherence as a phenomenon of intentionality. Another example 
might be the Fuzzy Trace Theory (Reyna, 2008), which  identifies experiences and decisions 
about medicines use as subjective, based on patients’ own conceptions, beliefs, knowledge 
and skills. This theory utilises the concept of ‘heuristics’, which could be considered as 
rules-of-thumb, describing patients’ knowledge as either ‘verbatim’ or ‘gist’. Within this 
theory is recognition of patients’ experiences of remembering the ‘gist’ of information 
about medicines, and whilst raising questions about patients’ construction of ‘gist’ and 
‘verbatim’ knowledge, this theory locates medicines taking as ontologically based in 
memory or cognition as a whole.   
The Necessity-Concerns Framework alternatively describes adherence as a relationship 
between the patient’s perceptions of posited need to take the medicine and concerns 
about taking the medicine.  Measured on an ordinal scale, the patient’s perceived levels of 
need and concern can be measured and compared to predict adherence; poor adherence is 
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predicted when participants have low necessity scores and high concern scores, with good 
adherence predicted when participants have high necessity scores and low concern scores 
(Horne et al., 2013, Stack et al., 2008). Within the framework, patients’ perceptions of need 
are considered as posited in reality, discoverable, observable and ‘out there’ ready to be 
found, supporting a definition of adherence that is based on patients’ beliefs rather than an 
ability to remember to and/or physically utilise medicines.  
Wu et al. (2008) conceptualises adherence through linking multiple factors together, such 
as ‘knowledge about the disease’ to ‘symptoms’, and ‘symptom control’ to ‘medicines use’, 
in relation to constructed factors such as ‘the prescriber, family and environment’ and 
‘habit-forming activities’. Whilst acknowledging there may be some interaction between 
targets, this position still supports a dissection of the experience into facilitators and 
barriers that result in a posited, normative outcome, rather than describing the experience 
as a whole. 
Intervention development 
As outlined above, the evidence base has focused on identifying reasons for non-adherence 
that are categorised as facilitators and barriers within different theoretical frameworks. 
The literature demonstrates that these theoretical constructs have underpinned the 
development of interventions, supporting the ‘interventionalisation’ of the phenomenon 
which in and of itself represents a positivist approach, here refers to an agenda that seeks 
to improve medicines adherence through various interventions embodied as products or 
services.  In a similar way to developing pharmaceutical products, understanding 
pathogenesis is a key to identifying targets for interventions. Identification of a target in 
drug development might be an active site in an enzyme or a receptor on the surface of a 
cell, however in relation to facilitators or barriers to adherence the literature is conflicting. 
Within the evidence base a single target can encompass many different parts of a patient’s 
life, linking barrier to facilitator and in some instances the two switch; a former barrier 
becomes a facilitator to good adherence and vice versa. For example, polypharmacy has 
been shown as a barrier to adherence, confusing patients with a high pill burden and 
resulting in non-adherence, yet there is a bulk of literature supporting the argument that 
polypharmacy might also improve adherence through a habit-forming mechanism 
(Williams et al., 2008, Virdee et al., 2013, van Bruggen et al., 2009, Tam-McDevitt, 2008, 
Chen et al., 2013, Adisa and Fakeye, 2013). Polypharmacy then may not readily present 
itself as a target for intervention development – yet products and devices are reported in 
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the literature that have done so (Virdee et al., 2013, Salam et al., 2013, Devabhaktuni and 
Bangalore, 2009, Bryant et al., 2013). This represents a disparity between understanding 
adherence at an ontological level through conceptual frameworks and the development of 
targeted interventions to improve adherence in the evidence base.  
Interventions in the literature appeared to be based on findings in specific contexts, yet 
applied to broader groups of patients without necessarily considering theoretical 
boundaries. The relatively narrow focus of intervention development in the literature 
highlights that intervention development tends to focus on adherence in one disease group 
or based on one specific barrier or facilitator of adherence. In turn this has led to the 
development of interventions that are narrowly focused. This approach speaks to the 
Integrative Model (Fishbein, 2008), which is made up of the Theory of Planned Behaviour, 
Reasoned Action Approach and Theory of Reasoned Action. It argues that behaviours are 
more likely to change if they are specific, thus rather than being concerned with 'improving 
health' or 'lowering blood pressure', behaviour change interventions are more successful if 
they are targeted to specific activities, within specific contexts and times, such as 'taking a 
pink pill, first thing in the morning, everyday for a week'. This theory typifies the approach 
to intervention development present in the literature, whereby interventions appeared to 
be developed in specific contexts. 
Despite many different types of interventions being developed, very few of these studies 
reported any sustained improvement in adherence that resulted in significant clinical 
improvements or improvements in patient satisfaction or experience (Haynes et al., 2008). 
This may be as a result of interventions being developed within contextually specific 
spheres that limit transferability or generalizability to other settings, or be a result of 
differing ontological and epistemological perspectives of the phenomenon.  
Information and education  
Information and education interventions are products and programmes that aim to provide 
patients with broad and deep information about their medicines and the conditions for 
which they have been prescribed. Interventions of this nature range from information 
leaflets to patient-practitioner consultation (Touchette and Shapiro, 2008). They are, 
broadly, based on the models of adherence that focus on patients’ attitudes, such as the 
Theory of Planned Behaviour, Fuzzy Trace Theory and Necessity Concerns Framework, 
outlined above.  
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Successful educational tools have been developed to target the educational issues 
contributing to non-adherence in patients with low health literacy and type two diabetes as 
well as those patients with a primary or secondary indication for statin therapy 
(Negarandeh et al., 2013, Nieuwkerk et al., 2012), which slightly increased levels of 
adherence. Interventions aimed at altering beliefs or perceptions about medicines as well 
as the consequences of disease may improve adherence, indeed 2-hour long interventions 
based on informing patients and motivating patients to use medicines as prescribed, 
showed promise in improving adherence in cardiovascular patients (Zarani et al., 2010).  
However when transferred to different disease settings educational tools appeared to be 
less successful; behavioural and educational interventions in epilepsy have proven 
inconclusive (Al-aqeel and Al-sabhan, 2011). Indeed interventions within the same disease 
context, but different setting failed to demonstrate improvements in medication 
adherence however did, surprisingly, demonstrate improvements in clinical outcomes 
(Tapanya, 1997) suggesting clinical outcomes might be improved due an unknown 
mechanism. Due to heterogeneity of data, a Cochrane Review and narrative synthesis 
concluded that educational interventions were inconsistent in their improvement of 
adherence (Ryan et al., 2011) suggesting as interventions move from setting to setting, 
locating the intervention within new contexts presents issues. 
Daily-living behaviours and forgetfulness 
Interventions that focus on reminding patients about their medicines using text messages, 
electronic reminder devices or alarms showed some short-term promise at improving 
adherence (Mahtani Kamal et al., 2011, Ryan et al., 2011, Horvath et al., 2012). Here 
reminder devices were considered in distinct disease groups (namely cardiovascular 
disease, diabetes and HIV respectively) with Ryan et al. (2011) calling for future work to 
consider these interventions in patients with multi-morbidity. For example, Vervloet et al. 
(2012) reviewed interventions based on reminder technologies, which were only able to 
demonstrate short-term improvements in adherence. This may be because these 
interventions position adherence as a function of memory, without necessarily taking into 
consideration the broader elements of how memory is experienced in everyday life.  
A key point here is that reminder devices needed to fit into patients’ experiences of 
everyday life in different settings. New technology such as the internet, telehealth, text 
messaging, videoconferencing, social media and ‘smart packaging’ (electronic packing, 
which records when a blister is opened), are favoured by patients as interventions for 
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improving adherence, with some evidence to support their use (Brath et al., 2013, Harris et 
al., 2012). Though again these studies report findings with the context of diabetes, which 
might limit how they can be interpreted in a different disease setting.  
Changing medication 
Interventions which are focused on changing medication, through simplifying medication 
regimens to once daily dosing rather than twice daily or combining medication into one 
dosage form, has repeatedly improved adherence (Kreyenbuhl et al., 2010, Choudhry et al., 
2011, Ryan et al., 2011, Schroeder et al., 2004, Feagan and MacDonald, 2012), although 
some studies showed no statistical difference in adherence outcomes after frequencies of 
drug administration were reduced (Barner, 2011, Jamous et al., 2011). Changing the 
pharmaceutical form, switching from a conventional pill to a disintegrating tablet, can also 
improve adherence and clinical outcomes (Navarro, 2010). A study found that any change 
in adherence due to changes in the dosing schedule were likely to be for patients with 
lower dosing or pill burden to begin with, suggesting once dosing burden is at a certain 
point, adherence could not be improved (Hauber et al., 2013). Again within this literature, 
data was collected within highly contextualised settings or abstracted from multiple studies 
conducted within specific settings. Empirical work is needed that considers these 
interventions within the context of multiple disease groups. 
Complex interventions 
Complex interventions are made up of a number of different interventions such as 
combining additional counselling at discharge, telemonitoring and videoconferencing with 
reminder devices and smart packaging. Complex interventions have the most supporting 
evidence however even here there is contradicting literature with not all investigations into 
complex interventions showing success in a comprehensive systematic review (Haynes et 
al., 2008). In the review, complex interventions show the most significant effect on 
adherence however as the interventions are complex they have a higher cost associated 
with implementation (Newell et al., 1999, Ryan et al., 2011, Schroeder et al., 2004) and 
only a minority of these studies reported substantial improvement in adherence. This 
suggests that the relationship between significant clinical improvements or improvements 
in patient satisfaction or experience within the context of these complex interventions, 
may need to be reconsidered in relation to adherence in order to determine future 
directions for intervention development. 
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The literature documents intervention development from a range of different yet specific 
contexts, generating a heterogeneous evidence base that draws on various ontological 
definitions and conceptual frameworks. Systematic reviews assessing the efficacy of 
interventions have not demonstrated long-term improvements in adherence. The limited 
efficacy of these interventions could be due to the heterogeneity of the research methods 
used to test the interventions or that conceptual models informed by patient-specific, 
disease-specific or medication-specific evidence have been used to develop interventions 
from particular perspectives. This identifies a gap in the literature for a novel description of 
the adherence phenomenon to help direct future intervention development. Furthermore, 
whilst the literature describes interventions within the context of theoretical frameworks, 
it does not include evidence of interventions that were located in patients’ lived 
experiences of medicines use – perhaps highlighting a disconnection between experiences 
of adherence and the development of interventions. 
Conclusion: An evidence-base framed by biomedicalism  
 
The literature outlined above has described heterogeneous ontological definitions of the 
adherence phenomenon underpinned by conflicting evidence concerning reasons for non-
adherence and fed by various theoretical framings. It has highlighted the very specific 
nature of the evidence base that may have limited the application of interventions to 
improve adherence in different or broader settings. A key inference from the literature is 
the over-arching normative, biomedical approach to understanding adherence that has 
systematically dissected the phenomenon, classifying component parts and 
‘interventionalising’ the phenomenon through the construction of normative theories. This 
approach positions different facilitators and barriers at one end of a schema and ‘perfect 
adherence’ at the other, with strategic interventions located as a mediator between the 
two, as shown in Figure 1 overleaf.  
 
   
 
Page 37 of 261  
 
Figure 1. A biomedical understanding of adherence 
The ‘biomedical approach to’ or ‘biomedical perspective of’ adherence has been used thus 
far and is used again here to describe the adherence literature. Inspired by the biomedical 
model of diseases, this perspective describes a trend within the literature to use ordinal 
measures to dissect and identify modifiable and non-modifiable facilitators and barriers to 
‘perfect adherence’. It could be argued that this perspective feeds the 
‘interventionalisation’ of the phenomenon, born from the, predominantly, medical and 
pharmaceutical professions, who might be considered to represent the driving force to 
understand adherence and develop interventions.  
Many of the approaches in the literature were based on positivism, fundamentally 
underpinned by a search for ‘an ideal truth’ that is ‘out there’ waiting to be uncovered 
through objective and repeatable methods of investigation. Wilberg (2011) writing about 
an existential medical model, describes a phenomenon whereby patient experiences are 
embellished within a pre-supposed description of the experience of illness due to the 
popular acceptance of the biomedical model. The popularity of this perspective may be due 
to, as Wilberg also describes, ‘the ability of the paradigm to conceptually separate the 
patient from the disease’. From this perspective, poor adherence or non-adherence can be, 
and has been, considered something that is separate from the patient, modifiable, and 
similar to symptoms of diseases. This separation that Wilberg speaks of is visible in the 
literature and policy – as outlined earlier, NICE explicitly separates the patient from 
adherence by positioning adherence as a failing of health service delivery rather than of the 
patient (National Institute for Health and Clinical Excellence, 2009).  
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A positivist spectrum of adherence would be paralleled by a health outcomes spectrum, as 
shown above. Non-adherence is often statistically associated with increased mortality and 
poorer health outcomes, whilst higher rates of adherence are statistically associated with 
optimum health outcomes (Simpson et al., 2006). Difficulties arise within this approach to 
adherence when the model is deconstructed and understood at an ontological level; 
positivism searches for a single eternal truth posited about an object or concept (Crotty, 
1998). For adherence, a posited truth or the ‘holy grail’ would be perfect adherence. Using 
numerical values to determine how close someone is to perfect adherence and statistics to 
determine if this is due to chance or a particular variable, arguably, undermines the human 
complexities of adherence, as demonstrated by the literature that links ethnicity to 
adherence, presupposing ethnicity as a function of skin colour. 
Whilst there are pockets of work that adopt an approach to understanding adherence from 
a holistic perspective, the over-arching narrative of the biomedical approach to adherence 
highlights a gap within the literature for a novel description of adherence, outside of the 
context of presupposed biomedical beliefs, which might present the experience of 
adherence from a new perspective.   
What is missing from the literature?  
An alternative approach might consider adherence behaviours more broadly within the 
context of day-to-day life across different settings, embodying the experience of adherence 
in lived reality. In this sense, rather than positing factors, facilitators and barriers, as 
external to adherence, an alternative approach would see these factors both constructing 
behaviours to adherence and being constructed by adherence behaviours. The influence of 
a person’s everyday circumstance has on health is well described, ‘generally people most 
susceptible to ill health are those who have the fewest material resources and who are 
least able to participate fully in everyday life,’ (Taylor et al., 2003). Everyday life here is 
subjectively constructed each day, with metaphorical ups and downs. This lends itself well 
to the description of illness by Bury (1982) as ‘biographical disruption to life’. Patients may 
be unable to adhere to their prescription as it represents a disruption to their constructed, 
everyday reality, disrupting yet being part of everyday life. However there is currently no 
description of patients’ experiences, theoretical framework or model that describes taking 
medicines as prescribed with such an emphasis on interactions of everyday life and how 
this feeds into subjective, constructed realities of lived experiences across different 
contexts and settings. 
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The popularity and familiarity of a ‘biomedical approach’ to adherence is undermined by 
activists like Ben Goldacre, author of ‘Bad Pharma’ (Goldacre, 2012), who argue that the 
medical and pharmaceutical professions promote positivism and biomedicalism as a vehicle 
to cultivate and construct a late capitalist model of society and consumption, similar to that 
described and critiqued by Marx, encompassed by a need and productivity schema, as 
shown in Figure 3. 
 
Figure 2. Capitalist model of medicines supply 
Marxist theory describes a constructed social world driven by need; a need for clothing, 
shelter and food (arguably not entirely constructed, with some underpinning physiological 
need) leads to investment in the manufacture of products (namely fashionable clothes, 
shelter, food and pharmaceuticals). Productivity then feeds into cultural and social norms, 
which in turn fuels need or perceptions of need. Illich describes a phenomenon, social 
iatrogenisis, that would account for the medicalisation of multiple aspects of life, resulting 
in the need for pharmaceutical or medical intervention (Illich, 1975). Political and social 
activists might argue that pharmaceutical industry marketing campaigns manipulate 
perceptions of need, to increase profit from the sale of the products they manufacture 
(Goldacre, 2012). Despite political motivations, within this ‘approach’ patients’ perceptions 
of need are influenced by society and in turn society is constructed by patients’ perceptions 
of need. 
Social science and qualitative researchers have used alternative approaches, such as 
sociological phenomenology, to understand medicines within society; with particular 
emphasis on the way medicines are constructed as part of patients’ lived realities. Much of 
this work locates medicines as objects of social construction, symbols of illness and 
embedded with social meaning (Cohen, 2010, Cohen et al., 2012, Cohen et al., 2001, Whyte 
et al., 2002). From this perspective, patients learn how to interact with medicines within a 
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defined situation. Whilst these theories have expanded understanding of medicines as 
social as well as pharmaceutical objects, it is difficult to deduce if their application to 
adherence has had an impact on the development of adherence interventions or 
understanding of the adherence phenomenon. For example theories of functionalism (that 
society is constructed of interdependent structures with particular functions), conflict 
theory (that people act in response to economic development) and symbolic interaction 
(that beliefs are constructed through social interaction) do not yet appear to have 
penetrated the literature as explanatory theories of the adherence phenomenon or in 
intervention development (Mooney et al., 2007).   
Whilst the alternative perspectives of adherence that draw on sociological or 
phenomenological methods appear to represent a different approach to biomedicalism, 
much of this wok has not penetrated practice, policy or intervention development. 
Sociological approaches may not be as easy to translate across disciplines, from sociology 
to biomedical disciplines such as pharmacy, and as such the incomplete uptake of these 
approaches may have limited understanding of adherence and intervention development.  
Summary 
The main inferences from this narrative review are constructed of three broad themes that 
are interpreted from the literature. The first describes issues within the literature that are 
concerned with the ontology of adherence, i.e. defining adherence through conceptually 
modelling the phenomenon (see Table 1, Appendix A). The second describes issues 
concerning the epistemology of adherence, i.e. how adherence can be measured (see Table 
2, Appendix A). The third is concerned with the ‘interventionalisation’ of the phenomenon 
(see Table 3, Appendix A) whereby the literature is not able to conclusively demonstrate 
the efficacy of any one intervention to improve long-term adherence, often directing 
practitioners towards complex, multifaceted and costly interventions. These three themes 
come together to demonstrate a space in the literature for work that describes the lived 
experience of the adherence phenomenon, presenting adherence from a novel perspective 
and delivering new approaches to intervention development.  
This narrative review describes and discusses three broad themes that are interpreted from 
the literature. The first describes issues within the literature that are concerned with the 
ontology of adherence, i.e. defining adherence through conceptually modelling the 
phenomenon. The second describes issues concerning theoretical modelling of adherence. 
The third is concerned with the ‘interventionalisation’ of the phenomenon, with little 
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evidence conclusively demonstrating the efficacy of interventions to improve long-term 
adherence. These three themes describe the adherence literature as located within a 
‘biomedical perspective’ and identifies a space in the literature for work that describes the 
lived experience of the adherence phenomenon from a novel perspective. 
Such a novel description of the adherence phenomenon should be approached from 
outside of a ‘biomedical perspective’ or under circumstances where previously held 
biomedical beliefs and constructs can be set aside, drawing on sociological or 
phenomenological approaches.  
This review has also raised ethical questions concerning adherence research, particularly 
from a perspective that focuses on the ‘interventionalisation’ of the phenomenon that has 
dominated the literature. Whilst this thesis was not dedicated to exploring ‘the ethics of 
adherence’, these tensions are discussed in the methods, Appendix C and the final chapter 
of this thesis draws on these questions to frame future work.  
Despite the ethical questions raised by this review, given the poor evidence base for 
sustainable improvements in adherence using current interventions, a novel description of 
adherence might also direct future intervention development.  
Purpose of the study 
The above outlines a perspective of the adherence phenomenon that highlights semantic 
issues and disparity between theoretical understanding of the phenomenon and the 
development of demonstrably effective interventions to improve adherence in disease 
specific silos.   
Aim 
To present a novel description of adherence to direct future intervention development 
Objectives 
The primary objectives are to a) contribute a novel description to the existing research on 
medicines adherence by taking a phenomenological approach and b) to provide a 
framework of findings that contributes to the development of interventions seeking to 
improve adherence. 
Research questions   
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i) What are the lived experiences of medicines adherence of adults taking medication 
across different disease states (including cardiovascular disease, diabetes mellitus, 
gout, cancer and chronic obstructive pulmonary disease)? 
ii) What are patients’ perspectives of currently available adherence interventions and 
interventions that are in development? 
iii) Do interventions aiming to improve medicines adherence need to be targeted to 
different disease groups? 
Structure of the thesis 
Chapter 3 describes a systematic review and thematic synthesis that engages with the 
phenomenological literature of adherence, identifying descriptive themes reported in the 
studies and analytic themes (identity and interaction) that go beyond the studies’ originals 
findings. This chapter demonstrates a need for further empirical work to understand 
patients’ experiences of medicines adherence in different disease groups from a 
phenomenological perspective.  
Chapter 4 outlines the epistemology and methodology of the empirical work carried out; 
describing the underpinning philosophy of phenomenology as well as the practical methods 
and materials that were used. Chapter 5 outlines the findings of this project briefly before 
each finding is reported and discussed in detail in subsequent chapters.  
Chapter 6 describes patients’ construction of personified medicines’ identities; outlining 
patients’ lived experiences of getting to know medicines, developing representations of 
necessity through micro-social interaction with the medicine and establishing micro-social 
routines that include episodes of short-term non-adherence. This chapter concludes by 
interpreting and discussing the findings. 
Chapter 7 outlines how patients experience adherence through macro-social interaction 
with wider society, embodied as healthcare professionals, family and friends, the media 
and policy. This chapter interprets these findings with the findings of Chapter 6, 
incorporating patients’ micro-social interactions with personified medicines’ identities 
within a broader macro-social interaction, to present a novel description of the 
phenomenon.  
Chapter 8 reports patients’ perceptions of current interventions, including patients’ 
experiences of educational interventions, multi-compartment compliance aids, reminder 
devices, peer-support and media as well as the poly pill. This chapter also reports a novel 
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finding that intervention use is conceptualised by patients as a negative necessity. This 
chapter interprets these findings and locates interventions within the context of a novel 
description of adherence, as outlined in Chapter 6 and 7. 
Chapter 9 and 10 discuss the findings within the context of current literature, synthesising 
and interpreting the study findings to answer the research questions. This chapter also 
highlights the limitations of and reflects on the study, describing the implications of this 
research and opportunities for future intervention development.  
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Chapter 2: Systematic review and thematic synthesis 
Introduction 
Given the conclusions in the previous chapter, it was important to complete a focused 
review of the literature describing patients’ experiences of medicines use from a 
phenomenological perspective, to consider the phenomenon of adherence a new, i.e. what 
happens and how it happens, without previously held presuppositions of biomedicalism. A 
systematic review and thematic synthesis was designed to identify phenomenological 
literature that described key components of the experience of adherence. This chapter 
highlights the need for a systematic review of phenomenological literature, describes the 
methods used to identify relevant titles and conduct thematic synthesis before describing 
the findings of the review and its implications on further study.  
Why was a systematic review needed? 
Systematic reviews and meta-analyses are widely accepted by health professionals as a 
gold-standard approach for pooling data from multiple studies. Formal statistical methods 
can quantitatively synthesise data from multiple sources in the literature, however where 
this is inappropriate, as is the case for qualitative data, a thematic or narrative synthesis 
can be an appropriate approach (Thomas and Harden, 2008). Thematic analysis of 
phenomenological research was therefore considered as a way to obtain insights into 
qualitative research concerning patients’ lived experiences of medicines adherence and 
was able to direct the research strategies for adherence interventions based on patient 
experiences.  
As a significant majority of research investigating adherence is conducted within a 
biomedical paradigm that is mostly quantitative, normative and positivist, an alternative 
approach to investigating the phenomenon was required to deliver insights, generate new 
understanding, and direct intervention development. 
Qualitative research can therefore provide that alternative approach, although disciplinary 
conventions, such as journal types and word length, can mean that research findings are 
not as pervasive in the field as they might be (Pope et al., 2000). Qualitative research 
provides rich, detailed data about a phenomenon and includes multiple methods of data 
collection such as semi-structured or unstructured interviews; focus groups; ethnography; 
and observational studies (Creswell, 2007). Within the qualitative paradigm, 
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phenomenology is positioned as a method and theoretical framework, based on the 
philosophical works of Heidegger and Husserl (Moustakas, 1994). The approach, outlined in 
more detail in the next chapter, considers how objects appear in consciousness as 
absolute, highlighting the immediacy of consciousness in the construction of reality. The 
approach has developed over the last century to embody a method of research, which can 
appear far removed from the scientific biomedical paradigm (Keen, 1975). 
Phenomenologists argue that phenomena, such as medicines use, are constructed through 
conscious interaction between subjective humans and the objective physical world. Thus to 
understand phenomena, researchers must engage with those that have ‘lived’ through the 
phenomenon (Moustakas, 1994). Collecting data is concerned with uncovering what others 
have experienced, through interviews and focus groups – as well as collecting ‘grey’ data 
from photography, poetry, and studying other artefacts (Moustakas, 1994). Data can be 
analysed through interpretative phenomenological analysis, where researchers seek to 
understand and explain conscious experience, or descriptive transcendental 
phenomenological reduction, where researchers seek to describe conscious experience, as 
well as more conventional thematic qualitative analysis, were codes are constructed that 
describe data (Lopez and Willis, 2004). These methodologies are explained in more detail in 
the next chapter. 
Whilst there are few phenomenological studies in pharmacy, phenomenology has a place 
within the healthcare research environment (Broekaert et al., 2010) with methods adopted 
by nurse researchers to add unique insights to the literature (Lopez and Willis, 2004), in 
areas such as heart failure and HIV, using medical devices to deliver continuous positive 
airway pressure (CPAP) and specific treatments, for example cholinesterase inhibitors in 
Alzheimer’s disease (Hutchings et al., 2010, Shoukry et al., 2011, Scotto, 2005, Jones, 2002). 
Phenomenological methods deliver insights into the ‘lived experience’ of healthcare 
phenomena of nursing, medical and pharmaceutical interest.  
The aim of this chapter is therefore to explore patients’ lived experiences of medicines 
adherence reported in the phenomenological literature, through systematic review and 
thematic synthesis, to direct future empirical work. 
Methods for systematic review 
Methodological limitations were assessed following the CASP Qualitative Research Tool and 
summarised by i) medicines/health issue, ii) methods, iii) sample size, iv) sample 
   
 
Page 46 of 261  
characteristics, and iv) major findings (Glenton et al., 2013). The review protocol was 
registered with PROSPERO [Registration number CRD42015029494]. 
The criteria for selecting records for inclusion in the review included studies that i) were a 
phenomenological investigation ii) were completed with adults iii) were published in a 
peer-reviewed journal iv) aimed to investigate patients’ experiences of medicines 
adherence. Excluded studies were not published in peer-reviewed journals; were not in 
adults; did not aim to investigate patients’ experience of medicines adherence and were 
not phenomenological investigations. To maintain consistency and homogeneity, grey 
literature was not included.   
Search strategy and study selection 
A systematic search was performed to identify phenomenological articles that investigated 
patients’ experiences of medicines adherence. CINAHL, PsychInfo, Web of Science, 
Sociological Abstracts, EMBASE and MEDLINE were searched (details of these searches can 
be seen in Table 2). Databases were searched individually using the search terms displayed 
in the table below. Additional records were identified via the snowball method through 
personal libraries, professional research networks and searching the references of the 
included records.   
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As “adherence” is a relatively new term to describe medicines-taking behaviour, 
“concordance” and “compliance” were also used as search terms to identify articles. 
Database specific subject headings were used to broaden the search to include 
appropriately indexed subordinate subject headings. To focus the search to 
phenomenological inquiries “phenomen*” and “DE phenomenology” were added to the 
search strategy. Search terms were truncated, such as “phenomen*”, to include 
phenomenological and phenomenology. The search was limited to articles published in the 
English language.    
Titles and abstracts resulting from the database search were reviewed and full-texts were 
retrieved for relevant articles or articles that did not provide enough information in the 
title or abstract.  The full-texts of eligible articles were then systematically reviewed for 
Table 1. Search Methodology 
Database Search Terms Years Number of Hits Included 
CINAHL MH ‘Medication 
Compliance’ AND 
phenomenolog* 
2002-2014 
 
Academic 
Journals 
 
In English 
33 13 
MEDLINE “adherence or 
concordance or 
compliance” AND 
“phenomen*” 
 
1980-2014 
 
[in English, 
Adult (19 
years+) 
126 18 
EMBASE SH “medication 
compliance” AND 
“phenomenology or 
phenomen*” 
 
 
2 2 
PsychInfo “DE treatment 
compliance” AND “DE 
phenomenology” 
2009-2014 4 2 
Sociological 
Abstracts 
Online 
“medicines 
compliance”, 
“medicines 
concordance”, 
“medicines adherence” 
and “phenomen*” 
1983-2009 
 
[Peer 
reviewed 
and in 
English 
9 3 
Web of 
Science 
“medicines adherence”, 
“compliance”, 
“concordance”, 
“phenomenological” 
All years 54 5 
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information about patients’ experiences of medicines adherence. Articles that met the 
inclusion criteria were reviewed in their entirety using the CASP Qualitative Research Tool 
(Critical Appraisal Skills Programme International Network, 2013). Figure 4 below shows the 
selection process.  
 
Figure 3. Systematic review schematic 
Data collection and synthesis 
Thematic analysis was conducted manually and with the use of Nvivo10 computer software 
[QSR International, Melbourne] according to the method outlined by Thomas and Harden  
in that data items were considered as all text pertaining to findings, in the abstract, results 
or findings sections (Thomas and Harden, 2008). Where text in the abstract and discussion 
related to new concepts, this was also collected for coding. Collected data was coded ‘line-
by-line’ to develop descriptive clusters, which were used to generate analytic themes, 
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which ‘go beyond’ the primary studies (Thomas and Harden, 2008). Data was also collected 
from each study to tabulate i) medicines/health issue, ii) methods, iii) sample size, iv) 
sample characteristics, and v) major findings as shown in Table 4, Appendix A (Cooke et al., 
2012). 
Phenomenological and qualitative research is inherently subjective and often perceived as 
being subject to bias. In phenomenological methodology, researchers are advised to avoid 
bias through a process of bracketing previously held presuppositions, referred to as 
epoché, prior to the investigation. Incorporating this with the CASP Tool, bias was assessed 
based on the documentation of a reflective or epoché by the study authors (Critical 
Appraisal Skills Programme International Network, 2013). Whilst there is not a principal 
summary measure, studies’ key characteristics and findings are summarised in Table 4, 
Appendix A. Risk of bias was not assessed formally across the studies and no additional 
analysis was performed. 
Findings of the review 
The search strategy identified 47 records of phenomenological investigations into 
medicines adherence. 25 records did not meet the inclusion criteria (details of these can be 
seen in Table 5, Appendix A). 22 articles were reviewed in their entirety using the CASP 
Qualitative Tool and included in a thematic synthesis.  
Study characteristics  
The majority of studies were set within the context of HIV (DeMoss et al., 2014, Enriquez et 
al., 2004, Jones, 2003, Jones, 2002, Mohammadpour et al., 2010, Nguyen et al., 2012, Sidat 
et al., 2007). Other settings included sickle cell disease (Abedian et al., 2010), asthma 
(Gamble et al., 2007, Scherman and Löwhagen, 2004), tuberculosis (Naidoo et al., 2009, 
Tadesse et al., 2013), mental health (including schizophrenia, depression)(Henriksen and 
Parnas, 2014, Kwinter, 2005, Muir-Cochrane et al., 2006), osteoporosis (Lau et al., 2008, 
Sale et al., 2011), and diabetes (Tilden et al., 2005). Two studies investigated the 
experience of adherence in older adults respectively (Sanders and Van Oss, 2013) and in 
patients with life-long dependency on medicines (De Geest et al., 1994) and who used 
treatment for headaches (Seng and Holroyd, 2013). Five studies investigated the 
experience in women only (Hansen et al., 2009, DeMoss et al., 2014, Lau et al., 2008, 
Nguyen et al., 2012, Tilden et al., 2005) whilst no studies investigated the experience of 
adherence specifically in men.  
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Sample sizes varied within the studies included in this review. The lowest sample size was 
1, whilst the highest sample size was 149. The median number of participants was 14. In 
qualitative research, theoretical data saturation often dictates sample size, however 
phenomenology appeared to offer flexibility concerning appropriate sample sizes and 
emphasises the depth of analysis (Crotty, 1998). The majority of studies were from the US 
and Europe although there was a wide range of geographical locations including the UK 
(Abedian et al., 2010, Gamble et al., 2007), Belgium (De Geest et al., 1994), America 
(DeMoss et al., 2014, Enriquez et al., 2004, Jones, 2003, Jones, 2002, Kwinter, 2005, 
Sanders and Van Oss, 2013, Seng and Holroyd, 2013), Denmark (Hansen et al., 2009, 
Henriksen and Parnas, 2014), Canada (Lau et al., 2008, Sale et al., 2011), Iran 
(Mohammadpour et al., 2010), Australia (Muir-Cochrane et al., 2006, Sidat et al., 2007, 
Tilden et al., 2005), South Africa (Naidoo et al., 2009), Vietnam (Nguyen et al., 2012), 
Sweden (Scherman and Löwhagen, 2004), and Ethiopia (Tadesse et al., 2013).   
Descriptive themes (results of individual studies)  
The synthesis of results identified four descriptive themes these were i) dislike of 
medicines, ii) survival, iii) perceived need including two sub-themes of a) symptoms and 
side-effects and b) cost, and iv) routine.  
Dislike of medicines 
Studies often reported a seemingly pre-predicative dislike for medicines engendered 
through fear of uncertainty (De Geest et al., 1994, DeMoss et al., 2014, Hansen et al., 2009, 
Jones, 2002, Jones, 2003, Kwinter, 2005, Muir-Cochrane et al., 2006, Sale et al., 2011, 
Scherman and Löwhagen, 2004), dependency (Kwinter, 2005, Scherman and Löwhagen, 
2004, Seng and Holroyd, 2013) and illicit drug taking (Muir-Cochrane et al., 2006, 
Mohammadpour et al., 2010, Naidoo et al., 2009). Uncertainty was often described as 
experiencing a lack of knowledge (Gamble et al., 2007, Hansen et al., 2009, Henriksen and 
Parnas, 2014, Jones, 2002, Lau et al., 2008, Mohammadpour et al., 2010, Muir-Cochrane et 
al., 2006, Naidoo et al., 2009, Sale et al., 2011, Seng and Holroyd, 2013) and related to 
patients accepting the biological causes of their illness (Kwinter, 2005, Scherman and 
Löwhagen, 2004, Sidat et al., 2007, Tadesse et al., 2013) or adoption of natural or 
alternative therapies (Hansen et al., 2009, Jones, 2003, Naidoo et al., 2009, Seng and 
Holroyd, 2013, Tadesse et al., 2013). Participants reported receiving knowledge (Abedian et 
al., 2010, Lau et al., 2008), obtaining knowledge (Gamble et al., 2007, Jones, 2002) and 
being ‘convinced’ to use medicines (Sale et al., 2011, Sidat et al., 2007).  
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Survival 
Survival, living and a readiness to adhere were reported extensively in the literature 
(Abedian et al., 2010, DeMoss et al., 2014, Enriquez et al., 2004, Gamble et al., 2007, Jones, 
2002, Jones, 2003, Kwinter, 2005, Lau et al., 2008, Mohammadpour et al., 2010, Naidoo et 
al., 2009, Nguyen et al., 2012, Scherman and Löwhagen, 2004, Sidat et al., 2007, Tadesse et 
al., 2013). This was described as patients ‘choosing to live’ and consequently being ready to 
adhere to treatment (Jones, 2003, Mohammadpour et al., 2010, Sidat et al., 2007). Papers 
also described adherence as an experience of life-long commitment, highlighting the 
implications of routine and everyday life on long-term outcomes, such as survival (Jones, 
2002, Lau et al., 2008).   
Perceived needs 
This theme relates to the frequently stated experience of weighing up the advantages and 
disadvantages of using a medicine in relation to beliefs about ‘need’ (Gamble et al., 2007, 
Hansen et al., 2009, Jones, 2003, Kwinter, 2005, Lau et al., 2008, Mohammadpour et al., 
2010, Muir-Cochrane et al., 2006, Scherman and Löwhagen, 2004, Seng and Holroyd, 2013) 
and was constructed from two sub-themes.  
i) Symptoms and adverse effects 
Studies reported the experience of symptom relief, ‘getting better’ and the medicines 
‘doing what it was meant to do’. Papers often recounted a negotiation between the 
symptoms of a disease and the adverse effects of the medicine (Jones, 2003, Muir-
Cochrane et al., 2006, Naidoo et al., 2009, Scherman and Löwhagen, 2004, Seng and 
Holroyd, 2013, Tadesse et al., 2013). This relates to theme i) dislike of medicines, in that 
adverse effects were often considered an inevitable part of the experience of adherence. 
ii) Cost 
Six papers reported that the risk benefit analysis included considerations of the cost of the 
medicine (De Geest et al., 1994, Gamble et al., 2007, Lau et al., 2008, Muir-Cochrane et al., 
2006, Seng and Holroyd, 2013, Tadesse et al., 2013). These papers were from a range of 
health economies, including the UK (Gamble et al., 2007), Europe (De Geest et al., 1994), 
the USA (Lau et al., 2008, Seng and Holroyd, 2013), Australia (Muir-Cochrane et al., 2006) 
and Africa (Tadesse et al., 2013). The cost of travel to access the medicine was also 
conveyed in these studies as central to the experience of adherence in contexts where 
access to medicines was limited geographically or financially through insurance-based 
   
 
Page 52 of 261  
healthcare models (Tadesse et al., 2013, Seng and Holroyd, 2013, Muir-Cochrane et al., 
2006, De Geest et al., 1994). 
Routine  
Lifestyle (Abedian et al., 2010, De Geest et al., 1994, DeMoss et al., 2014, Gamble et al., 
2007, Jones, 2002, Jones, 2003, Lau et al., 2008, Mohammadpour et al., 2010, Naidoo et al., 
2009, Sale et al., 2011, Seng and Holroyd, 2013, Sidat et al., 2007), time (Jones, 2002, 
Sanders and Van Oss, 2013, Seng and Holroyd, 2013), memory (Broekaert et al., 2010, 
Hansen et al., 2009, Jones, 2002, Jones, 2003, Keen, 1975, Sale et al., 2011, Thomas and 
Harden, 2008, Usher et al., 2013), and distraction (De Geest et al., 1994) were found to be 
components of the experience of an adherence routine. Papers reported task-based 
activities and the storage of medicines as structural components of the experience 
(Sanders and Van Oss, 2013, Seng and Holroyd, 2013, Sidat et al., 2007) as well as devices 
that might be used or prepared as part of the adherence experience (Whyte et al., 2002).  
Analytic themes  
The descriptive themes were analysed further to construct analytic themes, which attempt 
to ‘go beyond’ the findings originally reported in the studies (Thomas and Harden, 2008) 
and deliver insights into the experiences of a phenomenon that transcend the contexts of 
the primary research. The analytical themes identified were i) identity and ii) interaction. 
Identity  
Pharmaceutical objects were reported to exist within the experience of adherence as 
embodied actors within a patient’s life-world. Medicines were characterised by their 
efficacy to relieve symptoms and cause adverse effects; were associated with access costs 
and storage requirements as well as how they should be taken. These identifying features 
of a medicine represented structural components of the experience and are demonstrated 
in the quotes below.   
Most patients referred to penicillin as a ‘very powerful medication’ and this 
was demonstrated in their accounts that they believe that by taking the 
penicillin the threat and severity of getting serious infections would be 
reduced (Abedian et al., 2010) 
For example, one participant considered his bisphosphonate to be a “minor 
medication...just more like supplements than medication” (Sale et al., 2011) 
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The identity of the medicines also appeared to inform the participant’s identity, as below,  
And I think when Prozac came out somehow the brand name…I think 
Prozac became synonymous with crazy. For a lot of people. And so, people 
would say, “oh well, they’re on Prozac (Kwinter, 2005) 
As informed by the identity of the medicine, the identity of the patient emerged as part of 
the experience of adherence as noted in this quote,  
Many participants expressed feelings, such as loss of identity, loss of roles 
within personal relationships and embarrassment in relation to their steroid 
treatment. Loss of identity included issues such as personality changes, 
feelings of ‘not being themselves’, being unable to fulﬁl their normal role 
within the family unit, or being perceived as different by friends or 
family.(Gamble et al., 2007) 
Patient’s identity and personal values influenced adherence as they constructed ideals of 
right and wrong and how to live a perceived healthy life.  
These young women were determined to pursue a healthy lifestyle and 
considered medicine use to directly conflict with their health-related values. 
One informant felt it was “wrong” to take medicine, and shared her holistic 
view of healthy living: ”If you do the things, if you are healthy in your daily 
life, if you are less stressed out and stuff, then that makes it so that you 
have less of a need for medicine. Um. So I really try to avoid medicine, in 
every way”.(Hansen et al., 2009) 
A dislike of medicines as part of the patient’s identity was renegotiated by perceptions of 
need, ultimately leading to the modification of the patient’s identity, who they are, what 
they are and their ability to survive. This dislike of medicines is internalised and becomes a 
key part of patients’ identity.  
You know, I have been on medication now for 8 years and it’s [sic] such a 
part of my life and the knowledge, the simple knowledge that if I had not 
taken my pills I would’ve been dead by now is enough to keep me taking 
the pills. I am healthy as anything. I’d probably never been as healthy as I 
am right now but I’ve and I assume I’d be dead so… (Sidat et al., 2007) 
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In being prescribed a medicine to which they are expected to adhere, patients’ perceived 
need for the medicine means they often redefined their dislike of medicine and alter a key 
part of their identity in order to use medicines and survive. 
Identities of patients and of medicines appeared to be constructed through interaction 
with each other and wider social actors.  
Interaction 
Participants constructed identities through interaction with their medicines; with 
healthcare professionals; with family members; the disease and with ‘healthcare literature’ 
(for example blood results and hospital charts).  
In-depth research by participants paralleled the search for the ‘right’ health 
care provider and the ‘right’ HIV medication, and included activities such as 
reading magazines, looking for information about HIV treatment on the 
Internet, attending community HIV-related groups and listening to lectures 
about HIV disease(Enriquez et al., 2004) 
The metaphor that emerged from the data was Life in a Pill Bottle, which 
reflected the central focus of HAART in participants’ lives and describes the 
complex relationships that evolve between the person, the medications and 
the virus.(Jones, 2003) 
These interactions formed such a significant part of the experience of adherence, they 
often resulted in changes to the perceived identity of the medicine, particularly in relation 
to how it should be taken, which occasionally led to non-adherence, as demonstrated by 
the quote below,   
When I got out of the hospital, he (health care provider) was really giving 
up on me. I thought, ‘Well, this is not the person I want caring for me’. I 
decided, well, I want to live so I need to ﬁnd a new doctor, which I did. “I 
took them (the HIV medications) about two months and stopped because I 
did not like him (health care provider).”(Enriquez et al., 2004) 
Interaction between patients’ experience of symptom relief, adverse effects and their 
healthcare professional is demonstrated further in this quote, here the patient clearly 
modifies their medicines-taking to align with their beliefs about steroids, 
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I would be on my knees rather than take them, as time goes on and how I 
feel within myself, if I feel that I’m starting to come round. I will cut them 
down and maybe the consultant has said stay on two tablets until I see you 
in four weeks, but if I feel okay I won’t stay on those two, I mean I probably 
will cut them down again, maybe I shouldn’t but…(Gamble et al., 2007) 
Interaction with expert healthcare professionals tried to facilitate the construction of 
knowledge relating to the identity of the medicine, the disease and the patient that was 
congruent with predominant medical beliefs, consequently informing beliefs about ‘need’. 
This was not always successful, and led to contention between predominant medical 
knowledge and the patients’ own knowledge base, as demonstrated in the quote below, 
“so then I started to feel better and I started actually to get involved in 
more self-help kinds of things and reading stuff that was critical of most of 
what I had experienced in the mental health system. They really try to 
convince you that the illnesses that you have are biological and that if you 
take the drugs and do what we think you need to do, then you’ll be 
okay.”,(Kwinter, 2005) 
The construction of knowledge through interaction was often described as ‘convincing’ or 
‘being convinced’ and related to the identity of the medicine including it’s perceived need 
to be taken, and the patient’s identity and in relation to how they should use medicines. 
This is demonstrated below,   
“[the GP] that she automatically put women on bone density medication 
once they were fifty or over...So I was not convinced to take it because...I 
wasn’t convinced that I needed it. Not at all.” She was then referred to a 
specialist who gave her an in-depth explanation of her condition and about 
the medication itself. Following the visit with her specialist, this participant 
decided to take osteoporosis medication: “I felt very confident and secure 
once I spoke with her [the specialist] in detail about my concerns taking the 
drug. I just didn’t want to take any drug unless it was necessary. But she 
explained everything so thoroughly and had information to back it up from 
my charts. So she convinced me and she said she doesn’t mainly prescribe 
drugs either, nor does she like taking them herself unless it’s necessary.” 
(Sale et al., 2011) 
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The above quote demonstrates the interaction between identities of the patient and of the 
medication.  
Implications 
The findings from this synthesis suggest that a component of the experience of adherence 
is the interaction between the distinct, textural identities of social actors. Adherence is 
reported as an experience of dynamic routine, informed by knowledge about the patient 
and about medicines that is gained from wider society. The analytic themes of identity and 
interaction appear to embody the descriptive themes, whereby disliking medicines and 
being driven to survive are enacted as part of a patient’s identity and the perceived need of 
a medicine constitute the medicine’s identity as a tacit social actor, that relieves symptoms, 
causes side effects and costs money. Experiences of routine appear to represent 
interaction between the patient’s identity and the medicine’s identity. The 
phenomenological literature then describes the structural ‘essence’ of adherence as 
identity, of patients and medicines, and as interaction between the patient, their medicine 
and wider social interaction with friends, family, and health professionals. Knowledge and 
perceptions, constructed from social interaction, are reported to enable patients to modify 
medicines-taking beliefs and practices. Interactions with healthcare professionals were 
reported to focus on ‘convincing’ patients of the need for medicines, which was at odds 
with interactions with family, friends, and the media.  
This work supports that conducted using other approaches, which identified the 
importance of perceived need (Horne et al., 2013). Horne et al. argue that internal 
negotiations between the patient’s perceived need of a medicine and the patient’s 
concerns about adverse effects position adherence as a dichotomy. This was also seen in 
the reviewed phenomenological literature, as perceptions of need and of survival were 
explicitly described in relation to medicines taking within the context of symptoms and side 
effects. The construction of knowledge about the safety and efficacy of medicines, and 
hence the need of medicines, is also supported by other work, which identified 
construction of lay pharmacological beliefs (Webster et al., 2009). Conceptualising 
medicines as social entities, as well as biochemical ones, is described in literature outside 
the scope of this review (Whyte et al., 2002, Cohen et al., 2001, Anderson and Roy, 2013). 
Particularly the work by Dingwall and Wilson, which reported the ‘symbolic transformation’ 
pharmacists perform when dispensing medicines, changing medicines from biochemical to 
social entities (Dingwall and Wilson, 1995) frames interactional relationships as significant 
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parts of the adherence experience is also supported by other work (Chai et al., 2014, Laba 
et al.). This highlights the importance of initial support and reinforcement when medicines 
are first prescribed and crucially, throughout the life of the patient and the prescription 
product. 
Limitations of this review 
Synthesis of qualitative data is often controversial as qualitative findings are deeply 
contextualised and so difficult to transfer from one setting to another. Thomas and Harden 
argue that ‘the act of synthesis could be viewed as similar to the role of a research user 
when reading a piece of qualitative research and deciding how useful it is to their own 
situation.’ (Thomas and Harden, 2008). They go on to argue that context can be preserved 
if aims, methods, sample characteristics and settings of the manuscripts synthesis are 
shared as part of the synthesis, as in Table 4, Appendix A. Phenomenologists are 
encouraged to present their findings in creative and novel ways to engage wider public 
interest. Due to the varied nature of phenomenological research, it is possible some studies 
were not identified, such as those presented as art or poetry and not published in journals. 
As there is no standardised method for identifying or assessing the quality of this type of 
publication systematically, these works could not be included in this review or thematic 
synthesis.  
Whilst the findings support the use of phenomenology as a theoretical framework and 
method to investigate adherence, a further limitation of this review is that it only included 
studies that explicitly aimed to investigate the experience of medicines adherence. This 
meant that studies investigating only a part of the experience of medicines adherence, for 
example investigating beliefs about treatment, or studies investigating the broader 
experience of healthcare, such as self-management of diabetes, were excluded from the 
study. It could be argued that these excluded papers may have included relevant extracts 
however as their primary aim was not investigating the experience of adherence per se, 
these extracts may have been hard to identify or contentious in their relevance to 
adherence.  
Conclusion 
In relation to this thesis, this review has considered the literature by focusing on patients’ 
lived experiences of adherence. Identifying an interaction between identity of the patient 
and the identity of the medicine within very specific, lived, experiences. One of the 
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drawbacks of this literature is that the majority of studies were conducted within specific 
disease contexts. This highlights a gap in the literature that describes patients’ experiences 
of adherence across disease contexts.    
Of particular pertinence is the delineation of disease symptomology and how this 
constructs patients’ experiences of adherence. The literature, both outlined in Chapter 2 
and above, suggests that symptoms, and other somatic experiences such as side effects, 
play a key part in a risk benefit analysis that constructs perceptions of necessity, both as 
part of a patient’s identity, but also a medicine’s identity. However the literature does not 
adequately describe patients’ experiences of adherence across disease contexts that have 
varied symptom profiles. For example patients with gout and COPD experience symptoms 
of pain and breathlessness, where as patients with cardiovascular disease and diabetes 
might not experience symptoms. Indeed somatic experiences of side effects in some 
contexts can appear to be more detrimental than disease symptoms, such as patients with 
cancer. Understanding patients’ experience within the context of multiple disease states 
that embody varied symptom profiles would enable in-depth understanding of the 
adherence phenomenon. Disease areas that have high prevalence and have different 
symptomatic profiles, such as gout, COPD, cardiovascular disease, diabetes and cancer 
would ensure the inclusion of varied experiences across disease groups. 
Within the literature, the experience of symptoms, and arguably symptom relief, 
represents an interaction between the patient and their medication. This highlights an 
important area for future intervention development. However there is little in the way of 
evidence that directs future intervention development be aimed toward patients within 
specific or different disease contexts, i.e. that future interventions be directed to utilise 
patients’ interaction with symptoms to improve adherence.  Indeed that much of the 
literature is conducted within disease-specific silos might limit the transferability of the 
study findings to intervention development, where interventions might be directed 
towards patients with different disease contexts or comorbidities. Further understanding is 
therefore needed that locates adherence intervention development within the experience 
of adherence across different disease groups. 
These considerations present three questions; 
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i) What are the lived experiences of medicines adherence in adults taking medication 
across different disease states (including cardiovascular disease, diabetes mellitus, 
gout, cancer and chronic obstructive pulmonary disease)? 
ii) What are patients’ perspective of currently available adherence interventions and 
interventions that are in development? 
iii) Do interventions aiming to improve medicines non-adherence need to be targeted 
to different disease groups? 
The next chapter of this thesis outlines the conceptual framework, methodology and 
methods used to answer these questions.  
 
 
 
 
 
    
 
Page 60 of 261  
Chapter 3: Epistemology, methodology, and methods  
The previous chapter justified the need for a study that investigates patients’ lived 
experiences of medicines adherence in different disease contexts. This chapter describes 
the methods and materials used to carry out the study, as well as the principles of 
credibility, transferability, dependability and confirmability. In a sense, this chapter 
carefully considers ‘what was done’ and ‘why it was done’. 
Epistemology: The nature of knowledge 
Much of the research that has investigated adherence uses different methodology and 
arguments can be made (and has been made in an earlier chapter) about the 
appropriateness of those methodologies when investigating such a complex human 
phenomenon. Methodologies might be argued to be manifestations of epistemological and 
ontological positions and, for this study, the epistemological position of the approach 
informed the methods used.    
Philosophy is fundamentally integral to scientific disciplines (Crotty, 1998), however 
philosophy as a discipline has retreated back from the foreground of research and the 
practical application of philosophy can be hidden from view by the focus on a plethora of 
methods, methodologies and theoretical frameworks. More recently philosophy has been 
tied to the likes of theology and consequently, empirical natural scientists find 
philosophical inquiry obfuscated and erroneous. Ferguson describes philosophy as a ‘meta-
science’; encompassing all scientific practices and research based on reason, and therefore 
doubt (Ferguson, 2006, Berger, 1963). Doubt in turn can be considered to link all scientific 
practices to philosophical inquiry.   
As outlined in the previous chapters, the majority of adherence research is approached 
from a normative perspective - although pharmacy research from different perspectives is 
growing. One truth, posited by an object and only revealed through the scientific method 
of experimentation, repetition and validation is how pharmacists typically understand the 
world. What knowledge ‘is’ for a healthcare professional in a positivist paradigm then, is 
concentrated on prediction and certainty; confidence intervals and probability coefficients 
all aim to objectify experiences to better ‘know’ what will happen in the future; predicting 
survival based on certain behaviours, for example.  
    
 
Page 61 of 261  
The concept that there is more than one theory of knowledge can be quite jarring. 
Exploring different paradigms in an attempt to understand reality, and the way things ‘are’ 
(known as ontology) and exploring how what is known is known (epistemology) are areas 
that are very rarely discussed, taught or considered in the majority of healthcare settings or 
health education – although this appears to be increasing. Granted healthcare 
professionals may be too busy doing the day job, ontology and epistemology are areas that 
can dramatically alter the way research outcomes are understood and applied in clinical 
practice. A constructivist epistemology (as opposed to a positivist one) argues that meaning 
and knowledge are built through the subjective conscious perception of objective 
characteristics. A solid dosage form, such as a tablet, has objective properties, for example 
its colour, size, shape, and excipients, however tablets also have subjectively-perceived 
properties, including the social constructs of the tablet, i.e. a remedy, a choking hazard, an 
inconvenience. The social constructs of an object only exist when they are perceived 
through subjective consciousness and these constructs can only be accessed through 
conscious experiences. Ferguson (2006) describes consciousness as ‘not a picture of an 
absent world contained within the mind of an individual, it is the world’ (page 26), thus to 
study a phenomenon, such as medicines adherence, experiential data based on subjective 
perceptions of objective characteristics can be argued to be of paramount importance.  
Perceptions and experiences are rich, detailed and comprehensive. Traditional approaches 
in adherence research to capture experiences have, being framed by biomedical 
perspectives, predominantly used surveys or questionnaires to collect data. This allows 
statistical analysis to be conducted to identify any significant differences between 
experiences of adherence and to categorise variables that might mediate the experience. 
These approaches are often argued to be unable to capture the complexity of conscious 
experience (Moustakas, 1994, Crotty, 1998) and as such a qualitative approach must be 
considered. When investigating patients’ experiences qualitative research uses methods 
such as interviews, focus groups and observations to collect rich data pertaining to 
phenomenon and are often considered more appropriate to uncover the dynamic 
complexity of human experiences (Creswell, 2007). Many different forms of qualitative 
enquiry have been developed, with each purporting advantages and disadvantages to 
others. Grounded theory, narrative approach, phenomenology and ethnography are 
reputable and rigorous methods that could be used to study patients’ real-world 
experiences of adherence.  
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Deciding which qualitative research approach to use can be difficult. Philosophical, 
conceptual or theoretical frameworks or ideologies often underpin each approach. Aligning 
the aim of the research with the underpinning ontological, epistemological and theoretical 
perspective allows a theoretically congruent research approach to be adopted. As outlined 
in the previous chapters, medicines adherence can be defined and described using a 
plethora of conflicting conceptual or theoretical frameworks and so aligning one of these to 
a qualitative method presented somewhat of a challenge, as epistemologically it meant 
giving predominance to one ‘way of thinking’ about adherence. A narrative approach might 
elucidate an in-depth story of medicines taking and require collecting field notes and 
artefacts which would be difficult to do with a patient’s medicines - taking an artefact like 
empty medication packaging would reveal a participant’s identity, exposing a study risk of 
compromising participant confidentiality, unless it was defaced to remove confidential 
information, which would arguably decrease the integrity of the artefacts, and the study. 
Additionally, a narrative approach often details quite abstract concepts, which future 
readers might struggle with, if the outcomes of this research are going to influence 
practitioners and policy, they need to be translatable and easily understandable. Finally 
within a narrative approach, researchers subjectively reconstruct a phenomenon, 
potentially devaluing the chemical nature of medicines and the objective reality of 
medicines use. 
An ethnography, which includes observation of culture-sharing groups, would not be 
appropriate as identifying a culture-sharing group within disease states would be 
exceptionally difficult - just because two people share an illness does not infer they share a 
culture, indeed medicines taking appears across cultural groups and an ethnography would 
arguably discover more about other structures of culture than about medicines taking. 
Ethnography would elicit patients’ experiences of medicines use however this would 
require a substantial amount of time in the field and would make the practicalities of 
development expected during doctoral study difficult. For these practical reasons, an 
ethnographic approach was not chosen as the method of enquiry. 
Grounded theory attempts to produce a novel theory, interpreting the experience of the 
phenomenon to generate an explanatory model. Phenomenology, as an alternative 
approach, seeks to produce a novel description of the experience, as such, which would be 
constructed from the data by forcing the research team to identify and reject 
presuppositions and prejudices about a phenomenon through a process known as epoché.  
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Grounded theory and phenomenology could both have been used as appropriate methods 
to investigate experiences of medicine use within the context of different disease groups, 
as they both involve an element of basing findings in data rather than presupposed views. 
A grounded theory study would produce a model of the process of taking medicines and 
inferences could be made about differences between the models – trying to explain why 
patients in different groups might have different experiences. Conversely a 
phenomenology, whilst still adhering to many of the philosophical principles of grounded 
theory, i.e. trying to limit the influence of the researchers prior knowledge on the outcome 
of the research, would produce textural and structural descriptions of ‘what’ happens and 
‘how’ it happens when participants are taking medicines for their disease.  
Moustakas (1994) describes applying phenomenological methods to human sciences 
research by describing five characteristics of the methodology. The first is that 
phenomenology considers the whole nature of a phenomenon, free from preconceived 
biases from the natural sciences, and constructs an understanding based on what is given 
in the data. Concepts, judgments and understanding are developed through reflection and 
intuition to, without producing processes, models or explanations, describing what and 
how the phenomenon of inquiry occurs. Finally, phenomenology is intent on the 
interaction between the objective and subjective, allowing for a researcher to consider 
multiple aspects of the phenomenon from an almost pluralist perspective, without rigidly 
observing positivist or constructivist practices. After reading an extract of the 
phenomenology of time (Moustakas, 1994), it appeared that to adopt a phenomenological 
approach would produce a description that, after it having been read, a reader would 
understand the phenomenon more clearly.   
In contrast, Stern and Porr (2011) said that the four fundamental principles of grounded 
theory were ‘explanation never description’ whilst Moustakas describes phenomenology as 
providing a way to ‘understand something better’ (van Manen, 2011, Moustakas, 1994).  
After reviewing the literature, another theory would not contribute significantly to practice 
or research. However a phenomenology, which would provide a novel description of the 
phenomenon, to help practitioners, policy makers, and academics, ‘understand adherence 
better’, would make a novel contribution to the literature. A description of adherence, that 
is not trying to explain the process, but enhance our understanding of the experience of 
adherence, would be additionally useful if it were to direct intervention development. As a 
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result, phenomenology was chosen as the methodological and conceptual underpinning for 
this work. The conceptual background to phenomenology is outlined in more detail below.   
Phenomenology 
Phenomenology is a methodology used to explore experiences, described by Ferguson 
(2006) as ‘a philosophical movement combining rigorous science and mystical theology’. 
Phenomenology speaks to the importance of experience and experience that has been 
lived through. Husserl, a German philosopher who established a school of phenomenology, 
broke with positivist, natural science epistemology, stating ‘naturalists and historicists 
misinterpret ideas as facts…  transform all reality, all life, into an incomprehensible, 
idealess confusion of facts. The superstition of the fact is common to them all’ (Ferguson, 
2006). This quote essentially describes a constant doubt and casts a shadow on the 
elements of ‘certainty’ that have come to be expected from ‘scientific’ research when 
translated into practice or policy. Phenomenology then represents both a method of 
investigation and a conceptual framework. 
Constructivism argues that meaning and knowledge are built through the subjective 
conscious perception of objective characteristics. This paradigm or perspective lends itself 
well to phenomenology’s concept of intentionality. The subjective consciousness intends 
towards the objective characteristics to construct reality and experience (Ferguson, 2006), 
in other words, we think subjectively about objective things. The resulting subjective 
processes of conscious perception (that is knowing, judging, remembering, desiring) are 
intended towards the objectivity of the object (that is its size, shape, colour). The resultant 
consciousness is constructed from two sources; the subjective perception and the objective 
characteristic; this process constructs reality and experience (Moustakas, 1994). This 
description from Moustakas highlights the key role that phenomenology has for 
investigating adherence. Each medication will have objective, reproducible and predictable 
characteristics posited about its nature; a tablet might be blue, angular and hard where as 
a liquid may be bright pink, sticky and sweet. Those physical, chemical characteristics are 
unlikely to change from patient to patient. Within a phenomenological approach, the 
objective characteristics are interpreted and processed subjectively by each patient, 
obtaining meaning, influence and importance from a subjective perspective. In that sense, 
whilst medication maybe be objectively manufactured to have certain characteristics, 
patients might experience them differently, such as disliking the sweet taste. Experience 
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then is made up of the dynamic negotiation between internal psycho-social processes and 
external objective stimulus.   
Interpretation and description 
Multiple schools of practice exist within the phenomenological discipline. For the purpose 
of this thesis, two phenomenological practices are outlined. The first represents 
interpretive phenomenology, also known as hermeneutic phenomenology, which focuses 
on the interpretation of experience as consciousness and more readily accepts that any 
research represents the interpretations of the researcher (Moustakas, 1994, van Manen, 
2011).  
Alternatively transcendental phenomenology is focused on the description of phenomenon 
from constitutive parts, the ‘what happens’ and ‘how it happens’ of experiences that 
construct consciousness.  Whilst critics argue that all experience is interpreted through 
language (Gadamer, 1976) the transcendental phenomenological approach is argued to be 
more ‘scientific’ or ‘robust ’(Giorgi, 1997), as it provides a mechanism to recognise and 
address biases brought to research by the researcher (the epoché). As this study set out to 
provide an alternative description of adherence, transcendental phenomenology, as 
oppose to interpretive phenomenology, was adopted as the methodological framework 
that would underpin the study.  
Textural and structural descriptions 
A textural description of reality or experience was expected to include all aspects of the 
phenomenon, with ‘outliers’ brought forward for discussion and reflection to allow each 
dimension of the phenomenon to be given equal attention. Describing each aspect of 
adherence from many view points, collected through qualitative in-depth semi-structured 
interviews, until a “sense of fulfilment” (page 78) is achieved was needed to generate a 
detailed, comprehensive description of adherence (Stern and Porr, 2011, Moustakas, 
1994).  After describing the texture of a phenomenon, i.e. what happens, the analysis turns 
to reflecting the structural components that precipitated the phenomenon, that is ‘how it 
happened’. This was vocalised by participants, as feelings, thoughts and experiences 
constructed by conscious acts of thinking, judging, imagining and recollecting. Although the 
two constructs are described as different ‘phases’ of research, Keen (1975) advises that 
structures and textures of experiences are interlocking and consequently a 
phenomenological investigation is fluid and moves from structural to textural and vice 
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versa (Moustakas, 1994, Keen, 1975). Figure 4 demonstrates the actual steps taken during 
a transcendental phenomenological analysis.  
 
Figure 4. Process of transcendental phenomenology  
Based on the Vancouver School of Doing Phenomenology (Keen, 1975), the method can be 
fragmented into three identifiable stages; epoché, transcendental reduction and 
imaginative variation. Transcendental reduction focuses on the construction of codes, units 
of meanings or nodes to demonstrate the textural aspects of the phenomenon, whilst 
imaginative variation uses the researchers imagination to see connections between the 
structural aspects of the phenomenon that precipitate the textural aspects. Through this 
process of transcendental reduction and imaginative variation, the value of the data is 
highlighted, that data, as such, pertains only to ideas and it is ideas that are powerful, 
useful tools. For example, observing, experiencing and demonstrating that the colour ‘red’ 
exists only then describes an idea of ‘redness’; the idea is then toyed and played with 
conceptually to develop innovations of redness and it is this that consequently produces 
impact and deeper understanding. Conventional thematic analysis using coding software 
can be conducted during the two later stages to identify textural aspects (what happened) 
and the structural aspects (how it happened). A transcendental phenomenology identifying 
structures of multiple experiences, which transcend the contextual boundaries of those 
experiences was designed.  
Banton (2005) highlights that social research is influenced by the researcher’s personal 
traits and characteristics, with objectivity in the social sciences only achieved through 
interaction with other researchers. Interacting with other researchers can be reflective in 
nature; drawing on the experiences of different researchers, however Moustakas (1994) 
describes this as a difficulty of transcendentalism, ‘the challenge is to silence the directing 
voices and sounds, internally and externally, to remove from myself manipulating or 
Epoche
Transcendental 
Reduction
Imaginative 
Variation
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predisposing influences and to become completely and solely attuned to just what appears, 
to the encounter the phenomenon, as such’ (page 88). Moustakas also describes a 
seclusion and withdrawal of the phenomenologist during the research process of epoché, 
reduction and imaginative variation from the research environment to avoid adopting the 
biases, prejudices and presuppositions of those around him. He describes the influences of 
fellow researchers as something that may not be completely transcended, which might still 
be identified by the epoché, but might not be able to be rejected. Moustakas offers some 
hope in that with careful, intensive, and reflective epoché, the prejudices and pre-
conception of others can be faithfully revealed as such, and consequently be identified and 
analysis scrutinised.  
Bracketing 
Bracketing in phenomenology involves reflecting and rejecting any pre-existing or pre-
conceived ideas about a phenomenon; setting aside judgments about the natural world to 
enable the essential essence of a phenomenon to be understood. Transcending the 
physical and natural world, as healthcare professionals, can be difficult as the physical 
sciences are the territories that most health professionals are educated and practice in. For 
a pharmacist, the early years of education are built on a foundation of natural science. 
Coming to phenomenology as a pharmacist was refreshing; the epistemological and 
ontological changes required were very different to the quantitative paradigm of 
traditional chemistry, biology and physics. Epoché, to reduce pre-conceived biases, is a 
reflective and continuous process. In this respect, transcendental phenomenology not only 
tries to find the transcendental nature of the phenomenon, but also supports the 
researcher to transcend their previously held presuppositions and a priori knowledge.  
A view could be taken that it is impossible to completely transcend the natural sciences or 
sociolinguistic knowledge and as a result they mar all phenomenological investigations. 
Even if a complete sense of epoché cannot be achieved, a pharmacist-researcher, or any 
researcher, might still benefit by identifying biases and ‘opening up’ to the idea of a 
different perceived reality (Creswell, 2007, Moustakas, 1994). Bracketing out or identifying 
preconceived understanding of an experience prior to thematic coding, enabled reflexive 
anticipation of theme emergence, i.e. are these themes being identified due to previously 
held beliefs or are they in the data? Can this data be considered in a different way? 
Continuing this process through repeated epoché establishes if themes or codes are 
emerging due to pre-conceived ideas or due to the data. An example of how this could play 
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out during analysis is that, as a pharmacist prior knowledge about pharmacokinetics, 
pharmacodynamics and unwanted adverse effects, might have biased the coding such that 
adverse effects, pharmacodynamics and pharmacokinetic issues are identified 
predominantly. Epoché allowed codes to be critiqued and reflectively scrutinised against 
the transcripts for the presence of the code with repeated, informal epoché conducted at 
regular intervals to reduce biases generated from coding previous data. In essence then, 
bracketing and epoché acknowledges biases and attempts to circumvent them.  
An undated essay by Boghossian of New York University (Boghossian, Undated) draws on 
sociological constructivism and the sociology of knowledge; arguing that knowledge is 
subject to social forces (ideas, beliefs) and discusses Kant’s philosophy of transcendental 
idealism. Kant’s philosophy, resembling Plato’s shadow philosophy, proposes that there is a 
world that exists independently of the human mind and only when humans think, speak or 
remember to make sense of the world, that it is constructed. As humans make sense of the 
world it is constructed socially around them, demonstrated in that humans from different 
social groups make sense of the world differently, the philosophy argues that the world 
that is known is socially constructed. This is not too dissimilar to the fundamental ideology 
of phenomenology. Transcending the known world through reflexive reduction allows 
experiences to be seen for what they are, without being marred by preconceived ideas of 
truth or knowledge, better illuminating ‘the absolute’ (Moustakas, 1994).  
Husserl, was a German philosopher who wrote about the ontology, epistemology and 
philosophy of phenomenology and Moustakas quotes Husserl, “all scientific knowledge, 
rests on inner evidence” (page 26), in this quote, Husserl is describing knowledge as the 
culmination of inner reflections of scientists and draws together qualitative and 
quantitative researchers. This further builds on the work of Descartes’ philosophy of reality, 
where by all reality is subjectively perceived about an object. Perceptions of reality are 
constructed through a process Kockelman called ‘ideation’. In ideation, empirical 
experiences are transformed into essential insights, creating meaning. Indeed, 
understanding ‘meaning making’ through a philosophical lens underpinned the 
development of an understanding of epistemology, how what is known, is known. 
Philosophising and theorising about the nature of knowledge and reality presented itself 
almost accidently when bracketing. The philosophies of metaphysics (monism, atomism, 
pythagoreanism) to more cultural and ethical philosophies, like Protagoras’ relativism, 
helped to understand that ‘the scientific method’ as a combination of age old philosophies 
    
 
Page 69 of 261  
of reasoning (Parmenides, c515-445 BC), questioning (Socrates, 469-399 BC) and 
empiricism (Aristotle, 384-322 BC) meant that philosophy, formerly considered a ‘wooly’ 
discipline was actually an integral part of understanding the world that had perhaps been 
overshadowed by biomedicalism. Therefore to understand what was already known about 
the world, understanding the philosophical position was appropriate and an essential part 
of the epoché. Through epoché knowledge of the world that is constructed on 
presuppositions, prejudices and a priori knowledge can be identified and rejected.  
Epoché or ‘bracketing out’ of preconceived ideas about medicines adherence can be found 
in Appendix A. The text is presented in the first person and is included to demonstrate the 
adoption of the epoché process within the study. The text was used during the analysis to 
scrutinise the codes produced and provides an insight, and summary, of a priori opinions 
and beliefs about medicines adherence. Epoché was practised informally prior to 
interviews, focus groups and analysis and was regularly referred to throughout the analysis 
to recognise themes that may have been projected onto the data based on previously held 
beliefs.  
The extract represents views of adherence that might be described as typical for practising 
clinical pharmacists. Identifying these beliefs, views and values enabled them to be rejected 
or bracketed and research approached with a more open mind. This thesis now describes 
the methods and materials of the study.  
Reflexivity 
Using the approach outlined above was not without contention. Whilst theoretical epoché 
may be achieved to enable rigorous knowledge creation by a social scientist, the ethico-
legal responsibilities of a healthcare professional conducting social science research may 
not. As a pharmacist, upon disclosure of episodes of non-adherence, General 
Pharmaceutical Council standards dictate that the pharmacist must intervene. However, as 
a social scientist, researching non-adherence, intervention during research interviews 
obfuscates the nature of interview, to observe, elicit, listen. The dual identity of pharmacist 
and researcher investigating medicines adherence presented several issues, which were 
documented and worked through in Appendix C, the ethics of studying adherence.  
The role of the funder and theoretical positioning 
This research was funded by a joint grant from Durham University (60%) and AstraZeneca 
(40%). AstraZeneca acted in an advisory capacity preserving academic rigour, oversight, 
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freedom and independence. That AstraZeneca funded this work represents a theoretical 
juxtaposition. Thus far this work has recognised an over-arching biomedical approach that 
has driven adherence intervention development. Whilst this thesis is contributing to the 
process of interventionalisation, by investigating the phenomenon with a view to direct 
future intervention development, a critical reflection of this work can be made as to the 
paradigmatic alignment between describing patients’ experiences of adherence using social 
research methodology and underpinning drivers to develop interventions that manipulate 
that experience. Directing future intervention development is congruent with a positivist, 
biomedical approach to adherence that is located within a paternalistic relationship 
between the patient, their medication, healthcare providers and the industry. Whilst the 
work that directs intervention development in this thesis is posited within a 
phenomenological and sociological sphere, which is underpinned by a rejection of 
biomedicalism and by extension the need for intervention development. At this 
juxtaposition, a pluralistic perspective is needed that enables the two paradigms of 
positivism and constructivism to exist simultaneously, side-by-side, such that whilst the 
outcomes of medicines adherence can be physicochemical the experiences can be social. 
Returning to the notion that ‘medicines do not work in patients that do not take them’, the 
physical impact of medicines misuse through non-adherence has an impact on health 
outcomes and experiences of everyday life that exist beyond physicochemical boundaries, 
as sociological, psychological, spiritual and meta-physical phenomenon. It is in this spirit 
that this research is pursued.  
Methods and materials 
The sampling and recruitment strategies used for the study are outlined below and include 
the population studied, the inclusion and exclusion criteria, and the details of the 
pharmacies and the general practices that were involved in the recruitment. 
Sampling and recruitment  
Pharmacists and general practitioners (described below) identified participants with one of 
the following conditions; cardiovascular disease, COPD, gout, cancer or diabetes mellitus.  
These disease groups were chosen based on symptomatic profiles, as cardiovascular 
disease and diabetes mellitus type two are mainly asymptomatic diseases, which patients 
can be unaware of until diagnosis, whereas chronic obstructive pulmonary disease and 
gout are two diseases which have clear symptoms, that patients are acutely aware of, such 
as breathlessness and pain, respectively. Finally patients with cancer often have to take 
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medication that can give them worse side effects than the symptoms of the disease, 
presenting an area that was expected to offer a different experience of medicines 
adherence. These disease areas were chosen with input from the supervisory team at 
Durham University, the advisory team at AstraZeneca and the Division of Pharmacy Patient 
and Public Involvement Group as well as being based on my own clinical experience and 
knowledge gained from my familiarisation with the literature. A decision to limit the study 
to these diseases (rather than include additional disease contexts that represent different 
symptomatic profiles such as depression or anxiety) was based on the practicalities of 
research and ensuring the project was achievable. In instances of co-morbidity, participants 
were asked to identify which disease group they perceived to be their primary diagnosis or 
main concern. This allowed the research to be framed in patients’ perceived realities. For 
example, a patient may have hypertension, diabetes and gout however perceive their main 
condition to be diabetes, and so they would be recruited into the diabetes group. In a 
situation when participants discuss how they use their medicines in a relational context, 
this data added to the depth of the research and transcendental understanding of the 
contextual use of medicines in that population.   
Originally the study aimed to recruit fifteen participants to each disease group based on 
pragmatic qualitative approaches to theoretical data saturation (Guest et al., 2006, Suter, 
2012), however once data collection had started it became apparent that much smaller 
numbers of participants, approximately eight, were needed to reach saturation in each 
disease group.  
Participants were invited to participate by community pharmacists, general practitioners or 
a member of their care teams and handed a Participant Pack (see Appendix B). The 
Participant Pack contained a letter to the patient giving details of the study and inviting 
them to take part; a consent form for them to familiarise themselves with; a ‘Registering an 
Interest Form’ to complete and return to the research team if they want to take part; a 
stamped and addressed envelope; a ‘Participant Information Sheet’ containing more 
information about the investigation and contact details of the research team. Alternatively, 
general practitioners or pharmacists obtained the patient’s consent to forward their 
contact details to the research team and the research team contacted the patient directly 
to discuss their involvement with the study. Once the research team received the 
participant’s contact details (via post, telephone or email) they were contacted to arrange a 
suitable time and place for the interview. Participants were recruited for interviews until 
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data saturation had occurred in each disease area. Following analysis of the interview data, 
participants were recruited using the same technique to take part in focus groups however 
participants were also invited from local academic and professional networks.  
Given the aim of the study was to explore patients’ experiences of medicines adherence 
and the contention around measuring and defining adherence outlined in the earlier 
chapters, a decision was made not to define populations based on arbitrary definitions of 
adherence, such as adherent or non-adherent. As a consequence the sample had varying 
levels of adherence, from patients that had completely rejected pharmacotherapy, to 
patients who reported strict adherence practices. This was particularly useful during focus 
groups as differences between practices facilitated discussion. 
An observation of recruiting through community pharmacy and general practice was that 
this population might still be described as ‘adherent’ as they were still engaged with 
healthcare such that they still visited their community pharmacist or general practitioner. 
Recruiting in this way then, does not include populations that are non-adherent to the 
extent that they do not visit their community pharmacist or general practitioner. The views 
of this population may provide further insight into adherence and empirical work should be 
pursued to explore this – as discussed in the final chapter.   
Inclusion and exclusion criteria  
Inclusion and exclusion criteria are outlined in the table below.  
Table 2. Inclusion and Exclusion Criteria 
Inclusion Exclusion 
Adult (aged over 18 years old) Does not meet the inclusion 
criteria 
 
Willing to talk about experiences of medicines 
adherence 
English speaking 
Prescribed medication for cardiovascular disease, 
chronic obstructive pulmonary disease, gout, diabetes 
mellitus or cancer 
Has capacity to give consent 
The pharmacies 
The study sample was recruited from community pharmacies across Teesside and screened 
against inclusion and exclusion criteria. In order to prevent coercion, colleagues in 
community pharmacies were briefed about approaching patients for inclusion in the study 
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and no financial incentives were offered either to patients to take part in the study or to 
community pharmacies to recruit patients. If the patient wanted to take part in the study 
they were given the means (a stamped addressed envelope) to contact the research team 
who would then be able to answer any questions the participant had or give them more 
information before arranging an interview with the participant.  Participants were 
identified by community pharmacists and their teams when (including but not limited to) 
collecting a prescription, buying medicines, receiving a clinical service such as smoking 
cessation, medicines use reviews, new medicines services, minor ailment schemes or to 
obtain healthcare advice. The community pharmacy teams were not made aware of their 
patients’ involvement in the study unless the patient told them themselves.  
Pharmacies in Teesside were contacted to discuss their willingness to recruit participants to 
the study prior to recruitment beginning. Pharmacies were contacted through the 
professional pharmacy body (Royal Pharmaceutical Society), Local Professional Network 
and stakeholder events as well as existing academic networks. Geographically the 
pharmacies involved were from different areas of Teesside, including Yarm, Stockton and 
Middlesbrough. Pharmacies were selected to include a range of deprivation indices, 
including particularly deprived and particularly affluent areas, which, it was hoped, would 
result in a broad range of experiences of adherence.  
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Figure 5. Community pharmacy participant identification centres 
 
Pharmacies were selected based on a sampling framework that ensured there was 
maximum participant variation in deprivation. This was done by mapping pharmacy 
postcodes to the Index of Multiple Deprivation (IMD) 2010 deprivation index (Department 
for Communities and Local Government, 2011) and selecting patient identification centres 
placed in the low, medium and high tertiles, although this did not guarantee that patients 
that use those pharmacies have similar deprivation levels. Pharmacies that agreed to take 
part were visited to discuss the study and the recruitment process and issue Participant 
Packs. The number of Participant Packs given to each pharmacy was discussed and agreed 
upon on an individual and continual basis to prevent pharmacies feeling pressured to issue 
the packs (i.e. one pharmacist was happy to receive 150 Participant Packs whilst another 
was only happy to receive 50). Seven-hundred-and-fifty Patient Packs were printed and 
issued across nine pharmacies for distribution to potential participants (based on a 
theoretical 7-10% response rate). The number of participants identified by pharmacists and 
given a pack was not recorded. The fate of prescription packs not given to patients was not 
recorded.  
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There was a perception from the School of Medicine, Pharmacy and Health Ethics Sub-
committee that not all patients with cancer would receive medication from community 
pharmacy and that this may have presented difficulties in recruitment. Initially a view was 
taken that this was incorrect and that many patients with active disease or who are in 
remission will still take chronic medication that would be collected from community 
pharmacies. Additionally, patients with some cancers receive oral chemotherapy or 
adjuvant therapy such as tamoxifen, from community pharmacies. This view was generated 
from reflecting on personal clinical experiences of community pharmacy. However, during 
the study it became apparent that patients with cancer were not being recruited by 
community pharmacies. This issue was discussed with a selection of the community 
pharmacists that were identifying patients for the study, who explained that when they 
approached patients to be involved in the study, many patients felt that their involvement 
was not appropriate, as they no longer ‘had cancer’. Whilst efforts were made to recruit 
through community pharmacy, ultimately patients with cancer had to be recruited through 
general practitioners.  
The general practices 
Four general practices from across Teesside were asked to identify participants for the 
study. General practice locations were complementary to the geographical locations of the 
community pharmacies and included additional areas from the surrounding Teesside area, 
such as Darlington. General practices were based in a range of deprivation areas (mapped 
to the IMD as for the pharmacies) however the majority of patients that were recruited 
through general practice were from areas of lower deprivation. General practitioners 
obtained patients’ consent to forward their contact details to the research team, who then 
systematically contacted patients for involvement in the study. The number of participants 
invited to the study by general practitioners was not recorded. General practitioners were 
identified from professional and academic networks.  
Data collection  
Demographic data was collected relating to participants’ age, gender, postcode and 
consequently deprivation index, occupation, disease state and co-morbidity.   
Interviews 
Semi-structured in-depth interviews were used to elucidate the patients’ lived experiences 
of medicines adherence to their prescribed medication, i.e. what they experience and how 
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they experience it.  Each interview lasted between 60 to 90 minutes. After each interview, 
reflection with the senior research team discussed what went well, what could have gone 
better, and what would be done differently next time. The team debriefed either face-to-
face or by email for the first 10-15 interviews and this practice was then reserved for 
interviews that had been particularly complex or difficult.   
During semi-structured interviews participants are typically asked a number of open-ended 
questions, rather than closed questions, which enables them to describe experiences in 
their own words. Participants were invited to bring along their medication to be used as 
prompts throughout the interview or used their medicines as part of the interview in their 
home, this often involved retrieving medicines from cupboards in the kitchen or upstairs. 
Semi-structured interviews enable the focus of the interview to be shared between the 
researcher and the participant, unlike structured or unstructured interviews where the 
researcher or participant has complete control, respectively. This method therefore also 
enables the participant to share information they wished to disclose, as well as enabling 
them to hold back information they do not wish to share, which may be of a sensitive 
nature and is their prerogative. The disadvantage of using this method is that occasionally 
interviews can be challenging for both researchers and participants, particularly if the 
subject matter is sensitive or if the interview is lengthy (Crotty, 1998, Creswell, 2007).  
Interviews were conducted actively, in so much that the researcher nodded, made noises 
of agreement and asked probing questions, rather than a passive interview whereby 
researchers say very little. Whilst active interview techniques potentiate the risk of bias, i.e. 
the researcher may give subtle indications as to what the participant should say, it enables 
the research encounter to reflect reality to an extent that participants share rich, detailed 
information as well as enabling the researcher to probe areas of interest or confusion 
(Holstein and Gubrium, 2004). In this study, conducting interviews in patients’ homes 
enabled informal observations to be made in relation to medicines-taking paraphernalia, 
artefacts and products. During the interview participants shared and demonstrated their 
experiences of adherence, which were illustrated, annotated and enriched by being in the 
place where they most often experienced medicines use.  
Location of the interviews  
Participants were always interviewed at a time and place convenient to them; this was 
most often their home however at the participants’ requests, two interviews were 
conducted at the university, four in coffee shops and one was conducted in a local library. 
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Locations for interviews were conducive to obtaining data, i.e. not too noisy, in a safe 
environment where the participant and the researcher felt comfortable. All of the 
interviews were recorded using an audio-recorder and transcribed verbatim by the 
interviewer within a week of the interview.  
Interview schedule 
The interview covered participants’ experiences throughout the duration of their treatment 
and participants were asked to describe if this has changed over the course of their 
treatment.  Interviews used probing questions to explore patients’ experiences of others in 
their experiences of taking medications; how involved they were with the decision to start 
and continue the medication or prescribing of the medicine; how they felt about the future 
in relation to taking medicines as they’re prescribed; what their positive experiences of 
taking their medicines as prescribed were and what the negative experiences of taking 
medicines they had encountered; how they experienced taking and not taking medication 
as prescribed and how important they felt it was to take their medicines as prescribed.  
Participants were not asked to provide a full medical history or give detailed medical 
information other than to describe their experiences at the start of their treatment as part 
of their diagnosis.   
The interview guide, shown in Appendix B, was explicitly vague to allow the interview to 
flow naturally and the essences of the patients’ experience to be discovered - a more 
detailed interview guide would limit the flexibility and adaptability of the interview to the 
individual participant. This interview schedule also enabled participants to co-direct the 
interview, establishing a power balance between the interviewer and the interviewee. 
Where a participant had comorbid disease, questions were asked about the role co-
morbidities played on the experiences of medicines adherence. 
In some interviews participants’ spouses contributed to the research encounter. When 
participants’ spouses contributed significantly to an interview and he or she met the 
inclusion criteria, he or she was consented and enrolled into the study as a participant (i.e. 
given an ID number). When participants’ spouses only contributed sparingly or he or she 
did not meet the inclusion criteria, verbal consent was taken for their contribution to be 
included in the study findings (rather than being enrolled into the study).  
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Focus groups  
Focus groups are an additional method used in this study. Focus groups provide valuable 
data collected in a group setting, enabling dynamic discourse between participants 
(Creswell, 2007, Crotty, 1998, Barbour, 2007). This method allows ideas to be formulated, 
discussed, and disputed by study participants and provided a method for collecting data 
relating to adherence interventions and to validate the interview findings (Bader et al., 
2016). During the research encounter, observations can be made of how participants 
interact with each other and inferences made relating to the topic of discussion. For 
example, if a participant said something very quietly, whilst looking at the floor it infers 
something different to if a participant said something loudly whilst making eye contact with 
other members of the focus group. The downside of focus groups is that whilst a significant 
amount of data can be collected some data is arguably lost as it can be difficult for 
researchers to observe all of the interaction, or notice subtleties in larger groups. 
Additionally, transcribing the audio-recordings of focus groups can result in data being lost 
as participants speak over one another. Whilst researchers can attempt to limit this by 
establishing ‘ground rules’, one of the rich sources of data from focus groups is the 
spontaneous contribution of participants as they react to one another.  
The use of the focus group method within phenomenological research requires critical 
reflection (Bradbury-Jones et al., 2009). As outlined above phenomenology is concerned 
with interpreting or describing experiences. Philosophically, as experience represents 
consciousness, phenomenological investigations have traditionally favoured research 
methods that elicit individual experiences. Some argue that focus groups contaminate 
individual experiences and are therefore incompatible with the theoretical foundations of 
the phenomenological approach (Bradbury-Jones et al., 2009). Despite this, some 
phenomenologists adopt the focus group method due to its suitability to answer the 
research question (Kooken et al., 2007a, Kooken et al., 2007b), to enable participants to 
expand on their experiences (Jasper, 1996) and to clarify, validate or triangulate findings 
(Côté-Arsenault and Morrison-Beedy, 2001, Spence, 2005, Carey, 1994). Indeed the focus 
group method has been argued to be congruent with descriptive phenomenological 
philosophy, in that the group environment facilitates the identification of individuals’ 
assumptions, as individuals within the group challenge each other (Halling et al., 1994, 
Halling and Leifer, 1991, Spielgelberg, 1975). 
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Focus groups were convened after the interview data had been analysed to enable the 
findings from the interviews to be validated by participants (Bader et al., 2016, Côté-
Arsenault and Morrison-Beedy, 2001) as well as to expand and explore additional aspects 
of the experience of medicines adherence (Jasper, 1996), particularly interventions used to 
improve medicines adherence. The data obtained related to views and opinions on the 
outcomes of the research; including the results of the thematic analysis and feedback from 
participants on potential solutions to improve adherence to medicines within the context 
of their disease state. Participants that had been interviewed were invited to attend a focus 
group however none were able to attend due to co-ordination difficulties, discussed below. 
As a result participants for the focus groups were recruited from community pharmacists, 
general practitioners as well as through local professional and academic networks.  Three 
focus groups were conducted with a total of sixteen participants, seven in the first focus 
group, six in the second focus group and three in the third focus group, who had a range of 
diseases. Postgraduate research associates from the Wolfson Research Institute of Health 
and Wellbeing helped facilitate the focus groups. On balance the focus group method 
enabled rich data to be collected that in this study triangulated the findings, provided 
interesting findings of their own and also highlighted areas for further investigation.  
Focus group schedule 
The focus group schedule can be found in Appendix B. The focus groups used a Powerpoint 
presentation to direct discussions – a copy of this can be seen in Appendix B.  The 
proceedings were audio-recorded and additional, informal and unstructured, field notes of 
notable participant responses or behaviours were made. The focus groups lasted 60-90 
minutes. Recordings were transcribed verbatim and circulated amongst the senior research 
team. Findings from the focus groups added context and validity to the interview findings 
as well as providing data of patients’ views of interventions to improve adherence. 
Participants in the focus group were not made aware of who participated in interviews and 
were in control of what they disclosed, in terms of disease states and which medicines they 
take. 
Location of the focus groups  
Focus groups were held at a time and place convenient to the participant, this was planned 
to be at the university or a public place local to the participants. The co-ordination of focus 
groups presented a difficulty in that finding suitable sites for focus groups to take place 
without financial implications and using sites that were accessible for participants was 
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challenging. Furthermore recruiting participants to be available at the same time and able 
to get to the same place also presented some challenges. After consultation with the 
participants focus groups were held at places most convenient to the majority of the group, 
this included two at the university and a community centre, for three consecutive weeks 
between October and November 2015.  
Other methods of qualitative research 
Other methods of qualitative data collection were considered but were not pursued as a 
method that was suitable as part of this inquiry. For example visual analysis and 
photography may have provided further insights. In this method participants are asked to 
take meaningful pictures of their experiences, which are then visually analysed to identify 
key parts of participants’ experiences. This method was not chosen as it was expected that 
participants would take photographs of their medicines that might expose confidential 
information. Additional costs would also have been incurred, as cameras would need to be 
given to participants to enable parity of opportunity for those that did not have access to a 
camera.  
Other methods include formal observations, were participants are covertly or overtly 
observed as they experience or go through a phenomenon. Researchers usually make 
detailed field notes that are analysed and can be synthesised with other forms of data. 
Formal observations were not used as this method was considered to be too intrusive to 
participants’ and researchers lives, particularly as some participants might be taking 
medicines up to three or four times per day over a 12-hour period, requiring significant 
contact time between the participant and researcher.  
The interview technique was also considered, as outlined above, active interviews were 
used rather passive non-interruptive interviews. In this latter technique, the researcher 
usually asks one question and allows the participant to talk for as long as possible without 
interruption or engagement from the researcher (Health Experiences Research Group 
University of Oxford, 2015). Researchers must not nod or make sounds of agreement that 
might encourage the participant to speak about something in an attempt to allow the data 
collected to be determined entirely by the participant. This technique was not chosen, as 
passive interviews can be particularly difficult for novice researchers and can often make 
participants feel slightly uncomfortable if there is not an established relationship between 
the participant and the researcher. Despite acknowledging that these methods were not 
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appropriate for this study, adopting these methods to explore aspects of medication 
adherence may be appropriate in other projects. 
The participants 
Forty-one in-depth semi-structured interviews were conducted, the majority of which were 
conducted in patients’ homes, at the University or in a public place. An additional sixteen 
participants were recruited to take part in three focus groups that were conducted at the 
university and at a local community centre to the majority of participants taking part in that 
focus group.  
Key demographic details of participants are outlined in Table 4. The table below shows that 
the majority of participants in the study were retired (n=33) and male (n=34). Participants 
came from a range of deprivation indexes and were between the ages of 42 and 92 years 
old, with the median age of 69 years old. Over a third of the interview participants had co-
morbid disease (n=32). Additionally, the third focus group included participants who were 
diagnosed with hypothyroidism and anxiety as well as one participant (P54) who did not 
wish to disclose her diagnosis. Whilst these three participants did not meet the inclusion 
criteria (‘prescribed medication for cardiovascular disease, chronic obstructive pulmonary 
disease, gout, diabetes mellitus or cancer’) and the study did not seek to recruit 
participants with these conditions, from an ethical perspective as the participants had 
attended the sessions after hearing about it from participants who were recruited via GPs 
or community pharmacists and wanted to take part, it was felt appropriate for them to be 
included, as these participants might provide alternative perspectives that would add 
depth to the study.  
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Table 3. Participant Demographic Data 
Participant 
Number Age Gender 
Level of 
Deprivation Occupation Disease Category Comorbid 
1 01 83 Male High Retired Gout No 
2 02 38 Male High Unemployed (ESA) Diabetes No 
3 03 77 Male Low Retired Diabetes No 
4 04 42 Male Low Police Officer Diabetes No 
5 05 71 Male Intermediate Local Government Gout Yes 
6 06 70 Male Low Retired Diabetes No 
7 07 72 Female Low Retired 
Cardiovascular 
Disease No 
8 08 92 Male Intermediate Retired 
Cardiovascular 
Disease Yes 
9 09 71 Male Low Sales Exec (PT) 
Cardiovascular 
Disease Yes 
10 10 77 Male Intermediate Retired Diabetes Yes 
11 11 69 Female Intermediate Retired  
Chronic Obstructive 
Pulmonary Disease Yes 
12 12 61 Male High Unemployed (DLA) 
Cardiovascular 
Disease Yes 
13 13 52 Male High Unemployed (DLA) 
Chronic Obstructive 
Pulmonary Disease No 
14 14 74 Male High Retired Diabetes Yes 
15 15 67 Male Intermediate Retired  Diabetes Yes 
16 16 77 Male Low Retired 
Cardiovascular 
Disease Yes 
17 17 80 Female High Retired 
Cardiovascular 
Disease Yes 
18 18 80 Male High Retired 
Chronic Obstructive 
Pulmonary Disease Yes 
19 19 63 Female High Retired 
Chronic Obstructive 
Pulmonary Disease Yes 
20 20 73 Female Low Retired Gout Yes 
21 21 81 Male Low Retired 
Cardiovascular 
Disease Yes 
22 22 51 Female Intermediate Catering Assistant Gout Yes 
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23 23 60 Female High Unemployed (ESA) 
Chronic Obstructive 
Pulmonary Disease Yes 
24 24 69 Female High Retired 
Chronic Obstructive 
Pulmonary Disease No 
25 25 70 Female High Retired 
Chronic Obstructive 
Pulmonary Disease Yes 
26 26 71 Male Low Business Owner Diabetes Yes 
27 27 63 Male Intermediate Retired Gout Yes 
28 28 70 Male Low Retired 
Cardiovascular 
Disease Yes 
29 29 67 Male Low Retired Diabetes Yes 
30 30 67 Male Intermediate Retired Gout Yes 
31 31 76 Female Low Retired 
Cardiovascular 
Disease Yes 
32 32 69 Male Low Retired 
Chronic Obstructive 
Pulmonary Disease Yes 
33 33 52 Male Low Unemployed (DLA) 
Chronic Obstructive 
Pulmonary Disease Yes 
34 34 55 Male Low Managerial Cancer No 
35 35 75 Male Low Engineer Cancer Yes 
36 36 65 Female High Retired Cancer No 
37 37 61 Male High Retired 
Cardiovascular 
Disease Yes 
38 38 67 Female Low Retired Cancer No 
39 39 57 Female Intermediate Nursing Assistant Cancer No 
40 40 70 Male Low Retired Cancer No 
41 41 61 Female 
Low 
Retired  Cancer No 
42 FG1P1 56 Female High Housewife Hypothyroidism No 
43 FG1P2 54 Female High Teaching Assistant 
Chronic Obstructive 
Pulmonary Disease 
Yes 
44 FG1P3 88 Male High Retired 
Cardiovascular 
Disease 
No 
45 FG1P4 61 Female High Cake Maker Diabetes Yes 
46 FG1P5 56 Male High Construction Manager 
Cardiovascular 
Disease 
No 
47 FG1P6 55 Female High Barmaid Diabetes Yes 
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48 FG1P7 78 Female High Retired 
Cardiovascular 
Disease 
No 
49 FG2P1 69 Male Low Retired Gout Yes 
50 FG2P2 79 Male Intermediate Retired 
Cardiovascular 
Disease 
No 
51 FG2P3 78 Female Intermediate Retired 
Cardiovascular 
Disease 
No 
52 FG2P4 53 Male High 
Employment Support 
Allowance 
Cancer Yes 
53 FG2P5 76 Female Low Retired 
Chronic Obstructive 
Pulmonary Disease 
No 
54 FG2P6 54 Female High Carer 
No Diagnosis 
Recorded 
NA 
55 FG3P1 60 Male Low 
Local Government 
Officer 
Gout No 
56 FG3P2 85 Male Low Retired Anxiety No 
57 FG3P3 74 Female Low Retired 
Cardiovascular 
Disease 
No 
 
A broad range of experiences were included in this study, adding depth to the data. What is 
noticeable for the age of participants is that the experiences of younger adults, aged less 
than 40 years old, may not be adequately represented within the study. Participants in this 
study were from white British backgrounds only. This was not intentional however does 
raise questions about the inclusion of black, Asian or minority ethnic (BAME) groups in 
research. Whilst a broad range of participants appeared to be included in the study, the 
experiences of younger adults and BAME participants may not be represented. 
 
Materials and equipment 
Interviews and focus groups were audio-recorded using a Phillips three-microphone Voice 
Tracer. Recordings were stored on the device securely until audio files were transferred to 
a secure computer at the Wolfson Building (latterly the Holliday Building), Queen’s Campus, 
Stockton-on-Tees, after which point they were deleted from the device – to minimise the 
risk of breaching confidentiality. Audio-recordings were transcribed verbatim in full, using a 
secure computer and anonymised using a standard anonimisation model - participant 
number, disease group, gender. Confidential material, including any paperwork that 
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participants had submitted as part of their enrolment into the study was stored securely, in 
a locked filing cabinet, in a locked office, at Queen’s Campus, Durham University.   
Transcription 
Transcription occurred within a week of an interview or focus group, with salient field 
notes and observations added to the transcripts to add depth to the data. Transcripts were 
quality checked, which involved listening back to the recording of the interview whilst 
checking the transcript for errors or omissions. A standardised anonimisation process was 
used which assigned each participant with a unique combination of letters and numbers 
signifying their disease classification and gender as well as their participant number. Where 
patients discussed matters that might reveal their identity or the identity of the pharmacist 
or general practitioner who invited them to the project, alternative names were used to 
maintain confidentiality. Conducting the interviews and focus groups, transcribing and 
quality checking the transcripts provided preliminary familiarity with the data as well as 
developing a new set of transcribing skills. 
Analysis 
The audio-recorded interviews and focus groups were transcribed verbatim. Thematic 
analysis explores the boundaries between opinions in the transcript to develop ‘nodes’ or 
‘codes’. Codes then form clusters of themes, which are synthesised to develop a structural 
and textural description of the phenomenon (Creswell, 2007). The stages of thematic 
analysis (Moustakas, 1994) that were used on the transcribed data are represented in the 
figure overleaf,  
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Figure 6. Stages of analysis 
The stages outlined above not only describe conventional thematic analysis, but can also be 
mapped to transcendental phenomenological analysis. Analysis was conducted manually 
using paper and pen and also using NVivo10 [QSR, Melbourne], data management 
software. Thematic analysis was initially conducted after each interview had been 
transcribed, immediately prior to the following interview. This method of inductive analysis 
allowed nodes and codes to be assigned freely after each interview. Specific interviews that 
proved more difficult to analyse were given a greater time allowance for fuller and deeper 
analysis. Whilst the NVivo software enables the analysis to be presented in multiple ways, 
for example using tables or coding reports, a more dynamic reflection of the process can be 
seen in the manual coding and clustering as shown in Appendix A. 
The analysis for this study reflects the methods described by Hibbert and colleagues (2002) 
’[we] used data from the focus groups and interviews to construct conceptual categories, 
which characterised major themes or issues. It was our intention that any generalised 
theoretical statements would be grounded in these thematic categories, which in turn were 
derived from the data. Although the analysis drew on the associated technique of constant 
comparison, a ‘grounded theory’ approach was not adopted’ (Glaser B and Strauss AL, 
1967). Codes were identified during an initial familiarisation with the data. These 
descriptive codes were used to identify what the participants discussed during the 
interview in very basic terms such as ‘the doctor’ or ‘the drug’. Initial coding also included 
how the data related to phenomenon, i.e. positively or negatively. Associations were made 
between codes that were similar using the imaginative variation technique outlined by 
Keen (1975) that uses reflection to identify, scrutinise and corroborate links between codes 
Stage 6: 
combine the 
structural and 
textural 
descriptions to 
produce a 
description of 
the essences 
of the 
experience
Stage 5: transform 
codes into 
relevant, 
understandable 
and descriptive 
language; 
reflecting to 
ensure the 
meaning of the 
code is not lost. 
Stage 4: cluster codes 
together to produce 
strands of common 
codes that appear in 
all of the transcripts; 
systematically 
interrogating and 
reflecting on the 
meaning (Moustakas, 
1994)
Stage 3: code 
the phrases 
inductively, 
clarifying the 
meaning by 
comparison to 
other codes 
and the whole 
data set
Stage 2: 
identify 
significant 
descriptive 
phrases 
Stage 1: 
familiarisation 
with the data 
by re-reading 
transcripts
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by examining the data. This developed the codes into thematic clusters such as ‘survival’ or 
‘necessity’, which were then grouped together, using a One Sheet of Paper Method (Health 
Experiences Research Group University of Oxford, 2015). This was followed by the 
development of more refined, but more general strata, such as ‘interaction’ and ‘identity’. 
Throughout the process was an awareness of many factors that may have influenced the 
analysis, such as the researchers’ gender (male), age (mid-twenties), ethnicity (white, 
British) and social history (from working to middle class) as well as professional status as a 
pharmacist (Rathbone and Jamie, 2016). That given, the analysis can be described (as was 
done by Hibbert and colleagues (2002)) ‘as a product of a process of construction between 
the respondents and the researchers, as not representing a single ‘truth’, but rather one 
possible story amongst many.’ It is in this spirit that the analysis was carried out, informed 
by transcendental phenomenological theory and well-established qualitative methods.  
Trustworthiness 
Trustworthiness in qualitative research can be argued to be made up of four principles; 
credibility, transferability, dependability and confirmability. These principles were 
embedded in the research methods and are outlined below. 
Credibility  
Credibility is concerned with assessing if the research actually explored what it set out to 
do. In qualitative research, methods that are well established such as what procedures and 
processes were followed during data collection and analysis, are considered to enhance the 
credibility of the findings (Shenton, 2004). Credibility was added to this study by following 
the analytical procedures of other studies, as referenced above, and generating questions 
to ask using approaches adopted from other phenomenological studies. Familiarity with 
participating organisations such as the community pharmacies and general practices was 
established through utilising the networks already well-known with the University as well 
as personal visits, telephone calls and email exchanges. However there was an awareness 
and prevention of over-familiarity with participating organisations that might have led to 
extraneous influences on sampling.  
The study did not use a random sample, often regarded as being the gold standard for 
objective data collection in biomedical health research such as in a clinical trial, but rather a 
purposive convenience sample was used. This weakens the credibility of the findings as 
arguably participants could have been sampled due to unaccounted for influences from the 
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research team on general practices and community pharmacies. A random sampling 
technique may have avoided these influences however it may have also resulted in 
sampling participants who did not want to discuss their experiences of adherence and non-
adherence, or identifying patients with such similar experiences that a breadth of 
experiences could not be collected. A purposive convenience sample allowed the research 
to proceed pragmatically. Multiple sites were used to identify patients, with sites based in 
differing deprivation index areas, to broaden the demographics of the sample – this adds to 
the credibility of the study as it enables a ‘more stable view of reality’ (Dervin, 1983) to be 
collected. Data was triangulated through multiple methods, of interview and focus groups 
(Bader et al., 2016). Finally, the credibility of the work is enhanced when it is compared to 
existing literature, as is done in Chapter 10.  
Transferability  
Transferability pertains to the generalizability of the findings to similar yet different 
settings and can be achieved through detailed reporting of the study site, setting, of the 
demographics of participants who took part, the number involved, data collection 
methods, the number and the time period over which the data was collected (Shenton, 
2004). It is difficult to consider where the research may be transferred to and consequently 
reporting in as much detail as possible the contextual details of a study can enhance 
trustworthiness. The details of this study are documented throughout including details 
such as the location of community pharmacies and general practices used to identify 
potential participants, the location interviews and focus groups took place and the 
materials and equipment used.  Reporting such detail enables the findings to sit 
contextually within the literature, rather than positioning the findings as ‘the true reality’, it 
allows the findings to be considered as a version of reality within the reported contextual 
limits. This enables a deep and rich understanding of a phenomenon to be achieved of 
which elements might be transferred to different groups. 
Dependability  
Dependability relates to how reliable the findings are – if another researcher conducted the 
same study, using the same procedural and organisational methods would a similar finding 
be uncovered? As noted by other qualitative researchers, this concept is difficult to address 
in sociological research (Shenton, 2004). Often research of this nature is highly 
contextualised and often theoretically framed to such an extent that findings are 
representations of a specific temporal and spatial reality that is dynamic and ever changing. 
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Often qualitative researchers, and particularly phenomenological researchers, are part of 
the research process. The researchers involvement in the interviews, focus groups and data 
analysis is accepted as inevitable as researchers form part of the constructed reality under 
investigation (Crotty, 1998, Creswell, 2007). It seems that the only way to infer 
dependability is to critically report the effectiveness of the methods of study, and the 
suitability of the methods to investigate the phenomenon under investigation (Shenton, 
2004) as presented above.   
Confirmability  
Objectivity in social sciences is said to come from sharing research with other researchers 
(Banton, 2005) however it can be argued that confirmability of study findings can be 
inferred from transparent procedures in the form of an audit trail or from recognising 
predisposed beliefs through a reflective commentary (Shenton, 2004). In this study, 
confirmability can be identified and demonstrated in the epoché, whereby previously held 
knowledge and beliefs are considered prior to data collection and analysis which 
demonstrates the reflective nature of the study. Confirmability could also be considered to 
fit with how the findings can be confirmed readily by reality, although this can be 
challenged. In this sense, confirmability for this study could be inferred by the reader who 
might think ‘is this experience reflective of my experience or the experience of someone I 
know?’ Objectivity then is constructed from multiple different readers seeing something in 
the findings that they might confirm based on their experiences of reality. The findings of 
this study are confirmed by the comparison of data sets from interviews and focus groups 
(Bader et al., 2016), as well as other literature.  
Summary 
This chapter has outlined that this study is underpinned by the conceptual framework of 
phenomenology, that a phenomenological methodology was the most suitably aligned with 
the research questions and described the materials and methods used. This chapter did not 
discuss the ethical considerations that were raised by the study, as these are covered in 
detail as an additional chapter in the Appendix C. The process of obtaining ethical approval 
for this study presented many challenges particularly in relation to the dual identity of 
being a pharmacist and being a researcher when investigating medicines use. Reflections of 
this process have since been published (Rathbone and Jamie, 2016), describing how 
pharmacists who adopt qualitative methods might straddle interdisciplinary boundaries 
through effective epistemological and methodological positioning. Whilst interdisciplinarity 
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has been achieved to combine social phenomenology with pharmacy in this study, further 
development of ethical frameworks might be explored to advance pharmacy education and 
research.  
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Chapter 4: Micro-social interaction 
This section describes the first theme that emerged during the analysis of the data. It is 
presented as sub-themes of personification, necessity, micro-social interaction and episodic 
short-term non-adherence. Micro-social interaction here refers to personal experiences 
between participants’ identities and medicines’ identities. Participants report the 
construction of medicines’ identities, that is to say that medicines appeared to become 
social entities in participants’ constructions of reality. Medicines were given identifiers that 
appeared to be not only based on the physical characteristics of the dosage form, but also 
on the subjective, felt and experienced, interaction with the medicine. Medicines were 
understood as being ‘for’ something, as ‘doing things’, having a constructed necessity, and 
this fed into the creation of medicines’ identities, positing medicines as social actors, 
performing a role within a two-way micro-social interaction.  Additionally patients 
described an understanding that within defined situations, medicines did not need to be 
taken. This chapter ends by discussing and interpreting the findings within the context of 
current psychology and social science theories, highlighting the novelty of the findings.  
Personification  
Throughout the analysis of the interview data a strong emergent message described what 
happened when participants experienced adherence. They often described adherence to 
their medicines as an interaction with something, a relationship with an abstract being or 
entity; often speaking about that being or entity as if it were a person that was 
simultaneously embodied by physical medications but also an abstract identity. In the same 
way people are identifiable by how they look, where they can be found, what they are 
called and what they do or how they behave, a similar phenomenon was demonstrated 
when participants spoke about their medicines. It was clear in the interview data that these 
identities were not predetermined, or given, that is to say medicines did not inherently 
have known qualities, but rather knowledge about a medicine was constructed over time, 
as participants reported becoming more familiar with their medicine in a process similar to 
getting to know a person or people.  
For clarity, this theme does not speak to the concept of personalisation, whereby 
medicines are used in such a way that reflects a specific relationship between a person and 
their medicine, though it does encompass this. Rather this theme speaks to the abstract 
attribution of qualities and characteristics to non-human objects, i.e. medicines, which then 
come to embody those qualities and concepts. 
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The data described a phenomenon where medicines were able to take on some person-like 
characteristics. These personified qualities of medicines, constructed the medicine as social 
actors within a patient-product relationship, is described below by Participant 4, 
“it’s a slower acting one, it’s just to, it’s just to, regulate your blood sugar through 
the night if you take a higher dosage but obviously the strength isn’t, the same the 
day-time. So on a night-time generally I take an injection of eighteen of whatever 
the measurement is but on a daytime I usually take up to about, with breakfast, 
maybe nine and that acts immediately you can feel it working straight away” P4, 
diabetes  
The personification of insulin is constructed around the patient’s understanding of what 
the medicine does, as he goes on to describe his insulin as ‘slower-acting’, that is the 
medicine is ‘acting’ in a particular way, ‘to regulate your blood sugar’. Insulin then becomes 
an abstract embodiment of regulation. The personification of insulin here identifies insulin 
as the regulator, performing an action and so being an actor. The focus on how medicines 
act, the function of a medicine was seen throughout the data, as shown below,  
“that’s either a sleeping tablet or a pain killer. I’ll go for pain killer. My doctor says I 
have a very jippy stomach and he can’t prescribe for me the tablets I should have, 
so instead of the one or two that would be better and have some reaction, they’re 
prescribed as a combination to try and fight the problem as it were. I mean I’ve 
been on them now for five, ten years in the main, but obviously not the ones to do 
with er…the…blood up and down and things like that” P10, diabetes  
This quote above describes the patient’s construction of ‘pseudo social norms’ around why 
medicines are used and the function of the medicine. In this quote, P10 describes his 
prescription being personalised to him due to his physical experiences of a ‘jippy stomach’. 
He identifies the medicines as either a sleeping tablet or a pain killer, suggesting that within 
the participants’ conceptualisation of medicines there are succinct categories. He goes on 
further to describe his medicines as ‘the blood up and down things’ and ‘to fight the 
problem’ – in all instances he describes his medicines as ‘doing things,’ as acting to ‘do’ 
something. He goes on to describe how he came to be taking that medicine, as a result of a 
‘jippy’ stomach and how his prescription had been personalised due to the action and 
behaviour of the medicine, the interaction between his jippy stomach and the way the 
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medicine acted. Thus adherence is experienced as a phenomenon of personalisation and 
personification.  
The construction of personified medicines’ identities was also seen in other disease groups, 
such as in participants with COPD. Here too participants personified their medicines, 
describing and naming them as part of their role within the patient-product interaction. 
Just as a baker bakes or a builder builds, medicines were personified in that they took on 
these person-like qualities of defined characteristics; a sleeping tablet makes your sleep. 
Medicines were identified with names that were specific to each product. For example in 
the quotes below, the patient describes her prednisolone, a steroid used for the treatment 
of exacerbations of COPD, as ‘prednisiline’. Another patient recalls one of their inhalers as 
the ‘brown inhaler’ but their other inhaler ‘Ventolin’. This demonstrates a difference in the 
relationship between the patient and each of their medicines as unique social objects, 
rather than of interactions unique to the dosage form of the medicine.  ‘Ventolin’ is a 
branded version of the drug salbutamol, which can be used to relieve breathlessness. It 
could be argued here then, that this participant’s interaction with her Ventolin was more 
frequent, due to her experiences of chronic breathlessness and Ventolin’s ability to relieve 
breathlessness. Consequently her familiarity with this medicine was greater, compared to 
her less frequent interaction with the ‘brown inhaler’ which the participant described acted 
as a preventer.  
Medicines appeared to be given individual habitats or ‘homes’ and this was often related to 
how that medicine was taken and even where the medicine came from or was purchased. 
Medicines were also personified in that they were given occupations or jobs, that is to say 
specific responsibilities within participants’ constructions of daily life. Participants grew to 
trust that medicines, as personified abstract identities rather than physical chemical 
objects, would ‘act’ in certain ways, to relieve symptoms, prevent symptom reoccurrence 
or maintain survival. Medicines were ‘for breathless’ or ‘for phlegm’ or ‘for pain’. In this 
respect medicines came to have an identity, which participants came to know and trust 
over time through interaction.  This is demonstrated in the quotes below. 
“well I get a chest infection and I know it’s really tight and I’m really coughing and 
I’ll be bringing phlegm up and then I’ll go to the doctors and get either antibiotics or 
steroids..er prednisinline [sic]” P25, chronic obstructive pulmonary disease 
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Here it is clear that each medicine appears to have its own identity. Within that identity 
was an understanding of what the medicine was called, where it should be kept and what 
the medicine did. In some instances participants reported an understanding that medicines 
were personified such that they could interact with each other, independent of the 
participant, that medicines could know one another, 
“It’s just me. I just hate taking loads of tablets. I just can’t see what one knows that 
the other ones doing when you’re pumping all these tablets down you.” P23, 
chronic obstructive pulmonary disease 
Judgements about the behaviour of medicines were made based on the physical 
appearances of the products, as in these quotes,  
“as soon as I went on the colchicine, they, they done the trick […]…but looking at 
the size of them, they don’t look big enough to do anything… one of the doctors 
said they’re excellent…only little wee things… but he said they’re excellent but not 
very kind to your stomach” P1, gout 
Medicines were also remembered from how they acted, rather than specific names, as 
outlined by this patient,  
“my tablets on a daily basis but you had campaigns, ten days, because it knocks the 
stuffing out of you like, and at the end of it you’re weak…[do you remember what it 
was called]… [sigh] you know… some things you block out of your mind to be 
honest, and it wasn’t amoxicillin…[…]… amoxicillin that’s a penicillin, but I can’t 
remember the name. It was ‘the drug that was good for bowel cancer that is the 
best thing our NHS can prescribe’ so I just took a handful of that” P34, cancer 
In this respect, across disease states medicines’ identities appeared to be constructed as 
named personified actors; doers, knowers, blockers, stoppers, and openers. These abstract 
identities also included where products were located in space; by the bread bin, in the 
drawer, in the cupboard. Medicines were located in time; in the morning, in the evening, at 
4pm, before the news, after my breakfast, as demonstrated in the quotes below,  
“I just take them first thing on the morning, go to, in the kitchen we have a 
cupboard and I would say people would call that the medicines cupboard, because 
it’s got my tablets in, in a box, just has, I don’t… I take the strip out and there are 
seven strips in that box, and I know I have to take them out and put them in the pot 
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beside me breakfast [sic] and I don’t have to, I just automatically go to the 
cupboard” P17, cardiovascular disease  
“I’m trying to think where it was you know… it wasn’t Boots… erm, was it 
Sainsbury’s I know I buy anti-inflammatories in Sainsbury’s… I’m just trying to think 
what shop it was yeah, it was the pharmacy area, yeah it’s the supermarket 
anyhow…[…]…I’m just trying to think where I was, I don’t think I was out of town, 
but yeah, I thought, you know… yeah, but it’s amazing that I don’t think people 
realise they [emphasis added] can effect, especially when you’re taking quite a few 
through the day” P11, chronic obstructive pulmonary disease 
“they’re in the kitchen by the bread bin, 
[P18 wife] They’re so he can see them when he’s making his breakfast 
They come in little boxes, and I’ve got them all in a plastic box, a morning box and a 
night… stay there and I’ll show you” P18, chronic obstructive pulmonary disease  
 In this sense, medicines became more than chemical compounds in dosage forms. 
Becoming the abstract embodiment of a constructed identity with the participant’s 
perception of reality. One of the key components of medicines’ personified identities was 
their capacity to improve, enable, and maintain survival. This focus positioned medicines, 
not only as independent, conceptual social actors within a patient-product relationship, but 
also within a broader pre-supposed social context, which is discussed in more detail in the 
section below.  
Necessity  
Within this milieu of personification there was an underlying presupposition of the 
experience of adherence as a tool of survival or symptom management. At the heart of the 
experience was an over-whelming desire to live or continue to live as the participant had 
done, without the influence of disruptive symptoms on daily life. For patients in this study, 
many described feeling that they had no choice but to ‘take medicines.’ Medicines use was 
constructed as a way to survive across all disease states. Adherence as a tool of survival is 
seen in this quote, which is a long extract, from the interview with a participant with 
diabetes. Here the participant describes his ‘personal’ philosophy related to adherence 
directly linking taking medicines to survival and also highlighting that whilst adherence for 
survival is appropriate, this is dependent on one’s social position – as someone with 
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dependants, a family, or children, and more general social norms concerning survival-
seeking behaviours. P26 rationalises adherence as a choice between ‘living a normal a life 
as possible’ and ‘wilting away’, ‘sitting down and waiting for their eyes to shut’. This locates 
‘survival’ outside of the binary, life or death conceptualisation, but rather positions survival 
within the sphere of adherence as the survival of the patient’s everyday life. This desire to 
survive then, describes the experience of medicines use as a social phenomenon of 
survival, 
“My own philosophy is we’re only here once yeah, I don’t want to live forever, I’m 
not one of these people who will just keep taking tablets and taking tablets 
whenever for whatever and live until 155, I think when my day of not being useful 
or not enjoying life come then that’s your term you know, so… I don’t know how you 
could encourage somebody, that has… whatever philosophy about not taking 
tablets…you have to get them with some type of message across to them to say, 
you have to do something for yourself, if you want to first of all have a healthier life, 
sometimes if you stop taking tablets and you’re out of breath and you’re not very 
active, obviously once you get to that stage, it breeds more inactivity, less this, less 
that, less the other and you just end up wilting away, and some people are happy to 
die like that, they just sit down and wait for their eyes to shut… for somebody that is 
of a reasonable age who doesn’t want to take tablets to help them have a normal a 
life as possible with the aid of tablet, I just don’t see any reason why they’re just not 
going to do it. They can’t like their-self… and they’re only thinking of themselves if 
they do do that especially if they’re of an age where people are dependent on you, 
like if you’re the husband and you’re married with a wife and kids and what have 
you, these people don’t deserve to be left on their own with me being selfish, which 
they are really” P26, diabetes 
Here adherence is described as an experience of heart and mind, a personal belief system 
or approach to life and medicines taking. Participants in other disease groups also 
appeared to identify adherence, and ‘medicines taking’ as a necessity for continued 
survival, demonstrating that despite disease group participants’ experience of adherence to 
medicines had some transcendental qualities,  
“no, no, it’s not a matter of getting fed up of them, it’s that if you want to live, 
you’ve got to take them…[…]…the box is there, I know it’s there and I know I have to 
    
 
Page 98 of 261  
take them, it’s either take them or die, simple as that isn’t it?!” P18, chronic 
obstructive pulmonary disease 
“if it wasn’t for that [medicines] I don’t think I would be here today, taking those,” 
P19, chronic obstructive pulmonary disease 
“I don’t think they give you these tablets unless you need them… and if you stop 
taking them then you’re putting your life back at risk, therefore if anything happens 
then you’re putting your life back in risk, it’s the individual person… it’s up to them, 
you can’t twist their arms and put it down their throats, I don’t think they would 
give you them if you didn’t need them” P7, cardiovascular disease 
In participants with gout, survival was not directly linked to adherence, however medicines 
taking for other conditions, was linked to survival and so medicines taking overall was 
considered a necessity, 
“Well it’s life or death isn’t it with me heart but you never hear of anybody dying of 
gout?”  P30, gout 
Despite a poor association of gout medicines with survival, P22 felt that even though she 
did not want to take medicines, due to her gout symptoms, she felt she had no choice,  
“I personally think it must be a positive thing because…you must need them… to 
have to take them, erm, and they’re helping you aren’t they, I feel, erm… would I 
prefer not having to take them… yes course I would but, you know…. [why would 
you prefer not to take them?] … because I’d rather not have to take medication if I 
didn’t have to, because who knows really what it’s doing, mmm? Yeah, who really 
knows what it’s doing, what’s it’s really doing, what it’s kicking off or whatever. You 
don’t know do you? Because everybody is different, so… if I had the choice, I would 
prefer not to have to take them but right now I don’t have that choice” P22, gout 
The necessity of adherence here then, rather than being intrinsically linked to survival, was 
more strongly linked to the relief of symptoms, and the ‘survival’ of the participant’s 
everyday life, embodying participants’ experiences of adherence as one of necessity. The 
necessity of adherence was internally negotiated as the patients’ desire to survive and 
maintain everyday life; how the product acted physically, to cause side effects or relieve 
symptoms; and how society (embodied as healthcare professionals, friends and family, the 
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media) acted in response to patients’ experiences of medicines use. This can be 
demonstrated below,  
 “no matter how much they tell you what is going on no-one can tell you what 
chemotherapy is like til you’ve had it, and it absolutely wiped me out. I couldn’t, I 
couldn’t believe that you could feel that dead, and just on a drug, it was an 
extraordinary feeling, it was, about six days after I’d started I was just lying on my 
bed… I didn’t care about anything, death would have been a perfectly reasonable 
option, I didn’t feel ill, urm, I just felt so weakened, so didn’t care, completely out of 
it, and I rang up, I’ve always had people I can ring up and I rang up this nurse and 
she had a word with the consultant and they said just stop taking the tablets and I 
did and within a few days I felt more like myself but of course the tablets were 
working with the infusion and erm, so I became aware after a little while I’d really 
done myself no favours at all as far as the cancer was concerned but I really did feel 
so awful at the time I couldn’t contemplate going on because you really have no 
idea how terrible you’re going to feel. I mean friends that have been there since I’ve 
tried to tell them this so that they’re more aware of it, and I did get a marginal 
reduction in the capecitabine for the rest of the, the other sessions and erm, I’m 
frankly not sure that helped at all but by then I knew what I was going to feel like so 
I was able to endure it better.” P41, cancer 
In this quote it is possible to delineate the participant’s negotiation between necessity of 
chemotherapy to treat cancer and potentially live longer; her experience of a negative 
relationship with her chemotherapeutic agent; and her experience of how society 
responded to her medicines use. Here her experience of side effects within a patient-
product relationship sits within a wider interaction with the rest of society, initially enacted 
through her friends, that constructed chemotherapy as a ‘side effect producing agent’ and, 
latterly enacted through healthcare professionals, that constructed chemotherapy as an 
agent whose actions could be limited by reducing the prescription. This episode of non-
adherence, is essential to her experience of adherence, when she re-identifies the 
chemotherapy, not just as something that makes her feel ‘dead’, but as an agent of 
survival, she says ‘I’d really done myself no favours’ and goes on to say that on her 
adherence to her next cycle, ‘by then I knew what I was going to feel like so I was able to 
endure it better,’ here the participant appears to be describing an experience of adherence 
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that is underpinned by a desire to survive, despite the experience of significant side effects, 
when the medicine has been identified as a necessity.  
The experience of ‘getting to know a medicine’, constructed a personified identity 
incorporating the products necessity into how it should be used, were described as being 
constructed through continued interaction with the product on very personal level. This is 
described in the next theme, as micro-social interaction.  
Micro-social interactions with the medicine 
This theme can best be demonstrated with patients’ description of their use of co-codamol. 
For this participant co-codamol was prescribed for pain, this is prescribed ‘two tablets four 
times a day’, however that the medicine was prescribed for pain, and through exposure to 
the medicine meant that this participant identified the medicine as for sleeping or relaxing, 
meaning that the participant used the medicine as a hypnotic each night, rather than as an 
analgesic when required.  The indication of co-codamol for pain is knowledge that is 
generated socially, from socialisation with prescribers, healthcare professionals, the media 
and, importantly, exposure to the product and experiences of the product relieving pain. 
However here the participant’s interaction with co-codamol, how it acted and made her 
feel, was internalised and constructed a belief that co-codamol was a hypnotic. As patients 
construct an understanding of what medicines are for and how the medicines do what they 
do, the medicine becomes a social entity that is interacted with. Adherence to the medicine 
is the manifestation of this social interaction between the patient doing something and the 
medicine doing something.  
 “No I haven’t been on tablets, all I take is three inhalers and two co-codamol isn’t 
there? I take them because… on a night it relaxes me,” P24, chronic obstructive 
pulmonary disease 
How products acted micro-socially to make patients feel in relation to their symptom 
control, immediately and over time, fed into the identity of the medicine,  
 “Yeah I think it was pain killers, I was probably started on hydrocodeine and I’ve 
been on them ever since, and I know if I don’t take them I feel pain in the side of me 
face, back of me neck, not on the same day, the following day” P10, diabetes 
with the experience of medicines use feeding into patients’ feelings towards specific 
products,  
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 “when I first went on them I didn’t always do it, I would admit , erm… maybe if I 
just felt me chest a bit tight then yeah, ‘oh I haven’t used me sprays’ you know… 
erm, but as time… over the last couple of years, erm, then yes, I’ve appreciated 
them much more than maybe I did at the beginning, you know, I do believe they 
help,” P25, chronic obstructive pulmonary disease 
Personified medicines’ identities then interacted with participants over time, enabling 
further more detailed contextual knowledge to be constructed relating to the medicine’s 
identity. Interactions with medicines over time appeared to generate feelings of familiarity, 
habit and ease, despite previously held beliefs about medicines. These interactions then, 
whilst still informing, constructing and reinforcing beliefs and knowledge about medicines’ 
identities and adherence as a mechanism of survival, were experienced as routine. These 
interactions are described as such in the quotes below,  
“ I don’t see it as a problem, I mean lots of people like routine anyway don’t they? If 
they get into it then you just do it” P5, gout 
Despite being socially-informed as in the quote above, participants were able to deviate, 
and create their own personal interaction with the medicine by repackaging it,  
“with reluctance it’s just habit forming. And er, what I do, I am a naughty boy, I 
know it’s a naughty boy, I have these trays and I have these trays and I put all the 
medication out for the week” P3, diabetes 
Experience of these micro-social interactions with the medicine helped patients construct 
ways of dealing with problems associated with medicines taking,  
“I’m fine now because I’ve been diabetic so long I don’t really come across those 
problems like that so much,” P4, diabetes 
Routine interactions were also informed by patients’ experiences outside of the sphere of 
medicines use, informed by interactions with family as in the quote below, 
“Well I think like anything, me being an engineer I was used to having procedures, 
you know, processes erm, now, when I first went onto them tablets, my wife, bless 
her, she carried me all me life, but she would sort of organise them and that and 
then, she wouldn’t actually organise them, she would just say have you had your 
tablet and I would say oh alright, I’ll have me tablet but no, I think you just get into 
the routine and then it become second nature to you to be truthful” P40, cancer 
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Micro-social habits between the patient and product were able to withstand the influence 
of constructed knowledge from outside the patient-product relationship, as demonstrated 
in the quote below,   
“well I take them at night because when I first got them it said take them at night, 
but then when I spoke to the pharmacist I said do I have to take them at night or 
can I take them all at the same time and he said yes you can if you want we just did 
that till you got used to taking them, but as I’d always taken them at that time of 
night I just carried on” P7, cardiovascular disease 
The habitual, routine nature to these interactions appeared to construct adherence as a 
‘given’ phenomenon, something that was ‘just done’,  
“I wouldn’t say you come resigned [sic] but you just come to taking the tablet.” P26, 
diabetes  
Over time, micro-social interactions between the patient and product were able to embed 
medicines taking as routine, despite dislike of medicines, 
“It doesn’t really bother me, I just take them you know, a habit, put it that way, a 
habit you just automatically take them and hope that they’re going to do their 
work, I can’t say that I’m that keen on taking them but you do” P20, gout 
Micro-social interactions also appeared to be focused around other aspects of everyday 
life, including getting up in the morning, preparing for sleep and eating,  
“now it’s just a part a routine thing now, erm, and in the morning and in the 
evening, before the evening meal I give myself a jab” P6, diabetes 
The interaction between social entities (the patient and the product) represents a pseudo-
socialisation, a micro-social interaction, where patients normalise and habituate adherence 
to their medicines so that their medicine fulfils its perceived necessity within the patient-
product relationship. Socialisation here then, reflects the interactions between the patient 
and the product, generating participants’ understanding that the medicine can be taken 
habitually, automatically and in a ‘given’ way to achieve an outcome and fulfil necessity. 
This is further demonstrated by P13, in his experience of adherence that socialised him into 
using the medicine in multiple ways for multiple purposes, demonstrated here in relation 
to his experience of adherence to amitriptyline,  
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“Now amitriptyline is not only for, it’s for mental illness, it’s a drug to stop panic 
attacks but they’ve found it can also be used to boost pain killer response, because I 
can’t have an aspirin-based tablet because, it supresses your breathing, which isn’t 
good, to when my breathing is suppressed I get lung infections but it also can calm 
you down, because obviously [I’ve] been ill for fifty two years it can, I have days 
where I just can’t cope… yes, I mean it depends on the pain, if I’m having a good 
day I only take one, and the sometimes me arm, I’m in horrendous pain, then it’s 
two, because it also helps with the pain in my leg which I get now, 
[Do you have to tell them-] 
No, no, me GP knows me well enough that I can more or less self-manage, I’ve been 
taking tablets since I was four or five, as long as I’ve been old enough to sallow a 
tablet I’ve been taking tablets’ 
[do you ever stop taking  the medicines on those days] 
Fortunately no, because I know it’s be worse for Jo [pseudonym of carer and wife], if 
I go into crisis, it’s bloody awful, it means paramedics, it means a trip to the 
hospital,” P13, chronic obstructive pulmonary disease 
This participant had had life-long respiratory disease including multiple diagnoses and 
consequently had experienced significant social interactions with healthcare professionals 
and medicinal products. In his quote above, he describes the multiple necessities of 
amitriptyline. P13 goes on to describe that his micro-social interaction with the product is 
informed by macro-social interaction, as the social outcome of non-adherence would have 
negative ramifications for him and his wife and carer, Jo’s, lives more broadly. It appears 
here then, that interactions between the patient and product, on a micro-social level, sit 
within broader macro-social interactions with wider society (this is discussed further in the 
next chapter).  
The quote also demonstrates the participant’s confidence to use the medicine based on the 
behaviour of the medicine itself in relation to managing his symptoms and ‘working’. The 
participant has ‘got to know’ that his interaction with amitriptyline can vary, the identity of 
the product includes that it continues to act in the same way, despite not being interacted 
with in the same way, i.e. the medication continues to work despite being taken. This 
phenomenon was seen in multiple patients and is described in detail below.   
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Knowing it’s okay to be non-adherent: episodic short-term non-adherence 
Participants described this phenomenon of short-term non-adherence with some of their 
medicines, where they might miss one or two doses or ‘a few days’ worth of medication 
and that ‘everything worked out okay’. Participants reported a set of their own principles 
or routinized non-adherence practices, relating to pre-determined plans of ‘what to do’ if a 
medicine was missed by a short time (for example an hour or so) compared with a longer 
time (half a day to a day). Participants also described not being able to go longer than a few 
days without their medicines. This seemed to be as a result of established beliefs of the 
necessity of adherence, in relation to survival, as outlined in the quote below, 
“oh yeah, but what I don’t do, I won’t take them if I’m missed them in the morning I 
won’t take them late on of an evening if I’m going to have to take them of a night-
time, because that, in effect, on some of them is doubling them up – if I’ve survived 
that long, I’ll survive another couple of hours [laughing]” P3, diabetes 
Reminder devices were not described as preventing missed doses in relation to the timing 
of doses, 
“I’ve got somebody round and we’re talking, the phone goes off and I think ‘oh 
tablets’ I’ll remember that but of course they’re there for another hour maybe, I’m 
still talking, and when they go I haven’t thought anymore about the tablets so the 
alarm is pointless [laughing] yeah, I do [not take them], I wouldn’t say I do it often, 
but I’ve certainly done it several times” P9, male, cardiovascular disease 
However patients described that beyond a few hours or a few days, non-adherence may 
become problematic,  
“[How would you feel if you’d ran out of tablets and you couldn’t borrow any, how 
would you feel?] 
If it was just for a day, I’d be all right, but if it is more than that, I think it would 
start to have an effect on me” P18, chronic obstructive pulmonary disease 
 “when I forgot to take it I thought ‘oh my God, I’ve forgotten to take me tablet, I’m 
going to get another lump, what’s it going to do’ [high pitched voice] yeah, all in 
the same day, I think it was, I’d realised in the afternoon that I hadn’t taken it, oh it 
wasn’t like it was a full day I don’t think. But yeah, I did panic a little bit and I don’t 
know why I should, but you know you think, is it going to make any difference if I 
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miss one? Well you know it’s not really, this was at the beginning, I think this was in 
probably the first year, I mean, and you do think every time you get a new 
symptom, or you find something that’s….wrong, that shouldn’t be there, you think 
‘oh my god, has it come back again’ but as time passes, you get to be a little bit 
more, ‘calm yourself down a little bit, missing one tablet isn’t going to make any 
difference’ [angry voice] [laughing] I did worry at the beginning you know, if it 
would have any effect on me if I did forget but I’d only forgotten for about six hours 
so really, you know, it’s a bit silly you know, looking back on it now you know, ‘get a 
grip’ [laughing]” P36, cancer 
Micro-social interaction then seemed to be constructed by the participant’s own 
understanding of how the medicine ‘worked’ and acted as part of the products perceived 
necessity. Participants behaved as the medicines they were taking needed them to behave, 
to fulfil a medicine’s perceived necessity. As participants personified their medicines they 
appeared to construct lay pharmacology, suggesting that medicines are able to interact 
with each other as well as the patient, which fed into an understanding of the ‘role’ of the 
medicine. This was built on knowledge generated from exposure to healthcare 
professionals and peer-patients; by family and friends; and from sources of information on 
the internet, television, printed press, and radio, whereby participants appeared to be 
socialised into adherence and construct an understanding of how the medicine worked and 
what the medicine was for, based on socialised knowledge generated over time,  
“once you’re on them, then that’s it… oh yeah well especially with the allopurinol, 
he said once you go on the medication, he said you need to take it all the time you 
can’t just switch and stop you’ll have to take it, I presume because that’s making 
you body work in a certain way, and that reduces the, this  acid” P5, gout 
This knowledge of how medicines worked, and notions of the body as ‘a system’, appeared 
to be generated from interactions with healthcare professionals. Where dissonance or 
disagreement occurred between knowledge from micro-social and macro-social 
interaction, non-adherence could occur. This was particularly apparent in P2, who was 
experiencing an episode of non-adherence during the interview. He had had an altercation 
with his specialist diabetes nurse who had ‘called him morbidly obese’ and discontinued a 
prescription of liraglutide and restarted a prescription of metformin. P2 had a history with 
metformin and suffered side effects without really perceiving any benefit from the 
treatment. When the specialist nurse prescribed this new regimen, P2 crumpled up the 
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prescription and threw it at the pharmacist. He explained during the interview that he had 
gone almost a week without using any of his medicines, including his anti-hypertensive and 
aspirin.  
“because I was told I had to take it… I was told that this was the medication that 
you need to take… so I thought well, because obviously I’ve never been on it 
before… obviously, my body is…. Getting used to it… or however it does… when you 
start taking medication I think… I’ve been told your body takes a while for it to get 
into your system… and start doing the job that it’s meant to actually do….[but then 
the Specialist Nurse said] Injections have stopped as of now. You no longer use 
them. It’s wasting everyone’s time. It’s not doing you any good. Stop them. I’m 
going to put you back on metformin … [so]…I’ve decided that my medication is 
stopped until [the GP] sorts it all out. I’m not taking any more basically. I’ve had 
enough. Every doctor…. Like… other doctors that I’ve spoken to, other professionals 
that I’ve spoken to… are all telling me that I should be on insulin 
and what do you know about insulin? 
I don’t… I don’t know nothing. They just say because of your levels and the way you 
are you need to be on insulin to help control it 
and this woman, 
was just like no, not at all and it’s because you’re morbidly obese, and that is why” 
P2 
Although P2 is describing non-adherence, this had thus far only lasted less than a week and 
was within a context that he had been told, ‘by other doctors and professionals’ that he 
should be on insulin rather than his current regimen of liraglutide. Prior to this the 
participant reported being adherent to his liraglutide, getting on with it ‘really well’ and 
‘just taking it’. The participant’s reaction then, and experience of non-adherence to 
liraglutide and other medicines, could be argued to be socialised, in that his behaviour is 
the result of interactions between different social actors – the specialist nurse, his GP, 
‘other professionals’ as well as micro-social interactions with the product, metformin and 
insulin (as a personified social entities). The specialist nurse appears to be acting out-of-
sync with other actors the participant is exposed to and interacts with, who say that he 
should be on insulin. The internalisation of this belief, his experiences of using medicines 
previously and his continued survival, his short-term non-adherence is normalised to an 
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extent. Unfortunately it was not possible to follow P2 up to explore his experiences of non-
adherence further however the normalisation of short-term non-adherence may be an area 
for future work. 
Episodic short-term non-adherence represents a negotiation between the constructed 
identity of a medicine including its pharmacology, its necessity and its action within a 
routinized, micro-social patient-product interaction    
Interpretation and discussion 
These findings describe patients’ experience of adherence as a phenomenon that is 
underpinned by the construction of medicines as social actors, based on their ability to 
improve physical symptoms, extend binary survival and maintain patients’ everyday life.  
These findings provide support to arguments that position adherence as a phenomenon of 
necessity (Horne and Weinman, 1999, Horne et al., 2013, Horne R et al., 2006 ). Presenting 
the construction of beliefs about medicines and necessity of adherence as an integral part 
of the experience of adherence across disease groups. This work offers a description of 
adherence as composite of a micro-social interaction, between the product and personified 
product identity.  This is represented in the figure below. 
    
 
 
Figure 7. Patient identity and product identity 
This perspective identifies that adherence represents a micro-social relationship and 
presents pharmaceutical products as more than their objective chemical properties. This 
work acknowledges the social nature of pharmaceutical products; describing patients’ lived 
experience of adherence, as a two-way relationship between social entities. The 
personified pharmaceutical product is able, in the patient’s mind, to influence and change 
the behaviour of the patient by relieving symptoms, causing side effects and maintaining 
survival, and equally in the patient’s mind, the patient is able to influence and change the 
behaviour of the personified product, through adherence and non-adherence. Patients’ 
lived experience of adherence then can be described as a form of socialisation, where one 
actor can influence and change the behaviour of another (Thomas and Evanston, 1967). 
Patient Product 
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Adherence posited as the performance of behaviour in a two-way relationship, presents a 
perspective of the phenomenon typified by medical sciences. That medicines act within 
medical sciences refers to pharmacological or physiological action, for example, ‘a beta-
agonist acts on beta-receptors’. This pharmacological knowledge, that within medical 
sciences is very specific to particular drugs and physiological functions, appears to be 
transposed into a representation of a social interaction within a patient-product 
relationship. It is possible to imagine how expert scientific beliefs concerning the 
pharmacological action of a drug might be transformed into lay representations, for 
example as expertise moves from the laboratory bench ‘a beta-agonist acts on beta-
receptors’, reaches the clinic as ‘a beta-blocker that acts on the heart’, is experienced in 
society as ‘the blue one that acts on my heart.’ As the product, and knowledge associated 
with product, moves into the pharmacological sphere and into patients’ homes and life-
worlds, it is transformed from an entity of pharmacological action to social action.  
That products obtain social identities echoes findings by Whyte et al. (2002), however the 
synthesis of this perspective with patients’ experiences of short-term non-adherence and 
how this goes towards the construction of the product’s social identity is a novel insight. 
This finding argues that episodes of short-term non-adherence mean that some products 
become ‘miss-able,’ that they are able to be missed, and that this becomes part of that 
product’s social identity. This represents the product behaving in response to the patient’s 
behaviour. When patients’ behaviour changes in the short-term, some products continue 
to behave normally, preventing symptoms and maintaining survival. This feeds into beliefs 
about the necessity of the product in that whilst adherence may be a necessity in the long-
term, short-term episodes of non-adherence can be negotiated within the patient-product 
relationship.  
Conclusion 
This chapter has argued that patients’ lived experiences of adherence are underpinned by 
the construction of medicines’ identities. Getting to know medicines through 
personification and assignation of personal characteristics to pharmaceutical agents 
constructs these products as social actors. Medicines enact behaviours that, through micro-
social interaction with the patient, construct the patient’s perceptions of necessity of 
adherence, as well as constructing beliefs and habitual medicines taking practices that 
includes episodes of short-term non-adherence.  
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That medicines use can be interpreted and described as a social interaction highlights the 
importance of understanding the adherence phenomenon from alternative perspectives, 
that might challenge normative theories of adherence that locate adherence as the 
outcome of modifiable and non-modifiable facilitators and barriers, to medicines use. 
Within this study, rather than adherence being conceptualised as a calculable, objective 
enactment of a patient behaviour, adherence can be conceptualised as a two-way 
experience, both constructed by and constructing patients’ perceptions of product identity, 
necessity and medicines taking practices. This alternative perspective provides a new lens 
to consider the adherence phenomenon.  
Presenting adherence as an experience of social interaction between the patient and the 
product provides opportunities for further analysis to elicit how patients experience this 
phenomenon. This chapter has argued that participants’ construction of personified 
product identities (including perceptions of necessity and when medicines can be missed) 
occurs through micro-social interaction. The next chapter argues that this micro-social 
interaction between product and patient takes place within a broader, macro-social 
interaction with wider society that feeds into the construction of both the product’s 
identity and the patient’s identity.  
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Chapter 5: Macro-social interaction  
This section describes how interaction with wider society constructed medicines taking 
practices across disease states. ‘Wider society’ here refers to normalised social beliefs, 
social norms and practices that are internalised and inform individual practices. These 
individual practices, in turn, inform social norms, reinforcing individual behaviours and 
societal beliefs. Analysis of data suggested that medicines taking practices, including 
adherence, non-adherence and the use of interventions, were informed by macro-social 
interactions, stratified here as interactions with lay beliefs and practices, including those of 
friends, family and peers; with expert opinion, including healthcare professionals and 
evidence-based medicine beliefs; and with the mass media, including newspapers, the 
television and the internet. Knowledge and opinions from each of these domains was 
described as informing patients’ medicines taking practices, within the context of patients’ 
experiences of micro-social interaction with the product.   
An important element of macro-social interaction was how this interaction constructed 
participants’ beliefs about medicines, particularly the necessity of medicines, and informed 
medicines taking practices as part of the patient’s identity. 
Interactions with friends, relatives and the media 
Knowledge about medicines’ identities and how medicines should be taken, stored, and 
interacted with were constructed through interaction with non-professionals and lay 
knowledge. Adherence as a socially normalised phenomenon appeared to be reinforced by 
social relationships. 
 “I do it for my own good, but it’s not only, I don’t think it’s only for your own good, 
you want to live as long as you can, you want to see your kids and your grandkids 
grow up and that’s what my aim is, it’s to see my grandkids grow up” P19, chronic 
obstructive pulmonary disease 
“I think if I didn’t have the boys maybe I would have given in and thought bugger 
this but because I’ve got so much, it’s worth taking the tablets and fighting for it” 
P23, chronic obstructive pulmonary disease 
Interactions with lay practices were also reported, as below. This participant describes how 
his mother-in-law used medicines,  
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“my mother-in-law she had to take pills every day and she had dementia, and when 
she realised, she must have realised, I mean she really was away with the fairies, 
when she realised, deep down, that she’d had enough, she was in a care home and 
her hand had seized up, she couldn’t straight it up, and when the carers weren’t 
watching she was spitting her drugs out and shoving them in her hand, and 
eventually, there were so many, they were poping out the other side and falling out 
you know! And erm, she’d basically had enough, she stopped eating, she stopped 
drinking and she basically said to my wife, she said ‘I’ve had enough, I’m fed up’ 
and she just, went.” P32, chronic obstructive pulmonary disease 
In this retelling, medicines non-adherence represents a loss of the will to survive in severe 
illness. Constructing adherence as practice of survival, here medicines taking practices were 
passed from mother-in-law to son-in-law. In this sense, knowledge about medicines was 
generated socially without effort, with knowledge constructed according to defined 
situations. Participants reporting adherence behaviours and practices based on the 
experiences of interactions with, and lay knowledge obtained from, others,  
“it’s just some ginger I’ve had, my daughter must have been reading, and it’s 
apparently, the ginger, it’s good for anyone with COPD and the cough, and I’ve 
been having it, just drinking, and honestly it does, yeah.” P11, chronic obstructive 
pulmonary disease 
Medicines taking practices were described as a learned behaviour, ‘inherited’ from parents, 
particularly in relation to the dislike of medicines taking, 
“I mean my mother doesn’t, she doesn’t take stuff unless she has to either, mmm, 
even me father he never took anything, you even had to force him to take his blood 
pressure medication I think, mm,” P19, chronic obstructive pulmonary disease 
Constructing knowledge and medicines taking practices from lay sources, such as the media 
and family and friends, was also apparent where medicines were not necessarily 
pharmaceutical in nature, but could be described as nutraceuticals,  
“my mam was reading the paper and there was this local chap, who had had bowel 
cancer who was terminal, now I don’t believe whether he is still alive, I don’t know, 
but he’s taking this concoction of stuff and I looked into it, and I thought bollocks, 
I’m going to buy that. And again, I take this set of tablets, most days, when I 
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remember, when I can put them in my tablet dispenser, I’ll bring them down. […] So 
that’s my little anti-cancer.” P34, cancer 
In P34’s case, his understanding of what his medicines were for appeared constructed from 
social interaction with his mother and the media. In this sense, the knowledge generated 
from these wider societal interactions and the interactions themselves appeared ‘given’, 
predicative, ‘just known meaning that adherence was ‘just done’, as shown below, first in 
relation to the spatial elements of adherence (i.e. where medication is taken) and then 
secondly in relation to learning about medicines,  
“No, I’ve always taken it upstairs, I think yeah, I did it the same when I was taking 
the HRT, I did that at the same time everyday as well, you know….I’ve never 
thought of [why], it’s just something, it just feels right, do you understand? it’s just, 
maybes, where we keep…..mind you I do know yes, my mum and dad used to keep 
theirs upstairs, maybe inherited, maybe, because me dad was on medication 
because he had chronic obstructive airways disease, and the only thing he kept 
downstairs was his inhaler, everything else was upstairs. Yeah. I’d never thought of 
that. Yeah. … my mother kept hers in her knickers-drawer [laughing]” P36, cancer 
“I don’t read the buff, but my son-in-law says ‘if you get some different symptoms it 
might be one of those,’ and I said ‘well I don’t want to know what the symptoms 
are,’ he said ‘yes but you should read the symptoms’” P17, cardiovascular  
Interaction with the media also led to personification of medicines, as well as generating 
ideas about how medicines should be taken and what should be done as part of medicines 
taking practices, as below,  
“I would probably read more on the Internet to try and find out more. It’s like when 
you get a new pet you want to know what’s best for them and what you should be 
doing, gathering information” P4, diabetes 
Interaction between the media and healthcare professionals constructed medicines taking 
practices for patients on an individual basis. In the quote below, the patient negotiated his 
expectations of prescribers (taking blood to dose medication) with lay knowledge printed in 
national newspapers,  
“I’d read an article either in the Observer or the Guardian saying there was this big 
debate thinking that a lot of people were on too much of a high dose and… the next 
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thing, I got a letter from the, the GP saying they were reassessing all the 
medications… and they reduced it by half. Now that does, I thought they haven’t 
taken any blood or anything…“ P5, gout 
The interpretation of interactions between two domains of wider society (embodied here 
as lay knowledge in the media and expert knowledge from the GP) constructs socially 
normalised ‘ways of using medicines’, in this case, contradicting the patient’s expectation 
to have a blood test before medicines were altered.  
Through these extracts, it is possible to describe how adherence is experienced; as a 
construction of given beliefs and cultural values internalised through social interaction with 
knowledge from wider society and contemporary culture. Knowledge constructed from 
interaction with others, indicates notions of ‘this is how you adhere’ within micro-social 
and macro-social spheres. It appeared that whilst some interactions with wider society 
were described as given, interactions with other elements of wider society, such as 
healthcare professionals (as an embodiment of accepted expert knowledge, government 
policies and ‘them’), also fed into how adherence was experienced. 
Interaction with healthcare professionals  
Exposure to expert knowledge was often reported as an interaction with healthcare 
professionals. Participants described learning from healthcare professionals, that medicines 
could be used in particular ways and were ‘a necessity’, as shown in the quote below, 
“It’s just another way… it’s either I’m taking less or more, just so that they can keep 
me… you know… I want to say fit and healthy but I’m hardly… you know… if they 
keep me going so to speak… if they say take it, I take it, if they say don’t then I 
don’t… it’s fair enough” P12, cardiovascular disease 
A long extract from a patient with diabetes demonstrates how interaction with healthcare 
professionals constructs medicines taking practices, that may reflect social practices, rather 
than objective reality,  
“they took me off a cholesterol tablet, because I was on two and they took me off 
one, don’t ask me what it was [Dr’s Name] was the one to ask for that, because he’s 
had a couple of heart attacks, er but nothing else erm, no there was a couple of 
years ago they said to go back onto the diabetic tablets, metformin. Erm, as well as 
the insulin, er, and I was put on… a thousand milligrams a day, in one dose, er, 
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which I was taking, and it was [Dr’s Name] who said, who the hell had put you on 
[that], I said hospital he said ‘I don’t think you should take a thousand in one dose’, 
I said ‘righteo I’ll do as you say [Dr’s Name]’, which is what I do, I take two on a 
morning and two in the afternoon, they’re suppose to lower the sugar level, I 
always remember [Dr’s Name] saying ‘they’re supposed to lower your sugar level 
but we’ll take that with a pinch of salt with you’, I’ve come to the conclusion there 
are no two diabetics alike, erm, I think the older you get, cause I’ve been diabetic 
now for thirty odd years, I’m lucky, I do know most of the time when my sugar level 
is getting dangerously low…[…]...and I was getting aerated and I sat down and I 
thought er, get the glucogel out, he [Participant’s Companion] said ‘come here I’ll 
take your blood’ it was two point four, he said ‘you had a good breakfast’ and I said 
‘its nothing to go by with me’ and it’s not (underlined as the participant shouted 
this part)” P15, diabetes 
In this quote from P15, it is clear that the participant’s experience of adherence to their 
medicine is fundamentally structured around interaction with his general practitioner, who 
was also a family friend. It appears that the participant constructs his own understanding of 
adherence in diabetes, that there are ‘norms’ which do not apply to him and as a result his 
medicines use is personalised to how he experiences symptoms of hypoglycaemia. He 
described the ‘cholesterol tablet’ and the ‘diabetic tablet, metformin’ as recognisably 
different entities, and goes on to describe his adherence to metformin. He explains that his 
GP, and friend, challenged the dose prescribed by the hospital prescriber, ‘a thousand 
milligrams in one dose’ and how he personalised the prescription to ‘two on a morning and 
two on an evening’. From a social science perspective, it is clear the prescription exists as 
an interaction between the prescriber, the patient and the product. From a healthcare 
professional perspective, particularly a pharmacist’s perspective, metformin is available as 
500mg and 850mg tablets, for the patient to take two on a morning and two on an 
afternoon, he would at least be taking the same dose as the hospital prescriber had initially 
prescribed. Additionally, in the transcript, a note was made that the participant was 
pointing to 500mg metformin tablets [extract in Appendix D]. This suggests the participant 
was taking the same amount of metformin, despite supposed prescription changes. Here 
the prescription of a medicine and the experience of adherence to that prescription 
appears socially constructed, rather than reflecting the objective reality of the prescription, 
as quantified doses of physical products. The participant describes ‘taking’ the same 
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amount of metformin as different because it had been prescribed by his general 
practitioner rather than the different hospital prescriber.  
Using this quote it is possible to describe the patient’s understanding of the necessity of a 
medicine as constructed during a social interaction with his general practitioner  – ‘these 
supposedly lower the sugar level’, but that his adherence was also formed from 
interactions with the product, with biometric measures and with his physical symptoms, 
such as when he describes needing to use glucogel when he felt his blood sugar was too 
low, which was confirmed with a biometric test. The patient’s experience of the symptoms 
of diabetes centred on his understanding of ‘what to do’ when he experienced these 
symptoms, which had been constructed from interaction with general practitioner and 
through his own previous experience of using the product and the product’s capacity and 
efficacy at relieving his symptoms and improving blood sugar biometrics. Additionally his 
companion also reinforced his behaviour by offering to measure his blood sugar levels. In 
essence then, the structure of this patient’s experience appeared to be informed by a set of 
rules of how to behave in a given situation, constructed from interaction with his 
healthcare professional, his companion, and the medicines themselves.  This was also 
demonstrated by P10 in relation to social rules, 
 “They say the target is, two to three, if you’re within that scale they’re happy” P10, 
diabetes 
Participants describe interaction with healthcare professionals that reinforces adherence 
through the acceptance of a belief system that identifies medicines as ‘needed’ within 
defined situations, such as being diagnosed with diabetes, prescribed treatments or having 
biometrics within defined scales. Beliefs about adherence also appeared to be constructed 
from social interaction, when P6 describes the ‘reaction’ of the chemist to the patient 
running out of medicines. The chemist is described as ‘going out of his way to help’ and 
latently suggests that non-adherence is something that is not acceptable or ‘okay’ in their 
view. In essence, the participant describes a social interaction that constructs adherence as 
essential, that ‘medicines shouldn’t be run out of’, they should be taken as prescribed. 
“I think the whole thing is all connected with the kind of, kind of stabling everything, 
which they’ve done, the treatment I’ve got, in fact I wrote a letter after the mini-
stroke last year to the head of the hospital to say how pleased I was with the 
treatment I got after the stroke, generally speaking the treatment I’ve got is second 
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to none, including the chemist fella, who goes out of his way to help, if you run out 
of something” P6, diabetes 
“I guess I just put my faith in him, I have questioned once or twice cause now it’s 
into like four or five years, prior to that even… I must confess I wasn’t a good pill 
taker, I mean if I got a course of fourteen day penicillin or whatever it was I 
probably lasted about three days and the same with everything else, I never, ever 
ran the course and I used to be a bit of a twerp” P9, cardiovascular disease 
Interactions with healthcare professionals seemed to alter P9’s beliefs towards adherence, 
describing himself as behaving like a ‘twerp’ in relation to previous episodes of non-
adherence after interactions with his healthcare professional that saw him question the 
need for adherence. The negativity associated with non-adherence here infers that 
adherence to prescribed medicines confers positive, desirable attributes; that non-
adherence is not desirable.  
Challenging macro-social beliefs  
Despite the construction of non-adherence as a negative phenomenon, continued macro-
social interaction generated medicines taking practices and beliefs that questioned 
intentions of healthcare professionals,   
 “there is an element that if people are trying to sell you their idea aren’t they? Like 
the doctor wants you to take it so that you don’t get ill and go back isn’t it, so they 
want you to take it and the chemists they want you to take it because that’s their 
money isn’t it? So they all want you to believe that they’re right and buy into what 
they believe, and I mean, although if you were in a car crash or whatever you’d 
want to go to A&E there is an element that you’re, you know, taking their idea 
about what’s right and wrong and coffee is bad and chocolate is bad but actually 
you know coffee is good and it’s even nicer with chocolate [laughing] and it’s the 
same with the pills they say this is good but actually until you take it you don’t 
know? And if the side effects are bad then you know it’s just their belief, it’s not 
always right for you is it” P39, cancer 
This enabled participants to construct their own medicines taking practices, negotiating 
their physical and micro-social interactions with the product with wider societal practices 
about medicines uses. In the quote below, a participant with diabetes describes that whilst 
society (embodied as expertise from the consultant) believes glycerol trinitrate is needed 
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to treat angina pain, for him, glycerol trinitrate acted to give him a headache, his own 
medicines taking practices (and adherence) then, represents a negotiation of macro and 
micro-social interaction.  
“I’ve got diabetes and because of that I don’t get angina pain the nerves have all 
gone wrong by the heart, so, I remember having a long discussion with the 
consultant about this and erm.. so.. if I get an angina attack I don’t have any pain, 
so why the hell should I want to give myself a splitting headache? Because that is 
exactly what it does it gives you a splitting headache” P3, diabetes 
These inferences were challenged when physical symptoms or measurements did not 
change, however that expert knowledge, enacted through healthcare professionals, 
positions medicines as ‘needed’. This constructs the medicine, and medicines generally, as 
needed in the patient’s mind, generating fear, and leading to modified micro-social 
interactions between the patient and pharmaceutical products,  
“all they keep saying to you when you don’t take them is well you know you’re at a 
high risk of having a stroke or a heart attack or, but are you? I mean my blood 
pressure according to them has been very high, for about six months now, and I’m 
still fine [laughing]  I still feel okay, so is it just a fallacy, am I taking all the pills for 
nothing… I think that’s why I take just the odd one, because as I say I am frightened 
it comes back and it’s an awful pain, so maybe if that works, maybe they all work” 
P20, gout 
In these quotes above, the construction of a medicine’s identity appears to be located 
around necessity. In P20’s case, despite her gout not being directly related to her survival, 
and her continued absence of symptoms reinforced her beliefs about the necessity of her 
gout medicine, and other medicines that had been prescribed for her. 
Whilst some participants described challenging interactions with healthcare professionals, 
some participants described interactions with policy as informing their medicines taking 
practicing.  
Interactions with wider society through policy  
Participants reported the construction of the necessity of adherence through the process of 
obtaining medicines (which is ultimately determined by policy), that medicines were only 
available from healthcare professionals in response to symptoms of illness, constructed 
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medicines as objects of necessity and medicines use as based on beliefs about necessity. 
Whilst there was an acknowledgment that the act of consuming medicines was an 
individual’s choice, the necessity of medicines was inferred from the act of supplying 
medicines by experts within society, embodied below as ‘them’, that society provides 
medicines in response to necessity, constructs necessity when medicines are provided,  
“I don’t think they give you these tablets unless you need them… and if you stop 
taking them then you’re putting your life back at risk, therefore if anything happens 
then you’re putting your life back in risk, it’s the individual person… it’s up to them, 
you can’t twist their arms and put it down their throats, I don’t think they would 
give you them if you didn’t need them” P7, cardiovascular disease 
That patients experience a physical symptom, seek care and are given medicine, 
symbolically imbues pharmaceuticals with necessity, a reason for being. The necessity of 
medicines was also constructed more explicitly, through discussion with healthcare 
professionals who are directed by policy to ensure patients understand the necessity of 
using their medication, described by P28.  
“I was talking to one or two of the nurses and one or two other people, they said 
when you’ve got a heart problem I think simvastatin actually is, is, is a must, or 
there is a good reason that you’d actually want them” P28, cardiovascular disease 
Further inferences were made regarding the necessity of the medicine on a macro-social 
level in that society supplies medicines, and that harmful products would be kept away 
from patients through policy, or the good intentions of healthcare professionals,  
“they must be doing some good, otherwise they wouldn’t give you them” P20, gout 
Across disease states policy that directs medicines to be supplied only to patients that are 
ill, constructed medicines-taking practices as a necessity for survival,  
“no it’s just because the doctor tells you to take them, I mean they don’t give you 
tablets for nothing, put it this way, why go and see somebody for them to say you 
are ill you must take these tablets, you must take them for the rest of your life and 
that’s what he’s told me I must take these tablets for the rest of me life he says if he 
don’t, say if I left them alone for a week, I’d be probably dead. Because otherwise, 
why’ve you got them.” P18, chronic obstructive pulmonary disease 
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Macro-social interactions and the patient’s identity 
Adherence and medicines use also reflected patients’ perceptions of themselves within 
society, this links back to earlier findings relating to adherence as desirable, and non-
adherence as not desirable. In the quote below, the participant describes herself as 
implicitly adherent, as a ‘normal’ member of society that follows social rules when supplied 
medicines,   
 “[If I had been prescribed a medicine before] I would have simply taken them 
because that’s what you do” P41, cancer 
This experience was reflected by participants across disease groups, echoing experiences of 
adherence as part-and-parcel of being part of society, of their identity within wider social 
groups (such as being old or ill), such as P17 who remarked about the widespread use of 
statins, 
“everybody takes simvastatin these days, when you’re my age [laughing] I don’t 
know a single person who doesn’t take it” P17, cardiovascular disease 
This reflection of wider social beliefs on participants’ own identities further infers that 
adherence represents a phenomenon of social interaction. Here P30 refers to people that 
use medicines regularly as ‘tablet people’, 
“P30: generally we’re not tablet people 
[Interviewer: What do you mean by that?] 
P30: No, well you know like, some people if they’ve got an headache you know 
straight away they take a tablet for an headache where as we would sort of put up 
with that, unless it was really severe, and then you’ve got to take them, but for a 
little niggle you wouldn’t just sort of take them willy-nilly, it’d have to be really…. 
Yeah, 
[Interviewer: So do you feel like you are a ‘tablet person’ now?] 
P30’s Wife: Well yes really, we are 
P30: We can’t do without them,  
P30’s Wife: I mean if we could do without them we would, 
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P30: We would by all means 
P30’s Wife: But if we don’t take them, then we’d die quicker” P30, gout 
In this quote it is possible to delineate the meanings that using medicines, and 
consequently adherence, can infer on a person within the context of wider society. An 
essential structure of the adherence experience then, appears to be linked to wider social 
interactions, which goes towards building participants’ perceptions of medicines and thus 
the experience of adherence. As in the previous chapter participants’ experiences of 
adherence was described as a micro-social interaction between the personified identity 
(encompassing its necessity and propensity to continue working despite non-adherence) of 
the product and the patient, here the experience of adherence can be described as a 
macro-social interaction between the patient and wider societal practices and beliefs about 
medicines.  
Interpretation and discussion 
This chapter has argued that adherence practices are constructed through interaction with 
wider society, enacted as lay knowledge embodied by friends, family, the media and the 
Internet and expert knowledge embodied by healthcare professionals and policy. This 
chapter builds on the previous chapter, which described patients’ experiences of 
adherence as a phenomenon of micro-social interaction between patients and personified 
products. A social perspective of adherence is pushed further by this chapter, as it 
highlights the wider social environment within which micro-social interactions between 
products and patients take place. This is represented more simply in Figure 9, overleaf. 
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Figure 8. Macro-social interaction between the patient and wider society 
Figure 9 simplifies the findings outlined in this chapter. In this figure it is possible to situate, 
more clearly, the habitual, micro-social interactions described in the previous chapter, 
within a macro-social interaction with wider society described in this chapter. Macro-social 
interaction here is constructed by and constructs medicines-taking norms, which feed into 
patients’ identities such as ‘tablet takers’ or ‘tablet people’. This figure does not seek to 
represent another model of adherence, but rather describes the experience of adherence 
outlined in this chapter and the previous chapter, as a phenomenon of interaction between 
patients and products, framed by interactions with wider society.  
Whilst this work speaks to sociological concepts of interactions, alternative sociological 
approaches may be used to interpret the findings, such as functionalism. Adopting a 
functionalist approach to adherence (Berger and Luckmann, 1966, Berger, 1963), a 
manifest function of adherence at a micro-level could be interpreted to be to treat 
symptoms of disease and maintain everyday life, more latently however, at the macro-
social level, adherence could be taken to be about fulfilling social norms within wider 
society, behaving like ‘a good patient’. In interviews participants described their 
experiences of macro-social adherence, as a given, i.e. it is what ‘people do’ as part of their 
Policy (embodying legislation, 
and licensing) 
Family and Friends (enacting 
lay knowledge) 
The Media (enacting lay 
knowledge through 
newspapers, social media, 
television and the Internet) 
Healthcare Professionals 
(embodying evidence-based, 
expert opinion)  
Patient Product 
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life within wider society, to fulfil social roles, to maintain their identity and integrity within 
society and reach normalised aims. This lens opens up further avenues of adherence 
research, as to how the phenomenon is situated through sociological, as oppose to 
biomedical, approaches (Mooney et al., 2007).  
The findings of this study align more closely to symbolic interactionism, a theory outlined 
by Thomas (Thomas and Thomas, 1928, Thomas and Evanston, 1967) that describes the 
importance of subjective perceptions of objects or concepts that ‘define situations’ and 
construct behaviour. The approach postulates that subjective perceptions are generated 
from interaction with others and that this leads to particular behaviours or actions. A prior 
example of this within pharmacy might be the placebo effect, as a product is prescribed 
and supplied, other people (as embodiments of society) are acting as if the product will do 
something, will act in a particular way or perform certain behaviour. This constructs 
perceptions that the product will act, despite scientific evidence arguing the contrary. 
Symbolic interactionism argues that perceptions, beliefs and meanings are constructed 
from social interaction.  
As patients interact with multiple actors within society, embodied as friends and family, 
healthcare professionals or social media, their beliefs and perceptions about medicines are 
constructed, generating personified product identities – adding subjective value and 
meaning as per Thomas’s theorem. Where the findings of this study vary from the theory is 
when personified products are transformed into social actors, and begin to define 
situations when medication is needed and not, as outlined above as episodic short-term 
non-adherence. The findings realign with the theory as interactions with wider society also 
feed into patients’ beliefs about when medication is needed and not needed. These 
interactions feed into patients’ beliefs about their identity, described as ‘self-concept’, 
gradually constructing a personal, internal set of beliefs, practices or philosophy that 
frames their experience of adherence within the context of wider society and how others 
might see them. That the findings of this study can be located with the theory of symbolic 
interactionism represents a novel description of how patients experience adherence.   
One of the strengths of symbolic interactionism is that it provides insights into micro-social 
interactions, which can be explained as functions of subjective beliefs, explaining why 
objective situations can be interpreted and defined differently by different people. Equally 
this theory enables micro-social interactions to be considered within the context of wider 
social norms and wider social meanings that might be attached to particular behaviours or 
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objects. However, this theory does not necessarily account for the broader policy 
influences that were reported by patients, which are embodied by legislation (at least in 
this country) that governs the accessibility and availability of medicines. This suggests 
additional work may be needed to explore the role of policy and the construction of wider 
societal medicines taking practices.  A draw back of the application of this theory may be 
the intrinsically subjective nature of the construction of meaning, which may prevent 
quantification of patient interpretations and personification of their medicines, thereby, 
potentially limiting the ability to test the theory using more conventional biomedical 
approaches.   
Conclusion 
This chapter has outlined findings that described how patients experience adherence. 
Highlighting the importance of interactions with lay knowledge, enacted through friends, 
family, the television, the Internet and the media, and expert knowledge, enacted through 
healthcare professionals, policy and legislation.  
That medicines use was described as constructed through interaction with wider society 
locates the adherence phenomenon within a social sphere. The adoption of a sociological 
lens lends itself well to exploring the adherence phenomenon a new, enabling a novel 
description to be made and insights gained into patients’ experiences of medicines use. 
Understanding the adherence phenomenon from this novel perspective provides a 
structure for further work, which will locate patients’ perspectives of current adherence 
interventions within patients’ experiences of adherence, forming new directions for 
intervention development, as outline in the next chapter.  
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Chapter 6: Interactions with interventions  
This project used focus groups to collect data on participants’ perspectives of adherence 
interventions. This data was used to validate the findings outlined in previous chapters as 
well as concentrate more directly on interventions within patients’ experiences of 
medicines adherence. Focus groups were carried out in accordance with the schedule in 
Appendix B. Outlining different adherence interventions that appeared in the interview 
data and in the literature focused the discussion, with participants given an opportunity to 
describe any additional adherence interventions they were aware of. In the focus groups, 
participants described their experiences of interactions with a range of different adherence 
interventions.  The analysis of this data is outlined below.  
Interactions with interventions  
Throughout the focus groups, participants described interventions as objects of necessity. 
Participants often described interventions as ‘not being needed, just yet.’ For example, in 
relation to reminder devices, participants appeared to conceptualise these devices as being 
reserved for the elderly or the more seriously sick. This seemed to posit reminder devices 
as objects of necessity, in a similar way to the medicines themselves. Within this theme, 
interventions were often described negatively across all three focus groups, 
“Facilitator: You mentioned that you worry how old people would get them out, do 
you associate adherence devices with older people?  
P5: that’s who they’re made for yeah  
P4: age yeah” Focus Group 1 
There appeared to be a link between intervention use and cognitive deterioration 
associated with old age,  
“P3: I think we at the moment, we’re reasonably compus mentus, I think it’s the 
ones that are starting with the Alzheimer’s that really do need assistance on that 
kind of thing, and some of the things you’ve raised there about reminder alarms 
and that sort of thing, I think may be useful for a portion but I don’t need that quite 
yet, perhaps as I go on I may” Focus Group 2 
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This constructed the need for an intervention as being undesirable, detached from 
‘appropriate’ medicines taking practices,  
“P3: no. I’ve set them up for other patients but no I’m not too bothered about 
meself, I’ve got a perfectly good packet that tells you what to do, if you write it in 
red on it then you’ll remember [P2: laughing] if you start forgetting taking things 
then you seriously are off  
P2: [laughing]” Focus Group 3 
The quote below refers to a reminder device, GlowCap, that reminds patients about their 
medication through audio-visual cues,  
“P2: it’s [Glowcap] good if you’re struggling to remind [sic], all the time, if you’re 
getting old and you do need reminded it would be good for that I think 
P6: not for me 
P5: I wouldn’t use them 
P2: when you’re older” Focus Group 1 
Interventions seemed to be something that was inevitable with increasing use of 
medicines, something that all of the participants were working towards, eventually, 
needing some sort of support to adhere to their medication,  
“P1: that’s not necessary I only take one tablet a day. I can see the sense of it, my 
mother used to, she had hundreds erm, she eventually graduated to one of those 
and as she started losing her memory as well it was really, canny useful but it just 
seems eminently sensible and logical to me, but it’s just not necessary for me at the 
moment” Focus Group 3 
The appropriateness of interventions appeared to be intrinsically linked to society’s 
conceptualisation of adherence and ‘ways of taking medicines’, with more technological 
interventions, such as electronic reminder devices and silicone chips, considered more 
appropriate for the ‘tech-savvy next generation’, 
“P1: but really in about fifty years time, that watch thing will work, because the 
people that are coming up with that technology now will live by it and those of us 
that didn’t live by it prefer human interaction and these kind of things, so maybe for 
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the future but it’s some time off for me, until I want to rely on that I would still 
rather do it on bits of paper even though I have a computer and a telephone” Focus 
Group 3 
This quote highlights the social nature of adherence and adherence interventions to wider 
society within contemporary cultural practices. What appears to be clear from these 
findings is a conceptualisation that adherence interventions are for someone else; either 
the elderly, the very sick, those on patients multiple medicines, or the next generation of 
technophiles, an indication that adherence interventions are products and services for not 
just someone else, but anyone else. This suggests that interventions are representations of 
failure with these ideas, seemingly, constructed from social interaction with others that 
had used these interventions. 
“P2: yes I can visualise a time when I might, possibly, want it but certainly not now 
P3: well you’ve got this far you wont need one” Focus Group 3 
In this sense, interventions were not described as different between participants with 
different illnesses, but rather participants seemed to describe interventions as having social 
capital, as representations of negative necessity, of an inability to use medicines as they 
should be used. As with the medicinal products themselves, the necessity of using an 
intervention appeared to be constructed of beliefs associated with survival,  
“P2: no, no, no, nope, I’ve got a little thing up there, Monday, Tuesday, Wednesday, 
Thursday I use and it’s just part of my life now and the main aim of the goal is to 
keep this side of the grass [laughing] if you know what I mean. The other side is 
worse [laughing]” Focus Group 2 
Participants also described their experiences with specific interventions. These experiences 
are grouped thematically and described below.  
Educational Interventions, including patient information leaflets 
Participants often reported educational interventions positively; although the patient 
information leaflet was often spoke about negatively. Educational interventions that were 
discussed included services delivered by pharmacists, doctors and nurses as well as 
‘reading up about the medicine’.  
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“P7: oh you mean when you go and sit with the chemist? Yeah we get called in for 
that all the time, now and again 
P3: yeah he wants to know what I’m taking and how I’m taking it, what for 
Facilitator: what was that like? Did it make you use them as they were prescribed 
more? 
P7: oh no, he was just checking up on us to make sure we take them” Focus Group 1 
More simplified information was sought, particularly about what the medication was for 
and how it should be taken. A particular example of this was during interactions with 
healthcare professionals or medicines information that directed participants to use 
medicines in particular ways,  
“P2: can I go back to the grapefruit thing because it does say on the thing, do not 
take this medication with grapefruit, now I could read that in two different ways 
like don’t take your tablets with grapefruit juice at breakfast but you could take 
your tablets at night when you’re not having your grapefruit or does it mean you 
must eliminate grapefruit from your diet full stop?  
P3: well our pharmacist said any fruit juice really 
 P2: yes, well he said swallow it with water  
P3: for that particular medication anyway  
P2: yeah, and of course a lot of pain killers, don’t drink alcohol and does that mean 
at all, or just to wash it down, but I would imagine you wouldn’t drink it to wash it 
down with but is it not at all so in the morning you took your pain killers and then 
you can’t have a drink in the evening. Well I just took it that I’m not having alcohol 
at all and I said this to him, a retired surgeon friend, he said ‘are you having a 
drink?’ and I said ‘no I’m on these pills and I mustn’t drink alcohol’ and he said, ‘oh’ 
he said ‘ditch the pills’ [laughing]” Focus Group 2 
This was also related to biometric measurements that had been shared by physicians, 
whereby one participant related their experience of forgetting to take metformin on an 
evening resulted in a ‘high measurement’ from her doctor, which prompted her to take her 
medication more regularly. 
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“P6: well I did, and I’ll tell you why for why [sic], I wasn’t taking the two on a night, I 
kept forgetting to take me two metformin on a night and when I went for my check 
up it was high, I don’t know what was high, but it was high, and I thought ‘it’s 
because I haven’t been taking it on a night’ since then I have been taking it properly 
like” Focus Group 1 
Participants also discussed using multi-compartment compliance aids as an interaction with 
their medicines that was aimed at improving adherence.   
Multi-compartment compliance aids, including pillboxes 
One of the key findings in relation to MCCAs was that different participants described or 
named them in different ways (none of which included MCCAs). Participants used a range 
of labels for these interventions, including ‘dosette boxes’, ‘medipacks’, ‘packets’, 
‘NOMADS’, ‘trays’, even ‘one of those Monday, Tuesday, Wednesday, Friday, things’. A 
participant that used an MCCA without knowing how to name it demonstrates this 
phenomenon in the quote below,  
 “P7: you can have a packet can’t you  
P1: yeah a medipack  
P7: oh is that what they call it 
P3: everybody should use them containers, with the erm Monday to Friday thing 
on” 
 Focus Group 1 
MCCAs were described as generally positive, both in relation to accessing medicines by 
preventing issues with ‘popping’ medication out of manufacturer-supplied packaging and 
confirming if medication had been taken.  
“P1: yeah. And like for old people on the back it’s quite difficult to snap them, you 
know  
P7: yeah it can be quite difficult  
P6: aspirin are the worst  
P1: well I think, for our mam, how the hell would she manage with that  
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P7: my husband sometimes struggles with that  
P1: when you’re trying to pop them out” Focus Group 1 
This quote demonstrates perceived difficulty of opening some medication and the use of 
MCCAs by older people. This quote also demonstrates that these difficulties associated 
with packaging feed into patients’ beliefs about the medicines identity, here P6 states 
‘aspirin is the worst’, which was reiterated by a different participant in a different focus 
group. Part of the constructed identity of aspirin then appears to include difficulty in 
opening the product. Repackaging products into MCCAs did not always resolve difficulties 
opening medicines; 
“P3: could I just make a point about getting the pills out of the little trays, I’ve got 
one at the moment which is really, really difficult. It’s got very thick plastic on one 
side and aluminium I think on the other side but I have real trouble getting one 
particular one out  
P2: yup yup  
P4: particularly aspirin for me” Focus Group 2 
Participants also referred to medicines’ identities further, in relation to the medication’s 
ability to be re-packaged. Participants raised concerns about the integrity of the dosage 
forms when medication was stored outside of its manufacturer-supplied packaging, 
recalling information from pharmacists and patient information leaflets that described 
medicines ‘breaking down’ if not stored in the original container. One participant related 
this to ‘a packaging system’, which was ‘conditioning the tablet’ – this was most often 
recalled by participants that had chosen not to use an MCCA.  
“P1: well what one of the pharmacists said to me before was, how do you know, if 
you’re opening your tablets prior to that, do they have the same effect because 
you’ve took them out of the blister,  
P4: oh right  
P1: yeah because they’ve been opened  
P5: like if it’s dissolvable? Any damp bits would get in it and a bit might fall off  
P4: oh right, I get it  
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P2: so does that happen to the other tablets? It might weaken them” Focus Group 1 
Here it is possible to see how the repackaging of products feeds in to the construction of 
medicines’ identities, as products become known to be able to be repackaged or not as 
patients ‘get to know’ the medicine through interaction not only with the medicine, but 
with wider society, embodied above as the pharmacist.  
In relation to how patients interacted with medicines micro-socially, these devices, rather 
than reminding patients to use medicines in the present, appeared to be more beneficial as 
reminders that medicines had been taken retrospectively.  
“P2: [..] I take three things, erm, but none of them for anything very serious but it 
has become part routine, I have two of them on the breakfast table, and I have one 
of those boxes with the days of the week, I would certainly forget what one had 
been taken if I hadn’t…[Facilitator: what made you start using one?] P2: well simply 
the difficulty of remembering to take them and knowing whether I’d taken them or 
not. I mean none of them are sort of, life threatening, or life preserving particularly 
but erm, erm… they’re actually for erm, that particular one is an anticoagulant, 
prophylactic, in case I were to get a clot, but er, yeah” Focus Group 3 
Re-packaging medicines was not considered helpful when non-adherence was due to 
changes in routine that involved leaving the house, this was often related to devices that 
were large or cumbersome, and could not be transported easily or were medication 
needed to be administered by a third party (such as a carer at a day centre) at a later time, 
“P2: yes and the other problem with adherence is if the patient goes to a day 
centre, so many days a week. The day centre are supposed to administer the 
medication, perhaps at lunch time, but the patient comes with a pill, in a little bag, 
haven’t a clue what they are, or who they’re for and it’s really confusing. I mean it’s 
alright, like he says, if you’re at home. But when you’re out of the house, it’s just a 
nightmare.” Focus Group 2 
Some devices could be broken down, to enable smaller compartments to be taken with 
patient as part of their daily routines, however this did not appear to facilitate better 
adherence.  
“P3: well I’ve found them very helpful, I couldn’t have managed without one, about 
twice a week I fill them up although actually it seems to come round about every 
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other day and that’s the way I’m measuring the passage of time. But yes it shows, 
there you can take an individual cell out and pop it in the pocket and get away with 
taking it if you’re going out for a meal or out for the day, often again, I couldn’t 
take that enormous great box out there so yes they’re very helpful but there again 
there are times when I’ve still got this rattle-y old pill in the cell in the lunchtime so 
it’s not infallible.” Focus Group 2 
Participants reported filling MCCAs positively, as an interaction that generated familiarity 
with supply levels,   
“P1: […] about once a week she does her counting out and if she finds that she is 
running out of a particular tablet she then knows to re-order it  
P2: that’s right  
P6: yes that is the benefit of them” Focus Group 2 
Medication reminder charts were considered to be ‘just like the’ MCCA and charts that 
required participants to tick or sign to indicate medicines had been taken were described 
as ‘too much of a faff’. Outlined by one participant below, 
“P5: and think oh I’m not going all the way there to tick that, that’ll be why you 
don’t do it, I mean I think these things are all alright and it’s easy enough to do 
them we could sit down here and do them all alright but that’s not life, in life you’re 
all over the place and you need something that will fit in with that” Focus Group 2  
Reminder Devices 
Reminder devices were overwhelmingly associated with ‘being old, ‘Alzheimer’s Disease’ 
and being on serious medication. Participants described these devices negatively, as 
something that they did not want to use or have to use.  
“P2: it’s good if you’re struggling to remind, all the time, if you’re getting old and 
you do need reminded it would be good for that I think” Focus Group 1 
“P1: I’d need to think about it, and as I say, where I am at the moment I don’t need 
it, if I got into a position where I would need it but at the minute I’ve got a lot of 
alarms coming out of my ears with this thing [mobile phone], my radio alarm and 
er, house alarm, burglar alarm and smoke alarm – I’ve got too many alarms going 
off and I can just imagine something like that, if it was just left, if my alarm were by 
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the side of the bed, and I’d left it there, I wouldn’t want to carry it around with me, 
and I wouldn’t necessarily hear it, so I’m not convinced unless you’re housebound or 
something, urm, at the moment I certainly wouldn’t need them, at all  
P2: I would agree with all of that I think  
P3: well I would no, I will rely on my brain otherwise I’m going to get Alzheimer’s 
even more quickly” Focus Group 3 
These devices were considered only useful for people that stayed at home, as an 
embodiment of a micro-social interaction between the patient and the product. One 
participant highlighted what would happen if a reminder device sounded, but someone did 
not have their medication with them and the anxiety this would produce.  
“P3: you’d have to have it with you all the time for when it goes off wouldn’t you? 
P5: it’s a good idea but it’s a waste of money cause it’s not going to help you take 
them 
[…] 
P3: so you get it, and it’s been set up for you by the chemist, you’re down the town 
and it goes off  
P6: what’re you gonna do, you haven’t got your tablets with you?  
P5: oh shit I’d never thought of that” Focus Group 1 
Two participants in separate focus groups expressed views that poor memory, which would 
make these devices necessary, might lead to users of these devices not being able to 
remember what they were being reminded about,  
“P1: this flashing thing is just, you know, if you’re starting to lose you memory that 
you’ve taken stuff then you’ll just be thinking what the hell is it flashing for all the 
time  
P3: yes that’s right 
 P1: so I think, my personal, I’ve got a start position that I don’t actually need it 
anyway at the moment so as, exactly as you’ve said P3 in the future, who knows 
where I am going to be, but the point is we’re trying to get very, very scientific and 
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controlled and I actually don’t like that control, I like support, I don’t like control and 
that’s what that is  
P2: well I use the timer in the kitchen when I’m cooking and I often can’t remember, 
when it goes off I have to think what it is that’s why I set it [laughing] [laughing]  
P1: that’s exactly  
P3: it adds to the fun of old age [laughing]” Focus Group 3 
Participants also reported concerns about becoming dependant on reminder technologies 
and what happens should the technology fail. Others highlighted concerns about airport 
scanners or other devices might cause interference with reminder devices, incorporating a 
macro-social element of everyday interaction on intervention use.  
“P1: two things concern me are what happens when it fails, when you come 
completely dependant on it, I mean I’ve been struggling for the last ten days 
without my laptop and having to log in through other and the number of things I’ve 
got set up to make things easy and it, it’s nearly driven me round the bend trying to 
find stuff on other systems and secondly, anything electronic you don’t always 
realise you’ve made a mistake and if you’ve had to do any setting up yourself, and if 
you don’t understand it, and you’re living on your own, in other words you haven’t 
got your grandchildren round to help you, erm, who is going to hold your hand to 
take you through it? Erm, now that might be relatively straightforward to set up, 
but I still wouldn’t like to rely on it completely. On the other hand, if I were, maybe 
in a few years time, maybe I would be getting forgetful more times than that would 
work” Focus Group 2 
All three focus groups remarked on the expectedly high cost associated with these devices, 
although conspicuous by its absence was who would pay for these devices (the participants 
themselves, the healthcare services or someone else).  
“P3: how much do they cost a piece? 
 P2: [laughing] 
[…] 
P5: it sounds alright but it would drive them mad [laughing]  
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P3: well it’s like those iWatches isn’t it it’ll cost a fortune ” Focus Group 2  
Another intervention that was mentioned briefly, and tied into using reminder devices, was 
collecting information about ‘how adherent’ a participant had been, to highlight to the 
participant their own medication-taking behaviours, which they might not be consciously 
aware of. This was described as being particularly beneficial to highlight cases of over-use, 
which would prompt participants to review their medication use. 
“P5: so I suppose it would show you how much you’ve taken like 80% or less or 
whatever as well as read your pulse  
P1: and probably your blood pressure and everything  
P4: he wants one! Do you think knowing how much you’d taken will make you take 
it properly though? 
 P3: well if it should you were misusing them, like taking too many  
P7: yeah then you would think oh I’ll have to stop” Focus Group 1 
Mobile phone applications were also discussed however participants in all focus groups 
described elements of technophobia, suggesting that some, more complex technological 
interventions may be best suited for particular groups of people who are interested in 
‘gadgets’ or the next generation. This draws on the notion that the patient’s identity (as a 
technophobe or technophile) might frame experiences of interventions. 
“P3: there are apps for your phone aren’t they, I take it this is something just a stop 
clock  
P4: well my son did it, we’re not able to do that kind of thing  
P6: we’re technophobic” Focus Group 2  
Participants described concerns about complicated reminder devices needing to be ‘set up’ 
by a pharmacist, a doctor or a carer, with some highlighting their own experiences of their 
children setting up alarms on their mobile phones.  
“P4: my son has now put an alarm on my phone, but the alarm goes off and 
depending where I am I might not have them with me, or I might just turn the alarm 
off and carry on doing what I’m doing” Focus Group 2 
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This quote describes a macro-social interaction, the reminder that the reminder was ‘set-
up’ by an external actor, that then itself goes on to enact the micro-social interaction 
between the patient and their product.  
Peer-Support and Media 
This theme relates to when participants described discussing adherence with others, 
through a peer-support mechanism or via media, including social media. These experiences 
describe macro-social interaction that structured the experience of adherence. For 
example one participant was reminded to take his medication on an evening through the 
theme tune for the 10 O’clock News followed immediately by a phone call from his wife.  
“P5: I take mine at ten o'clock most nights and I use the ten o'clock news bongs, 
bong, bong, bong [background laughing] then me phone starts ringing and I take 
me drink a water, answer the phone ‘hia, I’ve took me tablets’” Focus Group 1 
Another participant imagined notices in newspapers that might prompt readers to take 
medication, tapping into the routine nature with which they themselves read the 
newspaper. Other participants discussed interaction with others, typically a spouse, that 
acted as a reminder and one participant described the huge impact of living alone on all 
routine daily activities,   
“P5: but you’ve also got your wife to remind you, when you’re on your own, it’s 
vastly different and quite honestly until you experience being on your own, nobody 
knows  
P3: oh yes yes, she’s very good that’s right  
P5: I find a lot of things very difficult now because I’m on my own, you can’t rely on 
anything, but yourself” Focus Group 2 
Interactions with others was discussed in all of the focus groups, with one participant 
remarking that discussing ways of taking medication with her friends would be a good way 
to learn about medicines if she could play bingo at the same time, other participants 
suggested discussing medicines use with friends and family was something they already 
did, whilst another participant suggested that discussions might take place on social media 
platforms, 
“P4: I’d only do that if you could play bingo at the same time [laughing]  
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P3: it sounds like group therapy that  
P7: oh I’d be there 
 P2: well you talk about it at the bingo don’t you  
P4: they do, cause they take the same stuff don’t they  
P5: some people are proud of what they take  
P7: aye, so and so  
P2: I think you’re talking about me?  
P5: no not you just some people are very happy to talk about it, put it on Facebook 
and stuff asking for any extras or offering them away  
Facilitator: Do you use Facebook, Twitter or other social media to talk about 
medicines?  
P2: no cause I don’t want people to know what I take 
 P3: I think it’s dangerous  
P4: but you only talk to family about it  
P7: oh no I’ve got friends who I talk to” Focus Group 1 
Whilst some participants felt discussing medicines use with peers was acceptable, some 
participants were not as engaged with this idea, describing it as dangerous and not wanting 
other people to know what medicines they took. These views reflect the differences in 
medicines taking practices that were adopted by participants, on the one hand that 
medicines use was something to be discussed and on the other that medicines use should 
not be discussed with peers. These differences could be interpreted to represent the 
subjective nature of the construction of beliefs, values and practices through social 
interaction that might pre-predicatively construct taboos. Negative views associated with 
lay knowledge appeared to stem from a lack of credibility and trust of that knowledge, with 
some participants concerned about other people in the session that might think they know 
more than they actually do,  
“P3: if you don’t select the right people in the group you’re not going to get the 
right people in the group are you? You always get the one or two people who can 
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tell you more than you know and that goes for these online forums, how many 
people do you know that try and be a doctor by reading what they read on the 
forums? On Facebook?  
P2: online  
P7: they say a little knowledge is dangerous don’t they  
P3: you know what I mean?  
P4: people were looking online and 
P2: prescribing themselves of how to take the drug  
P7: well yeah you see people doing that because of what they’ve read in the 
newspapers as well, I think it’s dangerous really” Focus Group 1  
Participants also discussed how social media can been used to share medicines illicitly, 
potentially feeding into participants’ negative beliefs about social media and medicines. 
One participant reported that whilst he believed his medicines taking practices should not 
be discussed with others, he went on to describe how he offered advice about medicines 
use to others,  
“P1: oh I don’t think so, the only time I have ever discussed my tablets is coming 
here today, what it’s of nobody else’s business bar mine [laughing] and it’s not a 
kind of topic of conversation that I would like to have – although saying that 
occasionally I have said to people that have said they’ve got gout that I take 
allopurinol and that it’s worked well and then somebody else has said, oh you know 
I’ve been into the diagnoses game not that I’m anywhere near a pharmacist or 
doctors or anything, but if they say they’re suffering with this then I say oh bloody 
hell check with this because it might be gout, and this thing cleared it up for me” 
Focus Group 3 
This suggests that the participant had an idea that ‘medicines talk’ should be restricted to 
healthcare professionals and patients, however in reality ‘medicines talk’ was something he 
himself engaged in with colleagues at work. It is possible to interpret from this extract, that 
P1 through ‘medicines talk’ was constructing the social identity of allopurinol, as the pill 
that ‘worked well’ for gout, as part of an interaction with wider colleagues.  
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Indeed increased interaction with others about medicines was also suggested as a way to 
improve adherence, 
“P4: maybe we should start asking people as a greeting, instead of saying ‘good 
morning, how are you’ we should just say ‘hello, have you taken your tablets’ 
[laughing]  
ALL: [laughing]  
P2: ‘what’s the weather like, have you taken your tablets?’  
P4: that’s right, that’s right” Focus Group 2 
This data suggests that interventions that involved wider interaction with society may be a 
way to normalise medicines use, as well as normalise self-monitoring of medicines use. 
Discussion concerning overuse of medicines tied into wider discussions about reducing the 
amount of medicines prescribed and taken. This led to discussions of an idealised poly pill.   
Poly pill 
The poly pill or methods that included combining multiple dosage forms into one 
composite were discussed favourably in all of the focus groups.  
“P4: I think what they should be working on is a device that amalgamates all your 
tablets, were they grind them up and put them all together in one thing,” Focus 
Group 2  
Participants described taking just one pill per day as ‘beneficial’ and ‘convenient’, resolving 
many of their issues with adherence.  
“P3: well I would go with that a poly pill  
P4: where they make your own individual pill? Yeah  
P2: yeah I could do with that I think 
P3: that would be ideal  
P7: then you’d know what you’ve took cause it would all be in just one  
P1: that would be ideal  
P2: then you wouldn’t look like a druggy when you’re taking them all  
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P5: but depending how many you’re on it would be the size of an orange wouldn’t it  
P4: they’d be able to make it smaller though surely  
P5: but that would be expensive  
P3: but probably less expensive than not taking it and having a heart attack  
P1: I think a lot of people would prefer that“ Focus Group 1 
Changes to the characteristics of the medicine, i.e. its size, were described as a concern, 
with articipants often supposing to have each of their medications in it, it would need to be 
quite large. Some participants described the poly pill with concern, highlighting the 
significant cost and limited flexibility in prescribing that would be associated with using 
such an intervention.  
“P2: I think that’s much, much easier, much better but whether it can be done or 
not is, but I suppose pharmacies could do that, because they’re chemists as well 
aren’t they  
P7: but then what if you wanted to change it halfway through? Or stop taking one 
but not the other?  
P5: well they’d just make it again wouldn’t they, but you’d have to prove that it 
worked wouldn’t you?  
P2: well no but then it’s which one doesn’t agree with you, you wouldn’t know” 
Focus Group 1  
In these extracts participants describe the poly pill as an accumulation of different 
medicines’ identities, ‘which one doesn’t agree with you’. One participant argued that the 
poly pill would have to be shown to ‘work’, with another participant highlighting her 
modified-release medicines and another highlighting how nasal sprays and eye drops, 
might not be able to go into a poly pill. Other participants highlighted that non-adherence 
would be limited if medicines were supplied in one composite dosage form,  
“P5: you said your omeprazole, you’re meant to take two but you take one  
P4: yeah  
P5: well if it was made like this  
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P4: well I’d just take it then wouldn’t I because it wouldn’t be any option?” Focus 
Group 1 
Other participants raised apprehensions about how their decisions about which medicines 
to take may be compromised, describing a process of moving onto a poly pill following 
agreement with prescribers, 
“P3: well I’m just looking on the list up their, metformin, aspirin, statin and an ace 
inhibitor… well what happens if you don’t want to take one of them? 
Facilitator: Good point  
P2: scrape it off  
P3: well when patients used to say to me that they’re taking too many pills, I say to 
them well the only person who puts the pills in your mouth is yourself. You’re the 
only one person that does it, you can refuse it if you don’t want, like I refuse to take 
statins  
P1: well yeah but if the three or four are agreed and you want to debate one then 
keep that one separate for the time being. It’s so much more sensible to me, to 
have one rather than three or six or what have you, and if there is one you don’t 
want to take then just have it taken off” 
Whilst the poly pill was spoken about with much less intensity, it represents an 
intervention that may change the product’s identity as well as the micro-social interaction 
between the product and the patient. Inferences can be made about the impact this might 
have on patients’ identities, as active decision makers or passive accepters of prescriptions, 
in terms of their choices about what and how medicines are taken. 
Discussion and interpretation 
These findings describe participants’ perspectives of interventions as variable and dynamic. 
Whilst there is depth in the descriptive quotes that offer insights into each group of 
interventions, a key finding here is that interventions are conceptualised as objects of 
necessity. As other chapters described patients’ experiences of constructing personified 
medicines’ identities through micro and macro-social interaction, constructing personified 
medicines’ identities, these findings support previous chapters and suggest that adherence 
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interventions are also imbued with social meaning, representing interactions between 
products, patients and wider society.   
Interventions to support adherence were imbued with meaning, becoming objects that 
represent an interaction between the patient and society, in a similar way to the 
construction of beliefs about necessity of medicines use (Horne and Weinman, 1999, Horne 
et al., 2013, Horne R et al., 2006 , Thomas and Evanston, 1967). That interventions are 
reserved for the very elderly or the very sick could be interpreted to position adherence to 
medicines as a behaviour that is desirable, that ‘should‘ be able to be performed as a norm 
within wider society, feeding into earlier findings that adherence represents a 
phenomenon of social interaction. Equally, associations between being elderly and being 
very sick and polypharmacy might enable these perspectives of interventions to be 
interpreted as part-and-parcel of graduated medicines use, i.e. as patients get older, more 
medicines are needed and so adherence interventions are needed. These findings enable 
adherence interventions to be identified as embodiments of interaction, constituting part 
of constructed medicines’ identities or more directly as objects or practices that represent 
interaction between the product and the patient.  
Interventions were described as being part of the micro-social interaction between the 
patient and the product, becoming part of a product’s identity in the form of changes to 
packaging or dosage forms, as for the poly pill. Interventions in the form of reminder 
devices represented micro-social interactions between the patient and the product. In 
essence these interventions were micro-social interactions that framed how patients and 
products interacted with each other to establish routine medicines taking.   
These findings also support previous chapters that described patients’ experiences of 
adherence as one of social interaction with wider society. This perspective enables 
educational interventions to be presented as a representation of an interaction between 
the patient and wider society, enacted by healthcare professionals who deliver these 
interventions. The delivery of educational interventions creates an interaction between the 
patient and expert knowledge supporting a perspective of adherence as a phenomenon of 
interaction with wider society.  The data also highlights a small number of interactions with 
wider society embodied as peer support and the media. Whilst these experiences were 
reported less than changes to product packaging and reminder devices, they suggest that 
medicines use is contextualised to norms and beliefs established by interactions with 
others.  
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The location of interventions within a description of adherence underpinned by social 
interaction is represented in Figure 10 below. A diagrammatic interpretation demonstrates 
how different interventions embody interactions between the patient, the product and 
wider society. Interventions that repackage products were described most often by 
participants and are represented by the largest circle in the figure. These interventions 
construct the product identity, changing the medicine’s location, physical appearance as 
well as constructing patient knowledge about where it can be stored. Reminder devices 
were also discussed frequently by participants and embody interactions directly between 
the product and patient. Educational interventions represent the third most described 
intervention and can be located as interactions between the patient and expert knowledge 
from healthcare professionals. Finally a small number of interventions were described as 
peer-support and the media represented by the smallest circles in the figure, embodying 
both interactions with family, friends and the media. 
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Figure 9. Adherence interventions within a novel perspective of adherence 
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These findings demonstrate that the majority of interventions occupy interactions between 
the patient and the product, with smaller proportions of interventions representing 
interaction with wider society. This highlights an area for future intervention development 
that might seek to expand the number of interventions that embody interactions with lay 
knowledge enacted through friends, family, and the media. Whilst these findings enable 
current interventions to be located within a novel description of adherence, they also 
highlight directions of future intervention development.  
Conclusion 
This chapter has validated a novel description of adherence that presents medicines use as 
a phenomenon of micro- and macro-social interaction. This has enabled current 
interventions to be conceptually located; demonstrate that reminder devices and 
repackaging products, in MCCAs and pillboxes, represent the most well established ‘type’ 
of adherence intervention, thereby locating the majority of current interventions within a 
micro-social sphere of interaction between the product and the patient. This highlights 
novel directions for future intervention development, which might be established to 
embody, enact or exploit the wider social interaction that encapsulates patients’ 
experiences of medicines use. Finally further work is needed to establish if this perspective 
can be generalised to broader populations. 
Chapter 9 seeks to further synthesise and interpret these findings within the context of 
pharmacy practice, adherence research, and intervention development.  
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Chapter 7: Synthesis and interpretation 
This study set out to describe patients’ lived experiences of medicines adherence across a 
range of diseases, including cardiovascular disease, diabetes mellitus, gout and chronic 
obstructive pulmonary disease. Understanding lived experiences has contextualised 
patients’ perspectives of interventions, identifying areas for future intervention 
development. This chapter discuses each of the research questions outlined in the 
introduction, summarising the findings in relation to the research questions and locating 
the findings within the context of other research.   
What are the lived experiences of medicines adherence in adults taking 
medication in different disease states? 
This thesis describes patients’ lived experiences of adherence as a phenomenon of social 
interaction in a number of different disease states. Previous chapters have outlined that 
participants in this study experienced adherence as a relationship of necessity within a 
constructed medicines or product identity. This was experienced through micro-social and 
macro-social interaction. Participants’ perspectives to interventions were described in 
detail to a number of different intervention types, identifying that adherence interventions 
were conceptualised by participants as objects of necessity, imbued with social meaning. 
By synthesising and interpreting these findings it is possible to delineate novel directions 
for intervention development and ensure patients’ experiences of medicines adherence 
and perspectives of interventions contribute to this process. These findings support the 
argument that adherence intervention development should be directed towards utilising 
domains of wider social interaction to improve adherence. 
Adherence as a social phenomenon: a novel perspective 
This work has enabled the essential structures of adherence to be identified, generating a 
new description of the phenomenon. The findings can be summarised and interpreted 
using Figure 11 below,   
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Figure 10. Adherence as a phenomenon of macro and micro-social interaction 
This figure describes patients’ lived experiences of medicines adherence in this study. It 
represents how patients construct the experience of adherence socially, learning pre-
predicatively, without really trying patients are picking up information, prejudices, beliefs 
and approaches to medicines taking that will come to embody a set of values that add 
structure to their experiences of adherence as a lived phenomenon. The figure highlights 
that the micro-social interaction between the patient and the product is encapsulated 
within macro-social interaction with domains of wider society, identified here as family and 
friends, the media, policy and healthcare professionals.  
A phenomenological description summarises the findings in a way that seeks to help the 
reader understand the phenomenon better in a concise way;   
The lived experience of adherence is a fundamentally social phenomenon, 
constructed through social interaction with multiple actors including 
healthcare professionals, family, friends, the mass media, but also the 
medicines themselves, as integral social actors in a patient-product-peers-
Policy (embodying legislation, 
and licensing) 
Family and Friends (enacting 
lay knowledge) 
The Media (enacting lay 
knowledge through 
newspapers, social media, 
television and the Internet) 
Healthcare Professionals 
(embodying evidence-based, 
expert opinion)  
Patient Product 
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professional-press interaction that continues throughout the patients’ life 
and the life of the prescribed product.  
Social science research has identified the social meaning of medicines, as symbols of illness 
that are transformed from inanimate chemical objects to intrinsically social objects (Cohen, 
2010, Cohen et al., 2012, Cohen et al., 2001, Whyte et al., 2002, Dingwall and Wilson, 1995) 
Other work has demonstrated that patients learn from healthcare professionals (Mishel, 
1990), and where healthcare professionals have misconceptions relating to medicines, 
these can be internalised by patients (Angus, 2012). Positioning adherence as a 
phenomenon of social interaction also supports work that used Social Action Theory 
(Weber, 1978), whereby action is understood as the behaviour of individuals that has 
subjective meaning and takes into account the behaviour of others, to understand 
adherence (Gore-Felton et al., 2005). In the context of the results of this study, adherence 
actions are presented as social actions due to the constructed social identity embodied by 
the medicinal product itself, which acts responsively to patients. Social stigma has been 
highlighted as influencing adherence, supporting the findings of this study (Chai et al., 
2014, Anderson et al., 2015). Other evidence that suggests short-term episodes of non-
adherence are a function of interaction is also supported (Laba et al., 2015). 
Pharmacy-based research in this area has tended to use positivist methods and identified a 
number of facilitators and barriers to adherence. A well-established conceptualisation of 
adherence, the Necessity-Concerns Framework (Horne et al., 2013, Stack et al., 2008), is 
supported by this study, namely in that an essential structure of the experience of 
adherence in participants in this study was necessity. These findings add to the Necessity-
Concerns Framework, suggesting that patients’ construction of necessity is based on micro-
social and macro-social interactions. Whilst the Necessity-Concerns Framework was 
described by Donyai (2012) as ‘the psychology of the medication’ this work may have 
begun to explore a sociology of medication adherence.  
Interpretations of patients’ beliefs about the safety and efficacy of a medicine and their 
pharmacological actions as lay pharmacology are strengthened by the identification in this 
study of patients’ beliefs about the action of medicines (Webster et al., 2009). A study 
using a sample of ten participants, argues that beliefs and behaviours can be constructed 
through interactions with medicines (Jones, 2002). Statistical regression has demonstrated 
that patients with beliefs incongruent with wider societal constructs about ‘the chronic 
disease model’ were more likely to experience poor adherence (Mann et al., 2009), 
    
 
Page 147 of 261  
suggesting, as this study has found, that wider societal beliefs construct adherence 
practices. A meta-synthesis of phenomenological work argues medicines have meaning 
before they are prescribed for patients, further supporting the findings that patients 
interact with medicines through wider society, building beliefs about medicines from the 
social world, throughout their life. (Gamble et al., 2007, Shoemaker and Ramalho de 
Oliveira, 2008) 
This work is also supported by the Common Sense Model (Leventhal et al., 1992a) which 
describes common sense, i.e. rules of thumb or heuristics, across different classes as part of 
patients’ behaviour in response to symptoms. Two of the classes Leventhal describes relate 
to ‘social comparisons’ and ‘cultural beliefs and social experiences’, highlighting as this 
study does the importance of social interaction on health behaviours, such as adherence. A 
further deductive analysis of the data from this study may also find support for other 
classes of cognitive representations with the Common Sense Model. 
This novel perspective can be used to contextualise patients’ perceptions of interventions, 
facilitating future intervention development.   
What are patients’ perspectives of currently available adherence 
interventions and interventions that are in development? 
Patients’ perspectives of interventions varied dynamically. A key finding was the 
construction of interventions as objects of necessity, which enact interaction between the 
patient, the product and wider society. A second addition to the literature is the conceptual 
mapping of patients’ perspectives of current interventions onto experiences of adherence, 
identifying that the majority of interventions represent micro-social interaction and 
directing future intervention development towards macro-social interactions. This sits in 
contrasts to some normative approaches to adherence intervention development, whereby 
research has attempted to delineate a ‘path to perfect adherence’, that describe the 
experience of adherence as a standard outcome of modifiable and non-modifiable 
variables. These approaches position adherence as a standard of medicines taking 
behaviours and, as highlighted by Donyai (2012), enable individuals’ behaviours to be 
predicted, such as in the Health Belief Model or the Integrative Model.   
The Integrative Model (Fishbein, 2008) argues that behaviours are more likely to change if 
they are specific, rather than being concerned with 'improving health' or 'lowering blood 
pressure', behaviour change interventions are more successful if they are targeted to 
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specific activities, within specific contexts and times. The findings of this work, whilst 
suggesting that micro-social interactions are an essential part of the experience of 
adherence, suggest that interventions should not only target these individual micro-social 
interactions, but also broader, macro-social interactions. Further work may be needed to 
ratify elements of this framework, particularly parts pertaining to the 'impact' different 
interventions might have in relation to behaviour change. For example, the Integrative 
Model states that interventions based in different domains, considered to be social 
pressure, attitude and self-efficacy, might have different levels of impact on particular 
behaviours. Interpreting interventions as macro-social interactions, there is an opportunity 
for further investigation to explore the domains identified by this study (peers, press, 
healthcare professionals) and their impact on behaviour change - which may differ at an 
individual and societal level.  Further more, Fishbein's theory has been argued to embody a 
normative (logical, mathematical) approach to human behaviour and ‘does not take 
account of person-specific variables such as gender, mood and culture’ (page 84, Donyai, 
2012) which are accounted for in the description proposed by this study.   
This work is better aligned to the Fuzzy Trace Theory (Reyna, 2008), which does not adopt a 
normative approach and identifies experiences of medicines use as subjective, based on 
patients’ own conceptions, beliefs, knowledge and skills. This theory utilises the concept of 
‘heuristics’, describing patients’ knowledge as either ‘verbatim’ or ‘gist’. Within this theory 
is recognition of patients’ experiences of remembering the ‘gist’ of information about 
medicines. Similarly in this study, participants reported their own ‘gist’ or ‘rules of thumb’ 
about medicines’ identities and about adherence that had been generated from social 
interaction. For example, that participants could miss one or two doses (episodic short-
term non-adherence) could be described as a ‘gist’ in that rather than remembering that 
medicines must be taken everyday (verbatim) they are reminded that they need to be 
taken most of the time (gist). This theory is put forward by Reyna (2008) and suggests gist-
based intuition develops with age, reducing risky behaviour and that reliance on verbatim 
memory might reduce the performance of behaviours. It has also been argued that people 
prefer gist messages rather than verbatim (when given both people remember and act on 
the gist) (Donyai, 2012). The Fuzzy Trace Theory suggests behaviour change is possible 
when people interpret facts, knowledge and health information and represent it in their 
own minds in relation to their own experiences, which is supported by the findings of this 
study in relation to experiential learning of medicines’ identities and medicines taking 
practices. 
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Do interventions need to be targeted to different disease groups? 
As above, previous work has suggested that interventions to change behaviour are more 
successful if targeted to specific behaviours within specific contexts. The findings of this 
study do not dispute this, however, they do raise questions as to the targeting of 
interventions to groups distinguished by symptomology.  
Within normative approaches of understanding adherence, the experience of symptoms, 
such as pain or breathlessness, that can be relieved by medicines is considered to improve 
adherence (Cooper et al., 2009). A psychological approach to the adherence phenomenon, 
the Common Sense Model (Leventhal et al., 1992b) positions somatic disease symptoms as 
constitutive parts of an internal representation of disease identity. Approaches to coping 
with symptoms and disease, including when to seek treatment, how to use treatment and 
when to stop, becomes entwined with representations of disease constructed from 
previous experiences of illness, interaction with friends and family and healthcare 
practitioners. Where the findings of this project enhance the Common Sense Model, is the 
introduction of the notion of medicines’ identities that, data from this study would suggest, 
might represent an additional component of a patient’s decision-making processes. 
Representations that ‘drug X relieves symptom Y’ could be interpreted as a constructed 
characteristic of a product, a constituent of that medicine’s identity, as considered by the 
patient at a micro-social level, informed by their interactions at a macro-social level.  
The findings of this study diverge from existing models in that rather than conceptualise 
adherence as the output of an individual’s psychological decision-making process, this work 
describes adherence as an interaction between social actors. Patients are socialised into 
adherence, constructing medicines taking practices, rather than making decisions, that are 
pre-predicatively given through interaction with the product and wider society. In essence, 
whilst this work recognises that symptoms might encourage patients to use medicines, 
adherence practices are constructed from a broader set of beliefs and values constructed 
by society that locates symptoms as requiring treatment and medicines as symptom 
relievers.  
This emphasises that whilst society constructs patients’ experiences of adherence, these 
experiences construct society and so societal beliefs about medicines use. In the past, this 
may have perpetuated social norms concerning adherence, stabilising societies’ approach 
to illness as a ‘reaction to symptoms’ to fulfil economic agendas, whilst inadvertently 
encouraging non-adherence in the absence of symptoms as a representation of the 
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absence of disease. This study highlights a disparity between narratives of medicines use 
that locate symptoms as a key component of a cost-benefit analysis of the necessity of 
medicine use and experiences of adherence despite the absence of symptoms of disease. In 
this study, physical symptoms of illness were one of many representations of disease in 
both symptomatic and asymptomatic disease groups, with beliefs about medicines use 
constructed from interaction with wider society enacted through blood tests, referrals from 
family and friends, prompts from the media, interaction with healthcare professionals and 
policy changes. This study therefore locates adherence as a response to society, that 
constructs a response to symptoms. 
The medicalisation debate, which refers to a concept whereby healthy or ‘symptom-less 
states’ are becoming increasingly categorised as illnesses, is relevant to these findings 
(Conrad et al., 1987). Some authors go further to distinguish another phenomenon, 
pharmaceuticalisation, referring to the use of pharmaceuticals without a diagnosis that 
generates a ‘supra-normalcy’ only available through pharmacological intervention 
(Williams et al., 2011, Abraham, 2010). A shift in societal beliefs and practices, away from 
symptomatic medicines use towards asymptomatic medicines use, has been argued to 
have been achieved through careful management of clinical trials data and national clinical 
guideline production (Teira, 2014). Teira argues that during drug discovery, the 
physicochemical properties of a chemical are identified, and through careful publication of 
marketing materials and research, such properties becomes linked to the product. Products 
are then more intensively marketed, prescribed and used as part of treatment or 
prevention of particular asymptomatic states (such as hyperlipidaemia or hypertension), 
which constructs and reinforces social conceptualisations of both the product and the 
asymptomatic state. 
Whilst some may argue that this phenomenon represents scientific progress based on 
evidence, publicity around the changes to medicines use post-licence can be controversial 
(Gallagher, 2014). Teira labels this phenomenon as collision behaviour, when a risk factor 
for a disease (such as hyperlipidaemia for cardiovascular events) is transformed into a 
diagnosis in its own right – which appears to be the case for hyperlipidaemia following a 
1984 conference consensus (Tobert, 2014). Similarly hypertension, once noted as a risk 
factor for a cardiovascular or cerebrovascular event is now diagnosed through blood 
pressure measurements and represents the treated condition. This move symbolises a shift 
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in societal beliefs, reconceptualising medicines use as less driven by symptoms and more 
driven by wider societal constructs about ‘when medicines should be taken’.  
These phenomena move social practices away from using medicines to treat symptoms, 
towards adherence to pharmaceutical products without symptoms. These changes, which 
are argued to be an orchestration of the pharmaceutical industry, appeared to be reflected 
in the findings of this study, where experiences of symptoms represented a small part in 
the construction of beliefs about necessity that underpinned the experience of adherence. 
Indeed there has been documented increases in pharmaceutical use across the globe 
(Abraham, 2010) with particular criticism of the fierce marketing campaigns, involvement 
in guideline creation and influence over governmental and charitable organisations, that 
the pharmaceutical industry employs to promote their products. The interaction between 
beliefs about medicines and social interaction can be demonstrated through social 
marketing – between 1995 and 2005, marketing staff for pharmaceutical industry grew by 
59%, which led to increased uptake of pharmaceuticals (House of Commons Health 
Committee, 2005). This reflects back to a late capitalist model of society, outlined earlier in 
Figure 3, whereby society’s conceptualisation of need drive productivity and economic 
development. 
This is relevant to the development of interventions on a societal scale in two ways. Firstly, 
the construction of necessity (in the presence of symptoms or not) may, to critical 
observers of the ‘adherence agenda’, be conceptualised as ‘the next wave of 
medicalisation’. This could be argued to further demonstrate the influence of the 
bourgeoisie pharmaceutical industry on the beliefs of the proletariat, in the interests of 
profit. In other words, the construction of adherence as a socially normalised standard of 
medicines taking practices appears to have generated a necessity for medicines use, 
identified in this study as part of products’ personified identities, that is independent of the 
experience of physical symptoms, and instead, is based on interactions with wider societal 
practices. Secondly, further criticism may also be raised around the finding in this study, 
that locates adherence interventions as objects of necessity, that may represent ‘the next 
wave of pharmaceuticalistion’, that seeks to generate a second-line of economic 
opportunity that posits non-adherence as a socially negative phenomenon and thus 
interventions (in the form of products or services) as necessary to fulfil socially constructed 
medicines taking practices. Further work and careful consideration would be needed to 
explore how this might influence the development of interventions on a societal scale.  
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Limitations of the study 
Whilst the study findings can be described as valid, an integral part of the research process 
is reflectivity considering the limitations of the study.  
A limitation of this study was the sampling method used to identify participants. 
Community pharmacists and general practitioners were asked to identify participants for 
the study from their patients, and whilst community pharmacies and general practices 
were located in areas of low and high deprivation, and successfully resulted in a sample of 
participants from diverse sociodemographic backgrounds, all of the participants in the 
study were White British. This may not be surprising given the population profile of North 
East England. Whilst an advantage of a convenience sampling approach allows for 
participants to be recruited quickly and easily, a disadvantage of this approach in this study 
is that the sample recruited was not ethnically diverse. There is potential here then for 
further investigation of how ethnicity, as the embodiment of culture, language, social 
practices and social interactions, relates to adherence across different ethnic groups. 
Though a missed opportunity in this study, further investigation of the experiences of 
medicines adherence across an ethnically diverse sample may generate insights into how 
participants living in relation to cis- and trans-ethnic societies (for example, an Indian man 
living in India versus an Indian man living in England) may experience adherence in relation 
to socially constructed medicines taking practices, both chronically for settled migrants and 
acutely for those migrants moving between cultures.  
The sampling methods chosen, to identify patients through community pharmacists and 
general practitioners, may have prevented data being collected by those patients that do 
not access these services. Indeed these patients may be of particular interest as they could 
be described as being ‘so non-adherent’ that not engaging with healthcare structures might 
prevent access to prescribed medicines. A group that has lower interactions with 
healthcare professionals and perhaps interactions that differ from typical patterns of social 
interaction, may represent a set of patients with very different experiences of adherence, 
and occupy social spaces that do not conform to stereotypical practices of social interaction 
that might be reflected by the sample. Alternative medicines taking practices may be 
constructed in these groups, and so further work is necessary that uses a broader sampling 
approach.  
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On reflection whilst community pharmacies successfully identified participants for this 
study, more rigorous monitoring of their activity, such as how many participant packs were 
not handed out, how many patients said they did not want to be involved, could have been 
recorded to enable future studies involving patient identification through community 
pharmacy to be improved. Further details of the general practitioners involved in patient 
identification should be recorded too to enable future studies to be improved. Additionally 
feedback and development might be offered to support general practices and particularly 
community pharmacists as patient identification centres, as part of a research ready 
agenda that seeks to incorporate collaboration between academia and practice.   
Another limitation of this study, also stemming from the convenience sampling method, 
was the classification of the disease groups. The disease groups that were chosen 
(cardiovascular disease, diabetes, cancer, gout and chronic obstructive pulmonary disease) 
aimed to reflect a rage of disease states that were asymptomatic and symptomatic. 
Inadvertently this way of grouping disease states may not have adequately distinguished 
between physiological diseases and the psychosocial meanings attached to diagnosis. For 
example, when identifying participants with cancer, a range of participants were recruited 
with different types of cancer (including breast, colon, prostate and lung) which when 
considered on reflection, represent very different physiological diseases, but perhaps 
represent something quite similar to lay people who might understand cancer to be one 
disease.  Due to the broadness of the disease categories not all participants reflected the 
intended symptom profile. Whilst participants did not necessarily reflect the intended 
symptomology, this highlights that what is ‘known’ about the physiology of disease by 
adherence researchers, may not always be reflected in the reality of the lived experience of 
the disease. This emphasises the importance of the presuppositions of researchers in 
relation to study design. In some way such a varied sample can be interpreted as a strength 
of study, as participants were drawn from a range of diagnostic, physiological, symptomatic 
and lay perspectives that could be argued to add depth to the data.  
A final limitation of the study could be that the study reflects the experience of illness 
rather than adherence. Ingadottir (2009) explains that a limitation of her phenomenology is 
that rather than the experience of adherence, it reflected the experience of having 
diabetes. Ingadottir accepts the limitations of her work and suggests a way around this 
would be to investigate multiple conditions within a phenomenology of adherence, as has 
been done in this study. Despite the inclusion of participants from multiple disease groups, 
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it could be argued that this study represents participants’ experiences of long-term illness, 
of which medicines use makes up, whilst important, only one part.   To argue that this work 
is a phenomenology of the experience of chronic illness however, would negate other 
important aspects of that experience that were not included as part of this study, such as 
changes to diet and exercise or the use of medical devices, for example.  
The project adds to the adherence literature by presenting a novel description of patients’ 
experiences of adherence. Rather than being directed towards micro-social experiences of 
necessity constructed by an individual patient’s experience of medicines use, conceptually 
mapping patients’ perspective of adherence interventions has identified potential avenues 
of future intervention development that are opened up to experiences constructed 
through macro-social interaction, i.e. the social experience of medicines use. The 
implications of these findings raise questions as to the driving forces of the 
‘interventionalisation’ of the adherence agenda, as a representation of evidence-based 
progress or bourgeois economic development.  For some this may raise moral, ethical and 
legal questions whilst for others it represents evidence-based progress and economic 
opportunity. As such careful consideration of future work is needed to develop 
interventions that utilise macro-social interactions that positions commercial opportunities 
sympathetically to moral and ethical matters.  
Implications of this research 
Interpreting the results of this study with relevant literature has generated novel insights 
into patients’ lived experiences of adherence across a range of disease states and identified 
patients’ perspectives of adherence interventions. The insights developed from this study 
can be used to argue that the future direction of intervention development need not focus 
on symptom-specific interventions and might further explore the domains of social 
interaction. This is discussed in more detail below.  
Locating adherence interventions within social domains 
Whilst empirical work is needed to support these interpretations, thus far adherence 
interventions appear to be most commonly located within the micro-social interaction 
between the patient and the product. These interventions, such as electronic packaging, 
reminder alarms, and multi-compartment compliance aids, become part of the product 
identity and can be recognised as embodiments of unique relationships between a patient 
and a product. These interventions then go straight to the heart of the personification of 
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medicines, recognised and defined here as the abstract and conceptual identities that 
medicines take on in society, becoming the embodiment qualities and characteristic that 
improve, enable, and maintain survival. This focus positions medicines, not only as 
independent, conceptual social actors within a patient-product relationship, but also within 
a broader pre-supposed social context. Educational interventions, behavioural 
interventions and other complex behaviour change interventions all reflect an interaction 
between a patient and the beliefs of healthcare professionals, and go some way in 
attempting to construct patients’ beliefs, ideals, and values towards adherence. That is to 
say, that these interventions attempt to construct predicative approaches to medicines 
taking, such that patients’ values are changed and micro-social interactions between the 
patient and the product modified. What has yet to be explored as a direction of 
intervention development, is the construction of beliefs and values through social 
interaction with peers and press. Although already developed as educational and 
behavioural interventions, further exploration into interactions with health professionals 
might explore the consistency of interactions between healthcare professional groups, such 
as those with doctors, nurses and pharmacists, to ensure a consistent ‘message’ or ‘gist’ is 
being constructed during interactions.        
Interventions that use family and friends to improve adherence 
Engaging with family members, friends, and peer patients, to influence the adherence of a 
patient presents itself as a contrast to patient-centred or patient-focused care. Encouraging 
family members, friends and peer patients to ‘buy in to’ treatment plans and prescriptions 
may not represent a novel approach to improving adherence, in practice, engaging formal 
carers, who may be family members or friends, with prescribing decisions is well-
established. However a novel direction for intervention development may be to include 
broader family members, friends and peer patients, as part of the adherence intervention. 
Encouraging these actors to take on a role with an adherence intervention may cause 
concern for some patients, healthcare professionals and policy makers. An already 
developed intervention that could be interpreted as a macro-social interaction with friends 
and family might be peer-support groups or formal discussion groups that are currently 
used as part of rehabilitation plans. In focus groups these interventions were not viewed 
positively, rather participants appeared to have these interactions more informally, whilst 
doing other activities that contributed to their social life. There may be an opportunity here 
then for adherence interventions to target social activities, such as football matches, bingo 
halls and other social events. These interventions would be supported by Chartrand and 
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Bargh’s (1999) work on social interaction and the perception-behaviour link. Their work 
argues that just by seeing or interacting with people doing a particular task, people are 
more likely to match that behaviour, consequently such interventions may include the 
encouragement of self-administration of medicines in a social setting – this might be 
compared to other social changes such as smoking in enclosed spaces and wearing 
seatbelts. A concern here however is that non-adherent patients interacting with patients 
who are adherent might result in adherent patients becoming less adherent, thus any 
investigation would need to consider and mitigate the ethical implications of such an 
intervention. Further work might explore how informal interactions between patients, 
peers, family and friends can be optimised to improve adherence.  
Interventions that use the media to improve adherence 
Turning to another domain of macro-social interaction, the media, may present a novel 
approach to intervention development. In this context, press could be interpreted as all 
aspects of ‘social knowledge’ including that printed in newspapers and magazines but also 
heard on the radio, seen on the televisions and found on the Internet. At present, this 
domain of interaction is largely underdeveloped in relation to adherence interventions. The 
majority of interactions with the press present medicines taking as a construct of negative 
necessity (i.e. medicines should only be used to treat illness when needed).  Here 
interventions may be enacted through regular television advertisements, appropriately 
timed television or radio announcements, Internet-based pop-ups or even more simple 
strategies, that use pro-medicines material to posit medicines use as routine, rather than 
based on need as per current marketing agendas. 
Consideration should be given to how direct-to-consumer pharmaceutical advertising of 
medicines, such as in the United States of America and New Zealand, might influence 
patients’ adherence practices. The advantages of advertising are well identified; briefly 
including increasing patient empowerment through education, promoting dialogue 
between patients and healthcare providers, reducing under-diagnosis and under-treatment 
and improving adherence (Ventola, 2011). One way to reconsider advertising maybe to 
move the marketing message away from initiation of medicines and towards continuation 
of medicines and good medicines taking techniques. Concerns in the UK around direct-to-
consumers advertising centre on the overemphasis on the benefits of medicines use that 
misinform patients about the risks associated with medicines that may lead to 
inappropriate prescribing. Ventola also reports that increased advertising ‘manufactures 
    
 
Page 157 of 261  
disease’, highlighting the impact interaction with the media has on patients’ construction of 
necessity beliefs. Whilst the place of direct-to-consumer pharmaceutical advertising 
remains negotiable, its impact on the construction of medicines taking practices on a social 
scale must be carefully considered moving forward.   
This interpretation supports the development of interventions based on social media. 
Whilst these interventions might serve as reminders to patients initially, over time they are 
likely to become integral to the patient-product relationship, as creators of social 
knowledge that constructs medicines taking as normal, positive or neutral (as oppose to a 
negative necessity).  This domain of interventions may go some way in constructing pre-
predicative beliefs about adherence to medicines prior to the development of a patient-
product relationship (i.e. before the patient is prescribed anything), constructing patients’ 
knowledge about adherence and medicines taking as a phenomenon of everyday life.  
Interventions based on macro-social interaction through the television or radio may 
present ethical and legal dilemmas, in relation to how patients are encouraged to use their 
medicines, and consequently such interventions would need to be considered cautiously 
and supported with further evidence collected from patients, professionals and policy 
makers, to circumvent the inappropriate use of medicines. The use of television and radio 
media to promote medicines use may feed into concerns and debate on the 
pharmaceuticalisation of society, particularly in relation to funding arrangements, be it 
from the NHS, the government or the pharmaceutical industry. These tensions too must be 
carefully considered and supported with further work to prevent barriers to intervention 
development and implementation. 
Interventions that use policy to improve adherence 
Further reflection on wider social influences on adherence highlights policy as an arena of 
future intervention development. This may include changes to how medicines are 
conceptualised socially through policy, licensing and authorisation processes. In the domain 
of policy, medicines appear to be conceptualised as dangerous unless proven beneficial. 
This positions adherence as an embodiment of necessity, where medicines should only be 
prescribed, and taken, when needed as a negotiation of risk-benefit. This can be 
demonstrated when considering the policy on direct-to-consumer pharmaceutical 
advertising; the US Food and Drug Authority’s policy on advertising stipulates that 
advertisements that include product claims must also include risks. This has developed 
more recently so that rather than including every risk associated with a product’s use, only 
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the major risks need be included, with a caveat that patients are directed to sources of 
further information (Ventola, 2011).  A novel direction for adherence interventions then, 
might be to reconstruct the way medicines, as medico-legal objects, are governed, thereby 
reconceptualising medicines, and so adherence, as something other than a phenomenon of 
necessity. As participants did not refer to interventions that changed policy approaches 
during discussions on interventions directly, further work would be needed to establish if 
interventions that seek to change policy might lead to a change in the construction of 
beliefs about medicines as objects of necessity. 
The UK’s National Institute of Health and Care Excellence’s (NICE) guideline on medicines 
adherence (National Institute for Health and Clinical Excellence, 2009) advocates that 
interventions are tailored to meet patients’ individual needs, with an emphasis on patients 
being given an appropriate amount of information to make an informed decision. The 
guideline does not recognise medicines adherence as a social phenomenon, where 
information to make an informed decision is often generated through social interaction 
with lay sources of knowledge. Policy makers must consider the wider social determinants 
of adherence, such as exposure to information in newspaper headlines, on the Internet and 
generated through interaction with family and friends and consider using public health 
campaigns to help patients identify and ‘get to know’ their medicine as tacit identities. 
Additionally health professionals could highlight the need to scrutinise information about 
medicines that patients may be exposed to from social interaction, encouraging patients to 
discern between robust, scientifically informed medicines information and lay knowledge. 
Interventions that would seek to use media to promote adherence directing intervention 
development towards changing policy in relation to medicines sale, supply and advertising 
would require careful consideration and management of ethical and legal tensions, 
particularly in relation to popular debates concerning medicalisation and 
pharmaceuticalisation of society.  
Society and Pharmaceuticals: ethical implications of using social domains as adherence 
interventions 
Implications of this research have been considered in relation to intervention development. 
What has become clear during the course of this project is the ethical dilemmas presented 
when conducting adherence research, both on an individual researcher level (Rathbone 
and Jamie, 2016) but also on a broader level in relation to ‘interventionalisation’ of the 
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adherence phenomenon. A report by Abraham (2010) outlined the significant rises in the 
global use of pharmaceuticals (see Figure 12) and directed attention towards the behaviour 
of the pharmaceutical industry in relation to social marketing of pharmaceutical products. 
 
Figure 11. Pharmaceuticalisation of society (data from Abraham 2010) 
Whilst definitions of the phenomena vary, social media commentators of 
pharmaceuticalisation has become somewhat quasi-conspiratorial, with some extending 
the debate to public health (Camargo Jr., 2013, Figert and Bell, 2014). Ethical issues are 
raised where a macro-social intervention might try to change patients’ beliefs, values and 
behaviours to increase adherence, and so medicines use, for commercial purposes. 
Consumer scrutiny of the pharmaceutical industry, healthcare providers and healthcare 
professionals is generating concern over increasing medicines use, with deprescribing 
becoming a topic of research interest (Thompson and Farrell, 2013), which might increase 
following the development of a societal level intervention. Whilst the commercialisation of 
the adherence phenomenon may present itself as a difficulty for some, a view can be taken 
that in akin to pharmaceutical development, that without commercialisation, future 
funding for further research and scientific advancement may not be available. Despite this, 
the commercial incentive of ‘interventionalisation’ may raise issues for some, particularly 
when this leads to changes in societal values concerning medicines use.    
Indeed macro-social intervention may go further and wrest back patient choice from 
patients to professionals, returning the adherence narrative to the more paternalistic,  
‘compliance’ agenda of previous decades. As the ‘concordance agenda’ empowered 
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patients to make agreements with their prescribers about medicine use, and the 
‘adherence agenda’ arguably encouraged patient choice, ‘interventionalisation’ of the 
phenomenon, enacted through a macro-social interventions, may disempower patients at 
an individual level.  
There are clearly different interpretations of the ethical location of ‘interventionalisation’, 
consequently further work is needed to explore patients’ and professionals’ views of this 
phenomenon as well as consider the broader historical and sociological perspectives.   
Conclusion 
This work describes patients’ lived experiences of medicines adherence as constructed 
through micro- and macro-social interaction, describing the experience as a response to 
society, not merely a response to symptoms.  
The synthesis of findings from interviews and focus groups present a novel description of 
adherence, as a phenomenon of social interaction. The experience of adherence as a social 
phenomenon locating medicines use as a life-long experience whereby patients are 
continuously interacting with medicines, as personified products, or with wider society; 
constructing beliefs, values and medicines taking practices that structure experiences of 
adherence. Adherence interventions were identified as modes of interactions, forming part 
of the personified medicines identity or embodiments of macro-social interaction with 
wider society.  
Interpretation of this work has identified new avenues of intervention development in 
macro-social domains, directing future work towards large-scale social interventions rather 
than patient specific products. Further work is needed to establish the impact of 
interventions within these domains and identify key interactions that might be exploited to 
improve adherence. Care must be taken in relation to the development of interventions 
within a macro-social context, with particular sensitivity to debates concerning the 
medicalisation and pharmaceuticalisation of society. Debates concerning direct-to-
consumer pharmaceutical advertising might be re-engaged to initiate further discussion on 
types of advertising that might be used to promote adherence to medicines that are 
already prescribed, moving away from advertisement to promote initiation of medicines 
and towards advertisement of continuation.   
Patient interactions with healthcare professionals, whilst enacting established societal 
approaches to medicines use, such as evidence-based medicine, might construct conflicting 
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medicines taking practices in patients through divisions of expertise and differences of 
professional opinion and practices. Preliminary work has identified that improvements in 
adherence may be achieved where healthcare professionals share perspectives as to how 
medicines should be used (Rathbone et al., 2016). This suggests that additional exploration 
may be needed to identify the influence of inconsistencies between interactions with 
professionals (or other groups such as family and friends) has on medicines use. 
That medicines use exists as a response to society, how patients interact with medicines 
that have moved or are moving between societies represent another area of interest that 
will add depth to these findings. Medicines taking practices constructed in different social 
settings, such as a small town in India, may translate into difficulties with assimilation or 
the reconstruction of medicines taking practices were patients have emigrated to a small 
town in the UK. Additional conflict may also be experienced where patients move between 
cultures or social norms as they move through the domains of interaction outlined above. 
For example, using American products, reading and watching Indian media and mixing with 
family and friends from diverse ethnic backgrounds within a British policy context.  This 
framing of medicines use offers new opportunities of investigation of the adherence 
phenomenon from sociological perspectives.  
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Appendix A: Supplementary material  
Table 4. Summary of studies that conceptualise adherence  
Author Thematic or 
Conceptual 
Framework  
Outcome of the Study 
Garavalia, L., et al., Exploring 
patients' reasons for 
discontinuance of heart 
medications. J Cardiovasc Nurs, 
2009. 24(5): p. 371-9. 
 
The Health Belief 
Model 
The most common reason for non-
adherence was adverse effects that 
impaired daily life 
Garay-Sevilla, M.E., J.S. Porras, 
and J.M. Malacara, Coping 
strategies and adherence to 
treatment in patients with type 
2 diabetes mellitus. Rev Invest 
Clin, 2011. 63(2): p. 155-61. 
 
Jalowiec Coping 
Scale (Cognitive, 
Avoidant, 
Fatalistic, 
Supportant)  
Facilitating psychosocial factors, such 
as coping, must be carefully 
considered to foster optimal 
adherence 
Gault, I., A. Gallagher, and M. 
Chambers, Perspectives on 
medicine adherence in service 
users and carers with 
experience of legally sanctioned 
detention and medication: a 
qualitative study. Patient Prefer 
Adherence, 2013. 7: p. 787-99. 
 
 
Treatment 
Satisfaction 
Professionals and the relationship 
between the professional and the 
patient is essential for optimum 
adherence  
Girdwood, C.P., Predicting 
adherence in a multifaceted 
medical regimen. 2008, 
ProQuest Information & 
Learning: US. 
 
 
The Self-efficacy 
Adapted Health 
Belief Model 
Adapting the Health Belief Model to 
include self-efficacy did not improve 
the models capacity to predict 
adherence 
Gore-Felton, C., et al., The 
Healthy Living Project: an 
individually tailored, 
multidimensional intervention 
for HIV-infected persons. AIDS 
Educ Prev, 2005. 17(1 Suppl A): 
p. 21-39. 
Social Action 
Theory 
Tailored-intervention designed and 
are currently being evaluated 
Hampson, S.E., R.E. Glasgow, 
and D.J. Toobert, Personal 
Personal Models Composites of patients’ Personal 
Models were cause, symptoms, 
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models of diabetes and their 
relations to self-care activities. 
Health Psychology, 1990. 9(5): 
p. 632-646. 
treatment and seriousness and 
determine self-care behaviours  
Lai, W.A., W.C. Chie, and C.Y. 
Lew-Ting, How diabetic patients' 
ideas of illness course affect 
non-adherent behaviour: A 
qualitative study. British Journal 
of General Practice, 2007. 
57(537): p. 296-302. 
Kleinman’s 
Explanatory Model 
Side-effects were seen as a 
consequence of taking medication, 
which resulted in increased dosing to 
combat side-effects.  
Marshall, I.J., C.D. Wolfe, and C. 
McKevitt, Lay perspectives on 
hypertension and drug 
adherence: systematic review of 
qualitative research. BMJ 
(Clinical research ed.), 2012. 
345: p. e3953. 
Geo-Ethnic and 
Cultural 
Beliefs about adherence are 
remarkably similar across ethnic, 
cultural and geographic groups.  
Mohamed Ibrahim, O.H., F.J. 
Jirjees, and H.J. Mahdi, Barriers 
affecting compliance of patients 
with chronic diseases: A 
preliminary study in United Arab 
Emirates (UAE) population. 
Asian Journal of Pharmaceutical 
and Clinical Research, 2011. 
4(SUPPL. 2): p. 42-45. 
Chronic Disease Level of education and chronic 
diseases are not correlated with 
adherence 
Nurymberg, K., S. Kreitler, and K. 
Weissler, The cognitive 
orientation of compliance in 
short- and long-term type 2 
diabetic patients. Patient 
Education and Counseling, 1996. 
29(1): p. 25-39. 
The Theory of 
Cognitive 
Orientation 
Long-term adherence can be 
predicted through assessing patients 
goals, values and self-image.  
Parveen, M. and S. Piyarali, 
Treatment compliance to 
diabetes care: A cross-sectional 
study from Pakistan. Value in 
Health, 2011. 14 (3): p. A98-A99. 
Education Non-adherence should be identified 
and patients should be educated 
accordingly.  
Zarani, F., et al., Effectiveness of 
the information-motivation-
behavioral skills model in the 
adherence rate of coronary 
artery bypass grafting patients. 
Psychological Research, 2010. 
12(3-4): p. 24-43. 
Information-
Motivation-
Behavioural Skills 
Model (IMB) 
A theory-driven psycho-educational 
intervention improved adherence. 
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Table 5. Summary of studies that use different methods of measuring 
adherence 
Reference Name of 
Method 
How is it done or 
calculated? 
Reported 
Conclusion 
An, J.J. and M.B. Nichol, Impact of 
multiple medication compliance on 
cardiovascular outcomes in 
patients with type ii diabetes and 
comorbid hypertension controlling 
for endogeneity bias. Value in 
Health, 2011. 14 (3): p. A8-A9. 
Proportion of 
Days Covered 
Total days all 
medicines 
available/ days in 
interval = PDC 
range 0-1(Barner, 
2010) 
0.63 Diabetes 
0.69 
Hypertension 
0.53 Comorbid 
Barnestein-Fonseca, P., et al., Is it 
possible to diagnose the 
therapeutic adherence of patients 
with COPD in clinical practice? A 
cohort study. BMC Pulm Med, 
2011. 11: p. 6. 
Self-reported 
Adherence 
(includes 
Haynes and 
Sackett 
Method, 
Morinsky 
Green Test and 
Batala Test) 
The participant 
estimates how 
often they are 
non-adherent or 
answers questions 
about their 
disease 
100% (Hayes-
Sacke test ), 
60.8%  (Morisky-
Green Test) and 
46.9% (Batalla 
Test) respectively  
 
*Threshold 80-
110% 
Barnestein-Fonseca, P., et al., Is it 
possible to diagnose the 
therapeutic adherence of patients 
with COPD in clinical practice? A 
cohort study. BMC Pulm Med, 
2011. 11: p. 6. 
Dose Count  
 
Counts the 
number of doses 
administered over 
a specified time 
interval. Can be 
monitored 
electronically 
68.1% Adherence 
Carney, R.M., et al., Adherence to a 
prophylactic medication regimen in 
patients with symptomatic versus 
asymptomatic ischemic heart 
disease. Behavioral Medicine, 
1998. 24(1): p. 35-39. 
Electronic 
Packaging 
Product packaged 
in unobtrusive 
electronic 
adherence 
measure  
62.4% 
Symptomatic 
heart disease  
77.4% 
Asymptomatic 
heart disease 
 
 
 
Edwards, D.L., Psychological factors 
affecting adherence and metabolic 
control in diabetes mellitus. 1999, 
ProQuest Information & Learning: 
US. 
Self-reported 
Adherence 
(Questionnaire)  
Hierarchical 
regression 
analysis  
Results of the 
study associate 
conscientiousness 
with better self-
reported 
adherence, 
mediated by 
coping and self-
efficacy  
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Farmer, A., A.L. Kinmonth, and S. 
Sutton, Measuring beliefs about 
taking hypoglycaemic medication 
among people with Type 2 
diabetes. Diabetic Medicine, 2006. 
23(3): p. 265-270. 
Self-reported 
Adherence 
(Medication 
Adherence 
Report Scale -
measuring 
belief and 
intention) 
 
 
 
 
Ordinal 
Questionnaire  
Median Score 25 
Foley, K., G. Carls, and P. Roberto, 
Medication adherence and medical 
cost offsets: A review of the 
literature. Value in Health, 2012. 
15 (4): p. A20 
Medication 
Possession 
Ration 
Number of days of 
medication 
supplied / number 
of days between 
supplies (Barner, 
2010) 
> 80% adherence 
threshold 
Gialamas, A., et al., Does point-of-
care testing lead to the same or 
better adherence to medication? A 
randomised controlled trial: the 
PoCT in General Practice Trial. Med 
J Aust, 2009. 191(9): p. 487-91. 
Self-reported 
Adherence 
(Five-Item 
Medication 
Adherence 
Report Scale – 
MARS5) 
Abbreviated 
Ordinal 
Questionnaire  
39.3% 
Intervention 
37.0% Control  
Haynes, R.B., et al., Interventions 
for enhancing medication 
adherence. Cochrane Database 
Syst Rev, 2008(2): p. CD000011 
Medication 
Event 
Monitoring 
System MEMS 
(as well as 
others) 
Added to 
packaging to 
record each time 
packaging is 
accessed 
> 80% adherence 
threshold  
Jain, S. and S. Jadhav, Pills that 
swallow policy: clinical 
ethnography of a Community 
Mental Health Program in northern 
India. Transcult Psychiatry, 2009. 
46(1): p. 60-85. 
Ethnography  Discussion and 
observation from 
within a culture-
sharing group 
Medication has 
several symbolic 
meanings which 
differ between 
policy makers and 
patients 
Kohlmann, C.-W., et al., 
Associations between type of 
treatment and illness-specific locus 
of control in Type 1 diabetes 
patients. Psychology & Health, 
1993. 8(5): p. 383-391. 
Adherence as 
an outcome of 
Locus of 
Control 
Ordinal 
psychological 
scales  
Associated locus 
of control and 
knowledge of 
disease with 
adherence 
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Li, D.S., Patient centered care 
approach to adherence with 
cardiovascular medications: Self-
determination theory integration. 
2010, ProQuest Information & 
Learning: US. 
 
 
Survey Series of 
questions 
assessing 
adherence on a 
scale of 1 to 5 
Self-
determination 
theory patient-
centered care 
may improve 
adherence.  
Lou, Y., et al., The implications of 
evaluating medication adherence 
at different drug classification 
levels. Value in Health, 2013. 16 
(3): p. A13. 
Proportion of 
Days Covered 
(three 
methods) 
Method 1: based 
on drug class and 
weighted 
averages 
Method 2 and 3: 
based on drug 
indication (anti-
diabetic) and 
Medicare Generic 
Drug Identifiers 
(GPI6 and GPI 10 
respectively) 
0.64 Method 1 
0.69 Method 2 
0.69 Method 3  
Toussi, M., et al., A novel method 
for measuring patients' adherence 
to insulin dosing guidelines: 
introducing indicators of 
adherence. BMC Med Inform Decis 
Mak, 2008. 8: p. 55. 
Electronic 
Database 
Patient registers 
each dose on a 
database, creating 
a record of dose 
and time 
45% Absolute 
Agreement  
30% Relative 
Agreement 
2% Extreme 
Disagreement  
26% Under-
treatment 
30% Over-
treatment 
Van der Elst, E.M., et al., High 
acceptability of HIV pre-exposure 
prophylaxis but challenges in 
adherence and use: qualitative 
insights from a phase I trial of 
intermittent and daily PrEP in at-
risk populations in Kenya. AIDS 
Behav, 2013. 17(6): p. 2162-72. 
Qualitative 
Interviews 
In-depth 
interviews of 
participants in a 
trial 
Side effects were 
acceptable, social 
stigma, and 
complexities of 
daily life 
influence 
adherence 
Vervloet, M., et al., SMS reminders 
improve adherence to oral 
medication in type 2 diabetes 
patients who are real time 
electronically monitored. Int J Med 
Inform, 2012. 81(9): p. 594-604. 
 
Real Time 
Medication 
Monitoring 
Dose is registered 
on a system 
within a pre-
defined time 
interval 
50% with SMS 
reminder 
39% without 
reminder 
Weinstein, C., et al., Patient versus 
clinician assessment of compliance 
with study medication in a study 
Self-reported 
Adherence and 
Clinician 
Discussion by 
patients and 
clinician 
Over-estimates 
compliance by 
20% 
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with fixed-dose mometasone 
furoate/formoterol combination. 
American Journal of Respiratory 
and Critical Care Medicine, 2011. 
183 (1 MeetingAbstracts). 
Reported 
Adherence 
respectively 
Weinstein, C., et al., Patient versus 
clinician assessment of compliance 
with study medication in a study 
with fixed-dose mometasone 
furoate/formoterol combination. 
American Journal of Respiratory 
and Critical Care Medicine, 2011. 
183 (1 MeetingAbstracts). 
E-Diary Patients record if 
they took the 
dose or not in an 
electronic diary 
71% Adherence 
Weinstein, C., et al., Patient versus 
clinician assessment of compliance 
with study medication in a study 
with fixed-dose mometasone 
furoate/formoterol combination. 
American Journal of Respiratory 
and Critical Care Medicine, 2011. 
183 (1 MeetingAbstracts). 
Integrated 
Dose Counter 
Represents the 
number of 
remaining doses 
in the inhaler 
72% Adherence 
Williams, G.C., et al., Reducing the 
health risks of diabetes: how self-
determination theory may help 
improve medication adherence and 
quality of life. Diabetes Educ, 2009. 
35(3): p. 484-92. 
Self-reported 
Adherence 
Postal Survey 
assessing self-
regulation of 
medicines use 
Adherence linked 
to  psychological 
measures of self-
determination 
theory  
Wu, J.R., et al., Factors influencing 
medication adherence in patients 
with heart failure. Heart Lung, 
2008. 37(1): p. 8-16, 16.e1. 
Interview 
Content 
analysis 
In-depth 
interviews 
transcribed and 
analysed 
Desire to be 
healthy was the 
primary 
motivator in a 
decision to 
adhere to 
medication 
Yamada, H. and M. Nakashima, A 
new electronic event monitoring 
device for recording of medication 
compliance. [Japanese]. Japanese 
Journal of Clinical Pharmacology 
and Therapeutics, 2001. 32(5): p. 
249-253. 
Electronic 
Monitoring 
Device 
Novel device 
contains 
medication, 
opening device 
relases 
medication and 
records time and 
date  
100% Adherence 
– no pills were 
left in the device 
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Table 6. Summary of Medicines Adherence Intervention Review Articles 
Studies Disease Intervention Outcome 
Al-aqeel et al., 
2011 
Epilepsy 1. education 
and counselling 
2. behavioural - 
reminders 
Inconclusive review 
Al-Qazaz et 
al., 2011 
Diabetes 1. education Inconclusive 
Armout et al., 
2008 
Asthma,  
Diabetes, 
Cardiovascular 
Disease, 
3. pharmacy-
based 
Inconclusive review 
Bain-Brickley 
et al., 2011 
HIV 4. nurse-led 
home-based 
intervention 
5.peer-support 
group therapy 
6.patient 
medication 
diaries 
Inconclusive review 
Bangalore et 
al., 2004 
Tuberculosis 
Hypertension 
HIV 
Diabetes 
7. regimen 
simplification - 
combination 
regimens 
Slight improvement  
[poor definitions of adherence] 
Cutrona et al., 
2010  
Cardiovascular 
Disease 
8. person-
independent 
[automatic 
messages 
delivery via 
electronic or 
traditional 
means] 
9.person-
dependant 
[phone calls, in-
person 
interventions] 
56% of interventions were successful 
(67% of the successful interventions were 
electronic). In-person in-pharmacy 
interventions were the most successful. 
Further research needed.  
Dolder et al., 
2003 
Schizophrenia 1. education  
2. behavioural 
The greatest improvement seen with 
longer interventions made up of a 
combination of educational, behavioural 
and affective strategies.  
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Haynes et al., 
2008 
[Cochrane 
Review] 
Multiple 1.education 
2. behavioural - 
reminders 
5. peer-support 
group therapy 
10. more 
convenient care 
11.self-
monitoring 
12.crisis 
intervention 
13.telehealth 
Inconclusive review 
Higgins et al., 
2004 
Multiple 
diseases in 
patients > 65-
years old 
1. education 
14.external 
cognitive 
support 
Inconclusive review 
Lindenmeyer 
et al., 2006 
[Cochrane 
Review] 
Diabetes education 
2. behavioural - 
reminders 
15. packaging 
Although evidence was of limited quality 
due to problems measuring adherence, 
pharmacist-led interventions improved 
medicines adherence in diabetes.  
Linn, A et al., 
2011 
Multiple 
chronic 
medications 
16. Internet-
based 
interventions 
Further evidence is needed but there is a 
small amount of good evidence 
supporting the use of internet-based 
interventions to improve adherence. 
Internet-based interventions involve 
online assessment, tailored content 
delivery and feedback in the form of 
customised health programs.  
Lutge et al., 
2012  
Tuberculosis 17.material 
incentives 
(including cash) 
Inconclusive due to poor generalizability 
and overall quality of the evidence, 
although higher cash incentives showed 
slightly more promise than low cash, or 
other material, incentives.  
M’Imunya et 
al., 2012
  
Tuberculosis 1.education 
2. behavioural -
counselling 
Some evidence to support education and 
counselling techniques however 
magnitude of improvement varies 
between contexts. More research on 
matching the nature of the intervention 
to the reasons for non-adherence 
Mahati et al., 
2011 
[Cochrane 
Review] 
Multiple 2. behavioural - 
reminders 
Update to a Cochrane review concluded 
that there was evidence to justify the use 
of ‘reminder packaging’ but further 
research is needed to determine their 
usefulness in different diseases, age, 
differences between packaging styles and 
impact on clinical outcomes.  
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Newell et al. 
1999 
Cardiovascular 
Disease 
1. education 
2. behavioural - 
reminders and 
counselling 
7. regimen 
simplification - 
dose frequency  
17.telehealth 
18. supplying 
medication as 
confectionary 
19.Complex 
Intervention 
15. packaging 
No evidence to support physician-focused 
interventions, only complex interventions 
or reducing dose frequency showed any 
success but methodologies were not 
robust so no strong recommendations 
can be made.  
Odegard et 
al., 2007 
Diabetes  3. pharmacy-
based 
interventions 
2. behavioural 
interventions 
and reminders 
15. packaging 
17. telehealth 
19. Complex 
Intervention 
Inconclusive evidence to support 
interventions, although one study 
supported the use of a combination of 
interventions (made up of reminders and 
packaging)  
Ruppar et al., 
2008 
Older people 1. education 
2. behavioural - 
skills 
Gaps in the literature included reminders, 
self-monitoring strategies, carer-
strategies (as oppose to self-medicating). 
Further evidence is required  
Ryan et al., 
2011 
asthma 
glaucoma 
cardiovascular 
disease 
depression 
and 
schizophrenia 
malaria 
HIV/AIDs 
respiratory 
infections and 
Tuberculosis 
Diabetes 
contraceptive 
1. education 
2. behavioural - 
skills, change, 
reminders, 
counselling,  
3. pharmacy-
based services 
7. regimen 
simplification 
11.self-
monitoring 
15. packaging 
19. complex 
intervention 
No evidence for people with co-
morbidities. 
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Schedlbauer 
et al., 2010 
[Cochrane 
Review] 
cardiovascular 
disease (lipid 
lowering 
medication) 
1. education  
2. behavioural - 
reminders 
7. regimen 
simplification 
Reminders showed the most significance 
although overall evidence was low.  
Schroeder et 
al., 2004
  
Hypertension 1.eduction 
2. behavioural - 
motivational 
counselling 
7. regimen 
simplification 
19. complex 
interventions 
Heterogeneity of studies prevents firm 
conclusions, complex interventions 
showed greatest improvements in 
adherence, education alone was 
unsuccessful, motivational interventions 
were promising but regimen 
simplification should be deployed as the 
first-line until further evidence is available 
Touchette et 
al., 2008
  
Multiple 
chronic 
medications 
1. education 
(informational) 
2. behavioural 
19. complex 
interventions 
Combinations of interventions and 
simplification of medicines showed 
promise however the evidence base did 
not support any one intervention 
outright. Future research to focus on 
matching or tailoring interventions to 
patients.  
Van Dam et 
al., 2005 
Diabetes 5. peer-support 
13. telehealth 
(including 
internet)  
This systematic review concluded 
tentatively that social support must come 
from appropriate sources (peer-patients 
or healthcare professionals rather than 
spouse or family). Further research is 
needed with better methodological 
designs.  
Vervloet  et al. 
2012  
HIV 
Glaucoma 
Cardiovascular 
disease 
ASthma 
Contraceptives 
2. behavioural - 
reminders (SMS 
text 
messages/pager 
system) 
The long-term efficacy of reminder 
interventions was unclear although some 
short-terms improvements were made in 
adherence up to 6 months. The content 
and timing (weekly or daily) requires 
further research.  
Waterman et 
al. 2013 
[Cochrane 
Review] 
Glaucoma 1. education 
2. behavioural - 
daily-living and 
reminders 
7. regiment 
simplification 
11. monitoring 
Inconclusive, further evidence needed 
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Williams et al. 
2014 
Diabetes (type 
2) 
1. education 
2. behavioural – 
daily reminders 
3. pharmacy-
based services 
5. peer-support 
13. tele-health 
(including 
internet) 
Heterogeneity of studies makes 
conclusions tentative. 
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Table 7. Summary of Included Studies in Systematic Review 
Author Country Context Methods 
Sample 
Size 
Sample 
Type of 
phenomenolog
y 
Description of 
medicines 
adherence 
Summary 
Abedian et 
al. (2010) 
UK 
Sickle Cell 
Disease 
In-depth 
semi-
structured 
interviews 
10 
6 women, 4 
men, with 
HbSS 
genotype 
sickle cell 
anaemia, 
self-
identified 
Afro-
Caribbean, 
18-52 years 
Interpretive 
The study did 
not explicitly 
report a 
description of 
the 
experience of 
medicines 
adherence 
Patients understood the importance of using 
penicillin and were happy they had received 
enough information from their doctor/nurse. 
Adherence was influenced by polypharmacy, 
duration, schedule, dosage, 'lack of immediate 
consequences', lifestyle and physical and 
psychological adverse effects. The study concludes 
that simply educating patients about their 
medicines will not influence adherence; that 
patients’ concerns, beliefs and personal attitudes 
need to be elicited and redressed if adherence is to 
be improved.  
De Geest et 
al. (1994) 
Belgium 
with 
'lifelong 
medication 
dependenc
y' (patients 
with 
epilepsy, 
cardiac 
and renal 
transplant) 
Interviews 14 
7 women 
and 7 men 
Descriptive 
Adherence 
was described 
environmental
ly as a kin to 
eating and 
drinking, 
personally as 
negotiated by 
emotion and 
relationships 
Identified themes of i) personal attributes, 
including emotional distress, confidence in the 
physician, normalcy and perceived health status, ii) 
environmental attributes, including routine, 
distraction, social support and cost, and finally iii) 
self-efficacy, negotiated by adverse effects, 
formulation, medication aids and dosing schedule. 
The work attempts to map these findings within 
the context of Bandura's Self-Efficacy framework to 
produce a tool to monitor medication taking 
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with others 
and through 
self-efficacy, 
which was 
mediated by 
interactions 
with the drug 
and the 
regimen.  
behaviour.  
De Moss et 
al. (2014) 
America HIV 
In-depth 
semi-
structured 
interviews 
12 
Middle-
aged, black 
women, 
aware of 
their HIV 
status for at 
least 2 years 
from the 
'deep south' 
(Atlanta, 
Georgia, 
USA) 
Not reported 
Significant 
events lead to 
changes in 
perspective 
and 
motivation to 
adhere to 
HAART, 
recognition of 
'personal 
strength' to 
adhere to 
regime 
facilitated 
adherence 
and this was 
mediated by 
trust in the 
healthcare 
provider.  
This qualitative study of 12 middle-aged black 
women presents a novel understanding of 
adherence to HAART. The authors used in-depth 
interviews to explore themes related to adherence. 
The authors identified three main themes, i) 
significant life event ii) recognition of ability to 
adhere/be healthy iii) relationship with health 
services. This work speaks to the 'healthy adherer' 
concept whereby once women recognise their self-
efficacy are able to adhere 'more strongly'. 
Paradoxically this research also showed that 
negative experiences of health services promoted 
adherence to HAART as women avoided 
hospitalisation/further interaction with health 
services.  
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Enriquez, 
Lackey, 
O'Connor 
and 
McKinsey 
(2003) 
America HIV  
60-120 
minute in-
depth 
interviews 
using a 
series of 
open-
ended 
questions 
13 
Adherent for 
one year 
following 
non-
adherence 
who became 
adherent 
without 
formal 
intervention, 
11 men and 
two women 
Husserlian 
The findings 
from this 
study included 
i) cycle of non-
adherence 
and negative 
health 
behaviours 
following 
diagnosis, ii) a 
significant life-
event leading 
to a decision 
to be 
adherent and 
iii) readiness 
for adherence 
where 
patients 
adhered to 
treatment. 
This phenomenological investigation into the 
experiences of medication adherence to HIV 
treatment following a period of non-adherence 
elicited a detailed description of the phenomenon 
of readiness for adherence. Readiness followed a 
significant life event which triggered a desire for life 
and other healthy behaviours. The study was in 13 
HIV positive individuals (11 men and 2 women) 
recruited through secondary care. Their HIV 
adherence was measured according to a clinical 
marker.  
Gamble et 
al. (2007) 
UK 
Asthma/ 
corticoster
oids 
Interviews 10 
3 males, 7 
females, 
with 
'difficult 
asthma', 
aged 25-48 
Hermeneutic 
Interpretive 
Adherence is 
made up of a 
complex set of 
decisions that 
are iterative 
and dynamic, 
mediated by 
continual 
change 
The study identified five themes, i) fear of adverse 
effects ii) knowledge is power iii) weighing up costs 
and benefits iv) loss of self v) impact on lifestyle 
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Hansen, 
Holstein and 
Hansen(200
9) 
Denmark General 
35-106 
minute 
interviews  
20 
20 young 
women who 
have 
experienced 
taking 
medicines  
Schutz' 
phenomenology 
(life-world) 
Young women 
had negative 
attitudes 
towards 
taking 
medicines but 
this 
perspective 
was overcome 
by the 
demands of 
everyday life 
and the 
indication of 
the medicine. 
The study found that women generally have a 
negative attitude towards medicines taking but 
found that other goals took priority over their 
negative attitude. The goal, or indication of the 
medicine over-powered their desire not to take 
medicines.  
Henriksen 
and Parnas 
(2013) 
Denmark 
Schizophre
-nia 
Not 
reported 
Not 
reported 
Not 
reported 
Not reported 
The patient 
does not 
experience 
their initial 
self-disorder 
from which 
psychosis 
emerges as 
'symptoms' of 
an illness and 
consequently 
their existence 
and identity 
are not 
compromised 
internally, 
leading to 
non-
This phenomenological inquiry into insight in 
schizophrenia and it's relation to poor compliance 
provides a novel, detailed perspective of 
compliance. Although the paper does not state 
methods, data collection, analysis or empirical 
results, the paper delivers robust 
phenomenological insights.  
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adherence 
Jones (2002) US HIV/AIDS 
Semi-
structured 
interviews 
9 
3 women, 6  
men, with 
HIV infection 
from 
occupational 
exposure, 
sexual 
transmission 
and 
contaminate
d blood 
products, 
over 18 
years old, 
could speak 
English who 
had taken 
medication 
for longer 
than 6 
months, 8 
Caucasian 
and 1 
Hispanic 
Not reported 
Adherence to 
antiretroviral 
therapy by 
nurses with 
HIV was 
described as a 
double-edged 
sword. 
Describing 
adherence as 
'life-changing' 
The study used qualitative interviews to 
understand the experience of adherence to anti-
retroviral medication by nurses with HIV in the 
United States of America. The study describes 
adherence as a life-changing phenomenon and 
identified six themes, i) managing and being 
managed by the meds ii) coping with the meds iii) 
feeling lousy iv) negotiating the hassles and the 
cost v) living under a dark cloud and an 
encompassing theme of vi) becoming a patient. The 
authors highlight 'symbiosis', 'normalisation' and an 
appreciation of the 'life-long' nature of adherence. 
The work concludes by identifying participants as 
'wounded healers' and advocates support groups.  
Jones (2003) US HIV/AIDS 
Semi-
structured 
interviews 
10 
HIV positive, 
over 18 
years old, 
able to 
speak 
English, 
been taking 
HAART over 
Not reported 
Adherence 
was described 
as a reminder 
of illness and 
death (belief 
that God 
would keep 
them alive if 
The study identified three themes to describe the 
experience of adherence to HAART medication, 
these included i) commitment versus perseverance, 
feeling bad and healing helpers. Pills were 
positioned as reminders of illness, emphasising the 
importance of routine and adherence as an agent 
of survival. Describing a relationship with the pills.  
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6 months 
and willing 
to share 
experiences 
they were 
non-
adherent), as 
a relationship 
with the pills 
and 
negotiated by 
routine. 
Response to 
medication 
was also an 
important 
factor, where 
patients new 
an immediate 
response was 
felt they were 
more 
adherent (to 
insulin for 
example).  
Kwinter 
(2005) 
US Depression 
Semi-
structured 
interviews 
11 
8 women 
and 3 men, 
over 18 
years old, be 
using an 
antidepressa
nt for 
depression 
for at least 
the past 4 
months, 
engaged in 
Not reported 
Adherence 
was embodied 
through 
experiences of 
stigma, 
dependence, 
control, 
power and 
social system. 
Essentially 
describing 
adherence as 
This qualitative study used in-depth interviews to 
describe adherence to antidepressant medication 
for people reporting a diagnosis of depression and 
attending non-physician counselling. The study 
identified themes of stigma and dependence, with 
participants describing antidepressants akin to 
insulin for diabetics in that 'it keeps you from 
dying'.  
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psychothera
py with a 
non-
physician 
and able to 
conduct the 
interview in 
English.  
a social 
phenomenon, 
negotiated by 
social actors 
or institutions. 
Antidepressan
ts were 
described as 
preventing 
'feelings' 
being dealt 
with 
appropriately 
whilst on 
medication.   
Lau et al. 
(2008) 
Canada 
Osteoporo
sis 
Mixed 
focus 
groups 
37 
Post-
menopausal 
women 
using at 
least one 
prescription 
for over-the-
counter 
product for 
osteoporosis
, could speak 
English, 
cognitively 
impaired or 
unable to 
manage 
medication 
Not reported 
Adherence is 
mediated by a 
number of 
factors, most 
notably 
relationships 
with 
healthcare 
professionals, 
administration 
requirements 
and routine, 
and 
knowledge 
about the 
medication 
and disease  
This study used a mixed phenomenological 
approach to identify strategies to improve 
adherence, these were i) belief in the importance 
of medication adherence ii) medication specific 
factors iii) beliefs about medication and health iv) 
relationships with HCP v) information exchange and 
vi) strategies to improve adherence, which 
including sub-themes of using systems of 
adherence, using cues and reminders, 
understanding why medication is taken, regular 
follow-up and monitoring. Concluding that 
strategies to improve adherence should be 
individualised.  
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Mohammad
pour, 
Nasrabadi 
and 
Nikbakht 
(2010) 
Iran 
HAART 
/HIV 
In-depth 
semi-
structured 
audio-
recorded  
interviews 
and 
observatio
ns field 
notes 
19 
Hospitalised 
patients in 
the 
infectious 
diseases 
ward in 
varying 
organisation
s in Iran. 11 
men and 
eight 
women, 
aged 27-52 
years 
Interpretive 
The study 
identified four 
themes i) 
choosing to 
live, ii) 
strategies for 
adherence iii) 
relationships 
with HCP and 
iv) medication 
as motivator. 
The study used IPA to investigate the experiences 
of adherence to highly-active anti-retroviral 
therapy for the treatment of HIV in Iran. The study 
recruited 19 participants over 15 years old with 
clinical evidence of HIV infection, the ability to 
communicate verbally and a willingness to 
participate with varying degrees of education level. 
Data was collected through semi-structured 
interviews and field notes and analysed using 
thematic analysis. The researchers did not justify 
why particular 'topics, issues, concerns or events' 
were selected for a more detailed interpretation 
and go on to describe a systematic rather than 
flexible approach. The study identified four themes 
i) choosing to live, ii) strategies for adherence iii) 
relationships with HCP and IV) medication as 
motivator. The studies provide short quotes to 
support their arguments however go on to make 
recommendations around nurses’ involvement in 
decision making which does not appear to be in the 
data.  Unfortunately the text goes on to describe 
the limitations of the study from a positivist 
theoretic perspective (few participant, not 
generalizable) rather than emphasising the rich 
data that the study collected. Additionally, the 
discussion does not make any reference to the 
'ongoing' nature of adherence which is alluded to 
in the conclusion.  
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Muir-
Cochrane et 
al. (2006) 
Australia 
Mental 
health 
Semi-
structured 
interviews 
10 
16-24 years 
old (3 male, 
5 female 
(page 165?), 
homeless, 
have 
experienced 
mental 
health 
problems, 
could speak 
English and 
were willing 
to 
participate 
Not reported 
Adherence 
was described 
under the 
themes of i) 
obtaining 
medication ii) 
managing 
medication iii) 
adverse 
effects of 
medication 
and iv) 
interaction 
with illicit 
drugs 
A qualitative study that presents adherence in 
homeless young people as part of their daily 
struggle. It's finding conceptualise medicines 
adherence as a social phenomenon however the 
authors do not state this, rather their findings are 
presented as discrete themes of obtaining 
medicines (medicines as currency and financial), 
managing medicines (smaller packs,  keeping 
medicines at friends/relatives' houses), adverse 
effects (drowsiness is incompatible with a lifestyle 
where one's day is consumed with finding food, 
shelter and safety) and illicit drug (making their 
symptoms worse, being out of it). The study 
reports that the experiences of young homeless 
people adhering to mental health medication is a 
similar experience of adherence to other medicines 
in other populations.  
Naidoo, 
Dick and 
Cooper 
(2009) 
South 
Africa 
Tuberculos
is 
Pre-
interview 
questionna
ire, 
interviews 
between 
60-120 
minutes 
15 
Purposive 
sample of 
spread of 
men, 
women, 18-
57 years, 
recruited 
from a 
deprived 
clinic. 
Patients 
with 
psychiatric 
disorders, 
AIDS or HIV 
were 
Husserlian 
the authors 
did not report 
a description 
of the 
experience of 
medicines 
adherence but 
reported the 
two major 
themes of 
their findings 
"i) contextual, 
individual and 
disease 
factors 
associated 
Medicines adherence to tuberculosis treatment in 
South Africa is a complex, multi-faceted experience 
that is largely influenced through psycho-social and 
individual, disease specific factors, e.g. symptoms. 
The study used 15 qualitative interviews with men 
and women using treatment for tuberculosis. 
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excluded with illness 
experience 
and ii) 
psychosocial 
factors related 
to adherence 
to 
tuberculosis 
treatment" 
Nguyen et 
al. (2012) 
Vietnam HIV 
Qualitative 
interviews 
(as part of 
a 
longitudin
al study) 
15 
Women with 
HIV, average 
age 29 years 
old  
Not reported 
Adherence to 
antiretroviral 
therapy is 
argued as a 
social 
phenomenon 
of morality. 
Giving women 
their 'morality 
back' and 
avoiding 
'morally bad' 
behaviour 
such as 
deviance from 
social norms 
Qualitative interviews with 15 Vietnamese women 
using anti-retroviral therapy for HIV infection. The 
study positions adherence as a social phenomenon 
of morality. With adherence to medicines 
considered 'good' as it enables social norms, as well 
as prescriptions,  to be adhered to and prevents 'a 
bad death'. Fulfilling socially normal roles such as a 
'good wife' or a 'good mother' described adherence 
as social. The authors argue for medication regimes 
to better fit within the social lives of these women.  
Sale et al. 
(2011) 
Canada 
Osteoporo
sis 
Interviews 21 
6 male, 15 
female, aged 
65-88 years 
old, low 
BMD,  
Giorgi  
Adherence 
was based on 
decisions 
mediated by 
the 
relationship 
with a 
healthcare 
21 at high risk of fracture and taking medication for 
osteoporosis were interviewed to gain an insight 
into their experience of adherence. Decisions to 
take medication were mediated by the patient’s 
relationship with their healthcare professional and 
were embodied by a risk-benefit analysis. 
Adherence was reported as a dynamic process 
which was continually changing, based on 
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provider and 
based on a 
risk-benefit 
analysis and 
was dynamic, 
changing over 
time.  
perceived risks and benefits.  
Sanders and 
Van Oss 
(2013) 
America 
Older 
adults 
 
In-depth 
interviews 
149 
70 years old, 
no gender 
data 
reported,  
Not Reported 
No 'essential' 
description is 
given however 
the authors 
state that 
medication-
taking which is 
embedded 
within daily 
routines serve 
an aid to 
adherence. 
This qualitative study investigated strategies to 
improve adherence by asking participants 'how' 
they adhered to their medicines. Students 
conducted 149 interviews and data was analysed 
thematically using deductive coding established a 
priori. Data was also analysed quantitatively to 
deliver statistical insights. The authors conclude 
that patients embed medicines adherence in task-
based routines such as 'putting my rings on' or 
'putting the coffee on' which, if disrupted, can 
disrupt adherence. The authors also reported that 
more than 50% of the participants required 
assistance with medication adherence, and the 
most common locations for storing medications 
were the kitchen and bathroom.  
Scherman 
and 
Lowhagen 
(2004) 
Sweden 
Asthma/ 
Allergy 
In-depth, 
face-to-
face 
interviews 
30 
14 women 
and 16 men, 
between 18-
62 years old, 
histories of 
symptoms 
and a 
positive skin 
test, range 
of socio-
demographi
Giorgi 
Phenomenogra
phy 
The authors 
did not report 
a descriptions 
but presented 
the themes 
from their 
analysis which 
included 
i)access to 
medicines 
voices 
This longitudinal study investigated adherence in 
patients with symptoms of asthma or allergy over 
eight years. N=30, interviews were conducted and 
identified several themes; which included i)access 
to medicines voices discomfort and fear ii) body 
damage without cure (including a) becoming 
immune, b) self-healing is weakened c) bodies 
signals camouflaged d) stigmatised) and iii) 
medicines as commercial objects not aiming to 
cure. The authors aimed to discover if experiences 
of medicines changed over time and the authors 
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c 
backgrounds 
discomfort 
and fear ii) 
body damage 
without cure 
(including a) 
becoming 
immune, b) 
self-healing is 
weakened c) 
bodies signals 
camouflaged 
d) 
stigmatised) 
and iii) 
medicines as 
commercial 
objects not 
aiming to cure 
conclude that experiences of medicines can be 
stable and so clinicians must engage with patients 
to reach an agreement on how medicines should 
be used.  
Seng and 
Holroyd 
(2013) 
USA Headaches Interviews  21 
Mixture of 
male and 
female with 
varying 
symptoms of 
headache 
who had 
been 
prescribed 
at least one 
acute 
headache 
medication 
Not Reported 
Optimum 
adherence to 
acute 
headache 
medication 
required a 
number of 
different 
behaviours 
and 
consequently 
was part of a 
complex 
experience 
mediated by a 
This study investigated the behaviours involved in 
optimum use of acute headache medication. 
Adherence of 'when required' medicines is often 
difficult to conceptualise and so optimum use is 
often substituted. The study calls for better 
measurement and interventions to improve 
medicines use for acute headaches and concludes 
that behaviours involved in adherence/optimum 
use are many and varied, frequently interlocking to 
provide a milieu of optimum use. The themes 
identified by the study were These included i)lack 
of knowledge ii) forgetting iii) self-diagnosis iv) 
adverse effects v) inefficacy vi) access vii) role viii) 
social influences ix) preference alternative 
treatment. The study also identified cross-episode 
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number of 
facilitators 
and barriers 
to adherence. 
These 
included i)lack 
of knowledge 
ii) forgetting 
iii) self-
diagnosis iv) 
adverse 
effects v) 
inefficacy vi) 
access vii) role 
viii) social 
influences ix) 
preference 
alternative 
treatment. 
The study also 
identified 
cross-episode 
(i) accessible, 
ii) 
communicatio
n iii) limiting 
therapy) and 
episode 
specific 
behaviours 
(self-
diagnosis, 
medication 
(i) accessible, ii) communication iii) limiting 
therapy) and episode specific behaviours (self-
diagnosis, medication choice, time, alternative 
therapy, repeat administration). Whilst the findings 
of the study are complex and give us insight into 
the experiences of medicines adherence to acute 
headache medicines, the difficulty is transferring 
these findings into a practical application for 
practice or further research.  
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choice, time, 
alternative 
therapy, 
repeat 
administration
). 
Sidat, et al. 
(2007) 
Australia HIV/AIDS 
in-depth 
interviews 
10 
7 male and 3 
female, with 
100% 
adherence 
to HAART 
recorded 
more than 
six months 
ago 
Not reported 
The following 
issues 
emerged from 
the analysis i) 
readiness to 
start HAART ii) 
HAART as a 
life-line iii) 
100% 
adherence as 
living longer 
and healthier 
iv) 
relationship 
with HCP v) 
coping/lack of 
adverse 
effects vi) 
improved 
clinical 
10 participants that had recorded 100% adherence 
to HAART in the previous six months were 
interviewed and the data analysed 
phenomenologically. The interviews revealed that 
adherence is associated with longer and better life 
and that an ongoing relationship between the 
patient and physician, coping and a lack of adverse 
effects, as well as an improved clinical outcome 
(measured by T-cell counts) is needed to establish 
100% adherence. The authors conclude that whilst 
100% adherence may be attained, it might not be 
permanent, due to the ongoing and dynamic 
nature of treatment.  
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outcome 
Tadesse et 
al. (2013) 
Ethiopia TB 
in-depth 
interviews 
26 
11 male and 
15 female, 
between 18-
50 years old 
with TB 
accessing 
DOTS clinics 
Not reported 
Adherence 
was described 
as mediated 
by geographic 
access to 
medicines, 
concomitant 
financial 
burdens, 
traditional 
healing 
practices, 
access to 
social support 
and quality of 
health 
services.  
This qualitative study highlights the complex nature 
of tuberculosis treatment in Ethiopia. Geographic 
and financial access to services most influenced 
compliance. The authors support a decentralisation 
approach to delivering services to enable a great 
population geographic (and financial) access to 
medicines.  
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Tilden et al.  
(2005) 
Australia Diabetes case study 1 
26-year old 
female with 
early onset 
type 1 
diabetes 
Giorgi 
The 
experience of 
adherence is 
integral to the 
acceptance or 
rejection of 
self-identity.  
In this case study the participant, a 26-year old 
female with early onset insulin-dependent 
diabetes, was underwent 9 sessions of  cognitive 
analytic therapy. The sessions were audio-recorded 
and transcribed and the psychotherapist kept a 
reflexive journal. The data for the study was made 
up of the transcribed sessions and the reflexive 
journal. These were analysed using a 
phenomenological approach. This identified two 
major themes i) rejection of the diabetic identity 
and ii) integration of the diabetic identity. In the 
case study it is possible to see how a patients sense 
of self dominates the experience of adherence, 
when this participants sense of self was poor her 
adherence was poor however as the participant 
integrated her diabetic self with her own sense of 
self and this contributed to an improved 
experience of adherence.  It is difficult to assess the 
quality of the case study as most quality appraisal 
tools are based on the quality indicators of 
research using interviews or focus groups, rather 
than individual case studies.  
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Table 8. Systematic Review Search Methodology and Excluded Studies 
Database Search Terms Years Number 
of Hits 
Excluded at Screening Included 
CINAHL MH 
‘Medication 
Compliance’ 
AND 
phenomenolo
g* 
2002-2014 
 
Academic 
Journals 
33 4 Dissertations 
2 not including patients’ 
experience; 
Bender et al. (2011) 
Jones et al. (2002) 
 
11 not about experiences of 
medicines adherence 
Cardoso et al. (2013) 
Watts et al. (2002) 
Okumdi et al. (2013) 
Wang et al. (2014) 
Anderson et al.( 2010) 
Barnes et al. (2012) 
Martin et al. (2009) 
Anthony et al. (2008) 
Mosack et al. (2009) 
Chapman et al. (2004) 
Deegan et al. (2005) 
 
2 not in adults 
Mawn et al. (2012) 
Chen et al. (2010) 
 
Not in English 
Castro et al (2012) 
13 
 
MEDLINE “adherence or 
concordance 
or 
compliance” 
AND 
“phenomenol
ogy*” 
 
1980-2014 
in English, 
Adult (19 
years+ 
126 93 excluded not about 
experiences of medicines 
adherence 
Suttanon et al. (2012) 
Dean et al. (2005) 
Hyland et al. (2014) 
Abbasi et al. (2014) 
Mudge et al. (2006) 
Haas et al. ( 2012) 
O’Brien et al. (2010) 
Meis et al. (2014) 
Hinckley et al. (2014) 
Usher et al. (2013) 
Ebert et al. (2014) 
Aakhus et al. (2012) 
Evangeli et al. (2014) 
Morgan et al. (2014) 
Mataix-Cols et al. (2002) 
Kilbride et al. (2013) 
Tovazzi et al. (2012) 
Norlyk et al. (2013) 
Petursdottir et al. (2010) 
Matwa et al. (2003) 
Li et al. (2013) 
Chapman et al. (2004) 
18 
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Okumdi et al. (2013) 
Janes et al. (2013) 
Fitzpatrick et al. (2011) 
Hendry et al. (2012) 
Maclean et al. (1982) 
Hughes et al. (2011) 
Schuler et al. (2012) 
Richardson et al. (2010) 
Larsson et al. (2010) 
Peters et al. (2012) 
Flament et al. (2001) 
Watts et al. (2002) 
Carolan et al. (2012) 
Garnweidner et al. (2012) 
Cianci et al. (2011) 
Falter et al. (2006) 
Matthew et al. (2011) 
Badlan et al. (2006) 
O’Brien et al (2008) 
Porter et al. (2005) 
Smith et al. (2007) 
Benisovich et al. (2003) 
Hale et al. (2010) 
Sale et al. (2010) 
Mgutshini et al. (2010) 
Eldh et al. (2004) 
Walsh et al. (2000) 
Holmstrom et al. (2005) 
Whetstone et al. (1991) 
Sloan et al. (2009) 
Costain et al. (2008) 
Kinder et al. (2009) 
De Geest et al. (1994) 
Porter et al. (2007) 
Rasmussen et al. (2007) 
Thomas et al. (1993) 
Anthony et al. (2008) 
Dickerson et al. (2007) 
Zubenko et al. (2000) 
Johannesen et al. (2008) 
Barnas et al. (1985) 
Kim et al. (2007) 
Hinson et al. (2005) 
Niehause et al. (2005) 
David et al. (1990) 
Bates et al. (1993) 
Miller at al. (1993) 
Eldh et al. (2006) 
Fogel et al. (1992) 
Fu et al. (2005) 
Olesen et al. (1990) 
Voruganti et al. (2006) 
Masand et al. (2006) 
De Oliveira et al. (2006) 
Tunstall et al. (2000) 
O’Toole et al. (2004) 
Gibson et al. (2004) 
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Roberts et al. (1995) 
Wyatt et al. (2003) 
Forsyth et al. (2000) 
Beich et al. (2002) 
Bach et al. (1996) 
Carlson et al. (1998) 
Anstett et al (1980) 
Sheikh et al. (1995) 
Thomas et al. (1994) 
Larkin et al. (1982) 
Kugelmann et al. (1983) 
Jenkins et al. (1988) 
Schwoon et al. (1980) 
Courtemanche et al. (1989) 
 
 
5 not about patients’ 
experiences 
Fleming et al. (2013) 
Sissolak et al. (2011) 
Mercier et al. (2011) 
Hansen et al. (2009) 
Svedberg et al. (2001) 
 
 
8 duplicates 
Naidoo et al. (2009) 
DeMoss et al. (2014) 
Mohammadpour et al. 
(2010) 
Enriquez et al. (2004) 
Scotto et al. (2005) 
Seng et al. (2013) 
Sidat et al. (2007) 
Karamanidou et al.  (2014) 
 
2 not in adults 
Grossoehme et al. (2014) 
Cheung et al. (2012) 
PsychInfo “DE treatment 
compliance” 
AND “DE 
phenomenolo
gy” 
2009-2014 4 1 duplicate 
Mohammadpour et al. 
(2010) 
 
1 not about experiences of 
medicines adherence 
Neal-Barnett et al. (2010) 
 
 
 
2 
Sociologic
al 
Abstracts 
Online 
“medicines 
compliance”, 
“medicines 
concordance”, 
“medicines 
compliance” 
and 
“phenomen*” 
1983-2009 
 
Peer 
reviewed 
and in 
English 
9 6 not about medicines 
adherence 
Inclan (2005) 
Snortum (1988) 
Jones (2005) 
Strong and Huon (1998) 
White (1983) 
Pless (1984) 
3 
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EMBASE SH 
"Medication 
Compliance" 
and SH 
"phenomenol
ogy" 
 
Human, In 
English, 
Not 
MEDLINE 
 
1 Duplicate 
DeMoss et al. (2014 
0 
Web of 
Science 
“medicines 
adherence”, 
“compliance”, 
“concordance”
, 
“phenomenol
ogical” 
All years 54 36 not about experiences of 
medicines adherence 
Nolan (2013) 
De Portugal (2013) 
Peters et al. (2012) 
Aakhus et al (2012) 
Schuler et al. (2012) 
Haas et al (2012) 
Falter et al. (2012) 
Sissolak et al. (2011) 
Crawford et al. (2010) 
Chen et al (2009) 
Goodwin et al. (2008) 
Orfei et al. (2008) 
Johannesen et al (2008) 
Kim et al. (2007) 
Rasmussen et al. (2007) 
Voruganti et al. (2006) 
Hansen et al. (2006) 
Niehaus et al. (2005) 
Gibson et al. (2004) 
Wyatt et al (2003) 
Mataix-Cols et al. (2002) 
Forsyth et al. (2000) 
Walsh et al (2000) 
Carlson (1998) 
Newport and Nemeroff 
(1998) 
Bach et al. (1996) 
Barnes et al (1995) 
Roberts et al. (1995) 
De Geest et al. (1994) 
Solway et al. (1991) 
David (1990) 
Schwartz et al (1985) 
Mason et al. (1984) 
Lieberman et al. (1984) 
Kinston (1983) 
White (1983) 
 
1 Not investigating patients 
experiences 
Pirie et al (2007) 
 
5 not in English 
박정원; 임화윤 (2012) 
Song (2011) 
Maeda et al. (2009) 
Teike-Luthi (2007) 
Strydon et al. (2000) 
5 
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7 duplicates excluded 
Evangeli et al. (2014) 
DeMoss et al. (2014) 
Seng et al. (2013) 
Parnas et al. (2013) 
Sale et al (2011) 
Hansen et al (2009) 
Keck (1996) 
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The Epoché  
Epoché or ‘bracketing out’ of preconceived ideas about medicines adherence relates to 
Chapter 4. The text is presented in the first person and is included to demonstrate the 
adoption of the epoché process within the study. The text was used during the analysis to 
scrutinise the codes produced and provides an insight, and summary, of a priori opinions 
and beliefs about medicines adherence. Epoché was practiced informally prior to 
interviews, focus groups and analysis and was regularly referred to throughout the analysis 
to recognise themes that may have been projected onto the data based on previously held 
beliefs.  
“My current understanding of adherence is dually framed; the first, but by no means more 
significant framing, is based on my career and education in the natural sciences paradigm. 
A formal, scientific presupposition of adherence exists that links back to my formal 
education and professional career. Indicated for particular diseases, at particular dosages 
each therapeutic regimen is evidenced and validated by evidence-based medicine. 
Fundamentally adherence to medicines is governed by the physical characteristics of the 
medicine, its container and the patient’s ability to understand and execute the 
prescription. Pharmacists are educated to consider the following in relation to adherence; 
how will the patient open the container? Does the patient like the taste? Can the patient 
feel the benefit of the medicine? These questions fundamentally identify medicines as 
objects, and thus medicines adherence, is intrinsically linked to the physical characteristics 
of those objects. Additionally, medicines taking might be considered more as an action, the 
execution of an order rather than a self-motivated behaviour. Patients often appear to 
reject orders out-rightly or do not understand how the prescribed order should be carried 
out. Often adverse effects stop patients taking their medicines, if they feel dizzy, sleepy, 
nauseous or have gastrointestinal disturbances. Patients sometimes simply forget to take 
their medicines in the same way that we forget to do other things. Sometimes it is linked to 
routine behaviours, so that patients just take their medicines without really thinking about 
it or knowing why or what the medicine is for. Sometimes patients are addicted to the 
medicine and so they’re non-adherent because they take more than they should or they’re 
afraid of addiction to the medicine and don’t want to be addicted anymore so then they 
stop the medicine abruptly.” 
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Analytic Process 
Analysis Extract 1 below demonstrates manual coding, as transcript text became codes 
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Analysis Extract 2 below shows the One Sheet of Paper Method, whereby codes are fitted 
onto one sheet of paper using imaginative variation to link codes and build themes or 
clusters. 
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Analytic Extract 3 and 4 demonstrate how headline themes were formalised. 
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Appendix B: Study materials 
Participant Pack 
 
 
     
A phenomenological investigation in patients’ lived 
experiences of medication adherence 
Participant Information Sheet 
Who are we? 
The Chief Investigator is Adam Pattison Rathbone. He is a full-time PhD student at Durham 
University supervised by the senior research team Professor Andrew Husband, Dr Adam 
Todd, Dr Kimberly Jamie and Professor Pali Hungin. Adam will conduct the interviews and 
focus groups and will be the main contact for the study.  
Why are we doing the study? 
The study is trying to find out what patients experience when they take medication 
for certain diseases or conditions. This will help healthcare professionals have a 
better understanding of what it is like for patients to take medication and be able 
to improve the experience in the future.  This study is trying to document exactly 
what patients experience whilst taking medicines and if the experience differs 
between different groups of patients with different disease. For example, a patient 
taking medicines for high blood pressure might have a different experience to 
patients taking medicines for diabetes. This study is not trying to find out if you do 
or do not take your medicines; all we want to know about is your experience of 
taking medication.  
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Do I have to take part? 
No. You do not have to take part if you do not want to. If you decide you want to 
take part in the beginning and then change your mind halfway through, you can 
leave the study. You don’t have to explain why you want to leave. If you decide not 
to take part or withdraw halfway through your care will not be affected. If you do 
decide to take part, you will be asked to sign a consent form before we start (a 
sample form is given below for you to become familiar with).  
What will happen during the study? What is a focus group? 
A focus group is when 5-8 people sit together in a group and talk about something. 
In this focus group, I’ll tell you about what we’ve found from some earlier research 
into how people take their medicines and then we’ll talk about it. We’ll also be 
discussing ideas about how to help people take their medicines as prescribed.  
Who else will be in the focus group? 
Other people in the focus group may have already been interviewed as part of the earlier 
research or they may be new to the study. Either way, the views and opinions of all 
participants are important and just as valued.  
What happens after the study? 
After the focus groups, we will look at what everyone has said and produce a 
report. The report, or parts of it, will be presented at conferences and published in 
scientific journals. Your personal details will never be published and you will not be 
identifiable in any of the publications. 
Are there any risks or downsides to taking part? 
It is very unlikely you will come to any harm from taking part in the study. Your 
emotional and physical needs will be considered thoroughly. If you are concerned 
about your welfare or no longer want to take part in the study you are free to leave 
at any point.  
What are the benefits of taking part? 
Although there will be no direct benefit to you, by taking part in this study you will 
be helping healthcare professionals get a better understanding of patients’ 
experiences of taking medicines in the future. This may lead to better ways of 
taking medication or technology to help people take their medication more easily.  
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What happens if I change my mind and no longer want to take part? 
If you change your mind all you need to do is inform a member of the research 
team at any point during the focus group and you will be withdrawn from the study. 
However, we would keep any information we had collected up to that point and 
use it as part of the research.  
What if I’m not happy with the way the interview or focus group goes? 
Firstly, I’d like you to tell me, however if you would prefer you can contact a 
member of the supervisory research team, Dr Adam Todd or Professor Andy 
Husband on 0191 334 0542, or the Chair of the School Ethics Committee, 0191 334 
0210 There will not be any compensation arrangements in the unlikely event you 
are harmed during the study. If you are harmed during the study and it is due to 
negligence you may have grounds for legal action, which you may have to pay for.  
Who is paying for this research? 
Durham University in collaboration with AstraZeneca (a company that 
manufacturers medication). Durham University in collaboration with AstraZeneca (a 
company that manufacturers medication). AstraZeneca are not directly involved in 
preparing any documentation or shaping the research other than in a review 
capacity. AstraZeneca are asked to review documents and offer advisory comments 
– this enables the school to take advantage of the wealth of research experience 
within AstraZeneca. AstraZeneca will not receive or have access to the study data. 
The contract with AstraZeneca ensures full freedom for the team to publish the 
academic results of the research.  
Who will see information about me? 
If the Chief Investigator suspects you are a danger to yourself or to others, or you 
confess to serious crime (e.g. murder) or significant misuses of medication (e.g. 
giving adult medication to children) confidentiality will be broken and the relevant 
authorities informed. Otherwise, only I (the Chief Investigator) will see your 
personal information. Once you have agreed to be part of the study you will be 
given a unique code. All of the information we collect will be coded throughout the 
study and this will stop you from being identified. The only piece of information 
that will have your name on it, the consent form and ‘registering an interest’ form, 
will be kept under the control of Chief Investigator, under lock and key at the 
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Holliday Building, Queen’s Campus, Stockton-on-Tees. At the end of the study, the 
consent forms and ‘registering an interest’ form will be destroyed. AstraZeneca will 
not see any personal information about you.  
Who is checking what you’re doing is right? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and given favourable opinion by South-Central Oxford C Research Ethics 
Committee. Durham University Ethics Committee, AstraZeneca Research and 
Development Team and senior researchers from Durham University have also 
reviewed the protocols that will be used during this study.   
What do I do now? 
If you want more information please contact me on 0191 334 0368 or 
a.p.rathbone@durham.ac.uk or write to me at the address below.  If you want to 
take part in the study please fill out the ‘Registering an Interest Form’ below and 
send it back to me in the stamped addressed envelope and I will contact you to 
arrange the interview. If you’d prefer not to take part in the study, simply do not 
respond to this letter. 
For your additional information, here are the names and contact details of the 
Research Team involved with the study:   
Mr Adam Pattison Rathbone 
Chief Investigator  
School of Medicine, Pharmacy and Health 
The Holliday Building 
Queen’s Campus 
Durham University 
Teesside 
TS17 6BH 
Telephone 0191 334 0368 
Mobile  07904 220720 
Email a.p.rathbone@durham.ac.uk 
 
Prof Andy Husband  
Dean of Pharmacy (address to The 
Holliday Building) 
E-mail: a.k.husband@durham.ac.uk 
Telephone: 0191 334 0102 
 
 
 
 
 
 
Dr. Adam Todd  
Senior Lecturer in Pharmacy Practice 
(address to The Holliday Building) 
Email: adam.todd@durham.ac.uk  
Telephone: 0191 334 0542 
 
Prof APS Hungin  
Director in the Centre for Integrated 
Healthcare Research 
Head of School & Dean of Medicine 
(address to The Wolfson Building) 
Email a.p.s.hungin@durham.ac.uk  
Telephone: 0191 334 0375 
Appendix B 
 
  
Page 202 of 261 
 
Dr Kimberly Jamie 
Lecturer in Sociology 
School of Applied Social Sciences 
Durham University 
32 Old Elvet 
Durham 
DH1 3HN 
Email: kimberly.jamie@durham.ac.uk  
Telephone: 0191 334 1478 
 
 
 
     
Registering an Interest Form 
 
 
Please complete and sign this form and post it back to us in the enclosed stamped 
addressed envelope. Please complete this form in BLOCK CAPITALS. Your details will 
be managed confidentially and destroyed at the end of the study. Thank you.    
 
Contact Details Sheet  
Name (what you’d like us to call you):  
Gender  
Address:  
Age  
Occupation  
Telephone Number:  
My main diagnosis is (please circle or add 
diagnosis as appropriate);  
COPD (bronchitis or emphysema) 
Cardiovascular Disease (including high blood 
pressure or heart problems) 
Gout 
Cancer 
Diabetes (type I or type II) 
Best time to contact you:  
“By signing this form I am confirming that I 
want to be contacted to be involved with 
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the study looking into experiences of 
medicines adherence” 
Signature: 
Date:  
 
 
Participant Consent Form 
Please initial the 
boxes to confirm 
you agree with 
each statement  
 
1. I confirm that I have read and understand the information 
sheet dated.................... (version............) for the above study. I 
have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am 
free to withdraw at any time without giving any reason, and 
without my legal rights, or care being affected. I understand 
that any information collected up until the point of my 
withdrawal will be kept and used as part of the research. 
 
3. I understand that by taking part in this research, this consent 
form and ‘Registering an Interest’ Form will be stored at 
Durham University under the direction of the Dean of 
Pharmacy. 
 
4. I understand I will take part in a focus group and the focus 
group will be audio recorded. 
 
 
5. I agree to the use of my anonymised quotes when this 
research is published.  
 
6. I am willing to be contacted by the research team in the 
future regarding this project. 
 
 
7. I agree to take part in the above study.  
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Name of Participant:     Name of Researcher: 
 
Date:        Date: 
 
Signature:       Signature 
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Risk Assessment 
Please complete the following for your study. This form must be dated and signed by the 
Principal Applicant. Please describe the risks for both participants and researchers. Please 
note that all hazards relating to risk of injury/harm will be forwarded to the Health and 
Safety Officer for the School of Medicine and Health 
Location: Participants’ home  Activity: Interviewing participants  
 
Hazards Those at 
Risk 
Description 
of Risk 
Risk Controls Risk 
Rating 
Working in 
the 
community 
Researcher Interviewing 
participant in 
their own 
home 
Interviews will always be undertaken in 
daylight hours 
 
The research team will be informed when 
and where an interview will take place 
including interview times.  The 
interviewer will contact a member of the 
research team immediately before 
initiating the interview and immediately 
after.  If the interviewer fails to contact 
the research team when scheduled, the 
interviewer will be contacted by 
telephone by a nominated member of the 
research team – if there is no answer 
after three attempts, the emergency 
services will be called. 
 
A fully charged mobile phone will always 
be taken to the interviews.  This will 
contain contact details for members of 
the research team.  The interviewer will 
also have a unique code phrase that can 
be used to alert the research team that 
assistance is required without drawing 
attention. 
 
Durham University identification will be 
carried to each interview. 
Low 
Asking 
patients/inf
ormal carers 
about their 
experience(
s) of taking 
medication 
Researcher Interviewing a 
patient/carer 
about their 
experience of 
taking 
medication 
and becoming 
distressed 
The research team will establish sources 
of support available while undertaking the 
project.  The interviewer (which will be 
APR) has plenty of experience of 
interviewing patients and asking about 
their medicines taking behaviour. This 
experience will be invaluable while 
interviewing patients for this study. 
Additionally APR has attended Durham 
University interview training and will 
attend Oxford University training sessions 
on using interviews in qualitative 
Low 
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research. APR is seeking support from 
qualitative researchers (HH, HC), who 
have extensive experience of interviewing 
patients. APR will be supported by AH and 
AT who have a wealth of experience of 
interviewing patients. 
 
Asking 
patients 
about their 
experience(
s) of taking 
medication 
Patient Patients 
becoming 
distressed 
during and 
after the 
interview 
 
If a patient became distressed we would 
ensure that this was brought to the 
immediate attention of Dr Husband or 
Prof Hungin (and/or Dr Lisa Banks) who 
are senior members of the research team. 
 
The participants will be interviewed at 
home and it may be unusual for patients 
to be interviewed about their medicines 
in this setting, however all of the 
interview questions will be open-ended so 
the participant will be in control of the 
information they wish to disclose. 
Additionally if the patient does become 
distressed, there are likely to be things at 
home that will reassure and support 
them. Participants will be advised at the 
beginning of the interview of their right to 
withdraw and how the interview will end 
if they become distressed. The participant 
information sheet specifically states that 
the interview will focus on the patient’s 
‘experience’ of hospice care and no advice 
or guidance will be given from the 
researcher regarding the patient’s 
medicine.  We will make it clear to the 
patients that they are participating in a 
research project and not a clinical review 
of their medication.  In addition to the 
participant information containing this 
advice, we will also re-affirm this with the 
patient immediately before the interview 
takes place. 
 
 
Any distressed patient will always be 
given the opportunity to withdraw from 
the project.  After the interview, patients 
will also be left with a ‘support sheet’ that 
contains the contact information of 
support groups and the contact details of 
the research team to get in touch if they 
wish. 
Low 
Risk Rating = Likelihood x Severity =  LOW, MEDIUM or HIGH 
Assessor Name (Principal Applicant):     Adam Pattison Rathbone 
Signature:    Date: 01.12.2013 
Appendix B 
 
  
Page 207 of 261 
Section 2: Indemnity and Insurance Arrangements 
INSURANCE: please confirm that a copy of the application form has been lodged with the 
University’s Insurance Officer: [where, for example: application is made to an external 
ethics committee/organisation, including an NHS Ethics Committee; where a project is 
likely to fall outside or require an extension to the University existing insurance cover, (full 
details are available at: http://www.dur.ac.uk/procurement.office/) where there is some 
significant Risk involved, or where a funder/sponsor requires a particular insurance policy 
to be in place.] and that adequate insurance cover is in place for your study. 
Yes  
If no please explain: 
INDEMNIFICATION: please state below any special arrangements for indemnification in the 
event of injury and non-negligent harm to the participants. 
If not applicable please add not applicable below. 
Not applicable 
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Institutional Ethics Approval Letter 
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NHS Ethics Approval Letter 
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Interview Schedule  
Interviewer (Chief Investigator,) re-introduces himself as the researcher and thanks the 
participant for showing an interest in the study.  
Recaps the study, reminding the participant what the interview is about and that we would 
like to chat about their experiences of taking medicines as they are prescribed. The 
participant is reminded that if the Chief Investigator suspects abuse; if they confess to 
serious crime (e.g. murder), significant misuse of medicines or if they indicate they are a 
danger to themselves or others the Chief Investigator is obliged to break confidentiality and 
inform the authorities, as outlined in the Participant Information Sheet.  
Remind the participant that they will not be identifiable from the information that is 
collected and only the Chief Investigator will have access to the consent and ‘registering an 
interest’ forms with their names. Ensure the participant understands that this is an 
interview about their experiences of medicines taking and should not impact on how they 
take their medicines at all as this is not a clinical review. The interview will not impact on 
the care they receive and the information will not be shared with healthcare professionals 
involved in their care. Additionally, remind the participant that the interviewer will not be 
able to answer any questions about the patient’s medical condition or medicines. Remind 
the participant that if they do not want to answer any of the questions that can say ‘pass’ 
and we will move on and that they can end the interview at any point by saying ‘I’d like to 
end the interview now’ or something similar.  Additionally participants will be reminded 
that they can withdraw from the study up until the end of the interview or focus group. Ask 
the patient if they are still happy to be contacted via telephone in the future to discuss and 
confirm the findings. Re-confirm the participant’s willingness to be audio-recorded and that 
they still want to take part. Go through the consent form and sign it. 
“Now we’re ready to start, how did you feel when you were diagnosed with….? “ 
 This will include the participant’s experiences of being diagnosed with their condition; what 
happened when they were diagnosed and how it felt. This will lead onto the experience 
about first being prescribed the medication; how involved the patient was with the decision 
to start; faith or trust in the prescriber; knowledge about the disease; financial instability; 
loss of control and continue the medication/prescribing of the medicine; what they felt or 
believed then and if this has changed now 
“What are your experiences of taking your medicines as prescribed every day? “ 
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 This will include positive and negative experiences; if they find it difficult or easy to adhere 
and may identify strategies used by the patient to adhere to their prescribed medicines; 
how they feel about their medicines and if this has changed over time  
“What, if any, are your experiences of not being able to take your medicines as 
prescribed?” 
This will include how these experiences have changed over the duration of the course of 
treatment. What strategies (if any) the participant uses to ensure they take their 
medication as prescribed, such as help from friends or relatives. This question will also 
identify how the patient felt if they were not able to adhere to their regimen and what they 
believed would happen 
“Is there anything that you’d like to add that we haven’t discussed?” 
At the end of the interview, the participant will be thanked for their contribution and for 
their time and input and offer an opportunity for them to ask any questions. Additionally 
the patient will be asked if they would like to see the results of the study (if so they will be 
asked if they would like to receive them via email or via post). Participants will be given the 
‘Information for after the interview’ sheet (see Post-Interview Information V1).  
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Focus Group Schedule and Slides 
The Chief Investigator will introduce himself and the facilitator (this is expected to be a 
member of the senior research team or a Wolfson Research Institute Postgraduate 
Associate) and summarise the study to date. The Chief Investigator will present the findings 
of the study to date including potential interventions to improve medicines adherence. The 
Chief Investigator will then invite comments from the focus group about the findings, in a 
manner consistent with successful focus group technique (Crossley, 2002, Kitzinger, 1994, 
Morgan, 1996). 
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Appendix C: The ethics of studying adherence 
This chapter outlines some of the ethical tensions encountered during the study. This 
chapter outlines the practical solutions to some of the ethical issues of using qualitative 
research methodology to investigate medicines adherence before turning to consider the 
ethical tensions raised by studying adherence and being a registered pharmacist. This 
chapter finally describes some of the ethical conflicts related to adherence, the 
pharmaceutical industry and the pharmaceuticalisation of society. Despite the ethical 
issues described below, the project was reviewed and given favourable opinion by the 
Durham University School of Medicine, Pharmacy and Health Ethics Sub-Committee and 
the NHS Proportionate Review South-Central Oxford C Ethics Research Committee.  
Amendments were made to these approvals, which enabled participants for focus groups 
to be recruited through local academic and professional networks as well as through 
community pharmacies and general practices.     
Practical ethical considerations  
Preparing the study for ethical approval meant considering the practical issues that might 
arise during everyday running of the study. These included obtaining consent from the 
participant to be involved in the study; maintain confidentiality and adhering to data 
protection laws; limiting and dealing with distress; giving participants the chance to 
withdraw from the study and recognising and managing disclosure of medicines non-
adherence. Each of these issues had to be addressed as a matter of good research practice 
and how these issues were dealt with is documented below. 
Consent  
Full informed consent was obtained before the interview or focus group began and 
participants were given copies of the consent form at the point of invitation to maximise 
the length of time for them to consider their options. If participants had not given consent 
to be included in the focus group prior to the interview, consent was taken only to be 
involved in the focus group at the focus group. Participants were able to withdraw at any 
time up until the end of the interview or focus group without giving a reason. Participants 
were informed in the Participant Information Sheet and at the beginning of the interview 
and focus groups that their decision to take part in the study would not affect their care in 
anyway.  As the participants were first approached by their community pharmacy or 
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general practice team, it was possible that some participants may have felt that they were 
obliged to say yes to accept the invitation. In order to minimise the impact on the 
relationship between the community pharmacy or general practice teams and their 
patients, these teams were instructed to advise their patients to direct their questions 
about the study to the research team, whose contact details were within the Participant 
Pack. This prevented potential participants becoming confused about their community 
pharmacy or general practice team’s involvement with the study and altering the patient-
practitioner relationship. If the participant decided to take part in the study, the 
community pharmacy or general practice team would forward their contact details to the 
research team, or the patient would contact the research team directly. The community 
pharmacist or general practitioner assessed capacity initially when distributing Patient 
Packs and identifying patients for the study, as this is part of their routine work. To a 
certain extent, when participants contacted the research team directly, assumed capacity 
was taken. Prior to consent being taken at the beginning of the interview or focus group, 
the participants’ capacity was also assessed.  
Confidentiality and data protection  
Confidentiality was of paramount importance for this study and in all research and 
participants should feel reassured that their details would be kept confidential and only 
seen by a limited number of authorised members of the research team. Participants 
consent forms and ‘Registering an Interest’ forms were kept in a locked filling cabinet in a 
locked office at the Queen’s Campus, Stockton. The consent form stated clearly that the 
consent form and ‘Registering an Interest Form’ will be kept under these conditions and 
access to this was restricted, even to supervisory members of the research team. Quotes 
have been anonimised in publications and sensitive information altered to protect 
participants’ confidentiality – if quotes were edited to provide anonymity, any editorial 
changes were discussed by the research team and, where possible, with the participant to 
ensure the meaning of the quote was not changed. A secure password-protected computer 
was used to store electronic data (audio recordings and transcripts) and was kept under the 
supervision at all times. The transcript data collected from the study will be destroyed five 
years after the end of the study. AstraZeneca have not and will not have access to 
confidential participant information, such as names, address, date of births or contact 
details.  
Distress  
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Participants can become distressed during interviews if they feel under pressure to answer 
questions or to answer questions in a certain way. Participants in this study were reminded 
that they can withdraw from the study at any time without giving a reason simply by 
stating ‘I would like to stop the interview now’ or ‘I would like to leave the focus group’ or 
something similar. Additionally, if a participant did not want to answer a question they 
were able to say ‘pass’ and the interview moved onto the next question – participants were 
reminded of this before giving consent. As the questions were open-ended, the participant 
was in control of the detail that they gave and this allowed a sense of control for the 
participant and ensured an even balance of power in an attempt to limit distress. The 
research team had experience of speaking to patients about medicine taking behaviours 
and medicines adherence and this experience was utilised during the study to minimise 
distress to the participants. Interviews were paused if the participant showed signs of 
distress and offered the opportunity to pause, reschedule or terminate the interview. 
Participants were never left in distress and all participants were given a support sheet, 
entitled ‘Support Information for after the study’, this signposted participants to relevant 
areas of support, such as their local pharmacy and their general practitioner, if they felt the 
need to after the conclusion of the interview. Additionally this information advised the 
participant what to do if they were unhappy with how the interview went. If participants 
became or showed signs of distress during the focus group the session was paused, this 
gave participants the opportunity to recover themselves or withdraw from the focus group.  
Withdrawal  
As there were arguably two phases to this study (interviews and focus groups), participants 
were able to withdraw at the end of each phase, for example, if a participant was 
interviewed they did not have to take part in the focus groups. A practical approach to 
withdrawal was taken in that participants were able to withdraw from either the interview 
or the focus group at any time during the day of the interview or focus group. This meant 
participants had the opportunity to reflect on what they had said and contact the research 
team if they wanted to withdraw their data. After this point, it would be impractical to 
remove data as it would have been transcribed and coded and formed part of the overall 
analysis.  
Disclosure 
A broader ethical issue raised by this study was the possible disclosure of medicines non-
adherence behaviours and how a researcher with registered pharmacist status would 
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negotiate this. During the course of this study that experience as a clinical pharmacist may 
lead to the identification of potentially hazardous medicines-taking behaviours or 
medicines use issues. Registered pharmacists have an ethical responsibility to aim to 
improve or alleviate the participant’s medicines adherence issues (either directly or 
indirectly by referring the participant to their prescriber/family doctor). On the other hand 
however, the study context raised contention between the ethical responsibility of the 
identity of a researcher and the identity of a pharmacist. This is discussed in more detail in 
the section below and constitutes a paper published in Sociological Research Online 
(presented below) Unfamiliarity with the participants, not having access to appropriate 
medical notes and not having access to previous medication records or pharmacy records 
supported an argument that it would be unprofessional and inappropriate for any 
pharmacist to make clinical judgements pertaining to the severity of any identified 
medicines adherence issues in relation to the participants/patients overall package of 
health and pharmaceutical care. Furthermore, participants were invited to be part of the 
study and were advised that the study would not impact on their routine healthcare – if 
confidentiality was broken and the participant’s usual healthcare team informed of a 
medicines adherence issue, this would breach the agreement between the participant and 
the research team, causing distress to both parties. In light of this, and after much 
consideration, I decided not to breach confidentiality and report medicines adherence 
issues that come to light during the interviews or focus groups. The support page left for 
participants after the interview or focus group titled ‘Support Information for after the 
study’ contained information about what the patient should do if they are worried they are 
not taking their medicines as prescribed and this was deemed sufficient to directly signpost 
participants to necessary support.  
Despite a more hazardous disclosure occurring during the study, in the event a participant 
disclosed something else that was potentially hazardous, to either the participant 
themselves or another person in relation to the access or use of medicines, there was a 
plan to discuss this with the senior supervisory members of the research team, to consider 
the matter in a clinical, social, ethical and legal context, before attempting to discuss the 
issue with the participant. For serious clinical issues, the participant would be strongly 
advised that they should attend their GP surgery or their pharmacist to discuss the matter 
with their healthcare professional as a point of urgency. For minor clinical issues, the same 
procedure was planned however with less urgency. For non-clinical issues relating to safe-
guarding, social and/or legal issues, i.e. sharing medicines with children, there was a plan to 
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discuss the matter with the participant and inform them that due to the nature of the 
disclosure confidentiality must be breached and the social services and/or police will be 
contacted. However none of these instances occurred during the research.  
In addition to clinical and non-clinical disclosures, participants might have felt the need to 
change the way they take their medication after the interview or focus group. Participants 
were repeatedly informed that the study was not a clinical review and should not impact 
on the way they take their medication. Additionally participants were reminded that the 
study should not impact on the way they take their medication before and after the 
interviews and focus groups. As described above, participants were given a support sheet 
with information signposting to areas of expertise about their medicines and how 
medicines should be taken. On reflection, there were no instances were this was a 
suspected concern.  
Professional ethical standards and identity management 
The way in which the researcher presents him/herself to research participants has raised 
itself as a central ethical issue during this study and is not just concerned about how to get 
the most data but also about dealing with ethical commitments as a pharmacist. In this 
context there are two sets of ethical considerations to be followed, simultaneously. On the 
one hand, the customary social science qualitative researcher standards (or more formal 
British Sociological Association ethics standards) and on the other hand, the General 
Pharmaceutical Council Ethical Standards set out by the pharmacy regulatory body. The 
paper below was submitted to Sociological Research Online and accepted for publication in 
January 2016. This work was also presented at a John Snow College Seminar in 2015 and at 
the British Sociological Association’s Medical Sociology Conference in 2014.  
Transferring from clinical pharmacy practice to qualitative research: 
questioning identity, epistemology and ethical frameworks  
Abstract:  
Researcher identity can present methodological and practical, as well as epistemological 
and ethical tensions in sociological research. Identity management, such as the 
presentation of the self during a research interview, can have significant effects on the 
research encounter and data collected. An example of this is ‘white coat syndrome', the 
disjointed interaction between clinicians and patients arising from unequal power and 
expertise, which can also occur in research encounters. For clinicians engaged in qualitative 
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social research, identity management can be particularly challenging given the potential for 
'white coat syndrome'.  Drawing on the experiences of a registered pharmacist undertaking 
qualitative research, we discuss the epistemological transition many clinicians go through 
when embarking on sociological research. We suggest that identity management is not just 
a matter of optimising data collection but also has ethical tensions. Drawing on Goffman’s 
social role theory, we discuss the epistemic tensions between researchers’ dual identities 
through positivist and constructivist frames, discussing the professional and legal 
implications, as well as the methodological practicalities of identity negotiation. We discuss 
conflicting professional and regulatory ethical frameworks, and ethics committees’ 
negotiation of intervention and elicitation during research encounters and the conflict in 
managing professional, legal and clinical responsibilities whilst adhering to expected social 
research conventions.  
Introduction  
This paper is a reflection on the process of researchers crossing, and straddling, disciplinary 
boundaries and the challenges that this presents in terms of identity management and 
competing ethical obligations. It argues that the process of developing a sociological 
imagination presents challenges for those moving from a generally positivist discipline to 
conducting qualitative, social science research. This mobility requires a high degree of 
reflexivity, careful identity management and the negotiation of diverse, often competing, 
research design perspectives. This paper is structured to reflect the personal experiences of 
a pharmacist (APR) embarking on sociological research and frames the experience using 
Goffman’s social role theory, that people present different identities in different social 
contexts. It describes the difficulty faced by pharmacists, and other clinical professionals, 
that embark on sociological research when deciding to present their clinical identities. The 
paper then considers the ethical tensions presented by dual identities and closes 
considering how different paradigmatic approaches attempt to deal with disciplinarily 
mobile practitioners.  
We argue that clinicians, with traditionally positivist backgrounds, must negotiate 
conflicting epistemological, professional and ethical frameworks when conducting 
sociological research. We present here personal experiences and reflections of moving 
from the positivist disciplines and practices of medicinal chemistry and pharmacy into 
medical sociology. We suggest that such disciplinary mobility involves new epistemological 
engagement with the social world, which presents both opportunities and challenges for 
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those carrying out empirical research. On the one hand, this disciplinary mobility and 
epistemological fluidity offers the opportunity to engage with, and draw upon, a wider 
range of theoretical frameworks and methodological tools in addressing research 
questions. On the other hand, such mobility presents challenges; such as the effective 
bracketing of existing perspectives and developing a high level of trans-literacy. Moreover, 
we argue that such mobility can lead to what we might understand as ‘an identity crisis’ for 
disciplinarily mobile researchers. This identity crisis raises both practical and ethical 
questions. This paper, then, argues for a need for greater reflexivity in research design and 
ethical review to enable researchers to navigate identity management and conflicting 
ethico-legal obligations. To begin with, we offer some background context on the particular 
case we present here.  
Context 
This paper is a reflection on the challenges and tensions experienced by a pharmacist (APR 
– one of the authors) who trained and previously practiced in a predominantly positivist 
paradigm, and is now engaged in sociological qualitative research. Undertaking this 
sociological project necessitated a high degree of disciplinary mobility and led to the 
reflections offered here; firstly, we describe the project briefly.  
The Project 
Medicines adherence pertains to how a patient takes their medicine and if this is in 
accordance with the prescription – though many conflicting definitions exist. Healthcare 
disciplines (i.e. positivist disciplines) have provided answers to questions of patients’ 
medicines adherence but these have tended to be quantitative and so lacking the rich 
detail of qualitative data and have focused on demographic issues (e.g. age, ethnicity, 
gender) rather than taking into account the complex intersections of social life which might 
make people from certain groups less likely to adhere (e.g. women and caring 
roles)(Geertz, 1973). Moreover, despite attempts to provide a generalizable model and a 
definitive way to improve adherence, as is the aim of much of the research, the data to 
emerge from such studies has failed to reach a consensus (Nieuwlaat et al., 2014, Haynes 
et al., 2008). Some qualitative research has demonstrated that a more holistic approach 
that (a) samples a smaller number of patients, (b) looks to obtain rich, deep data and (c) 
locates the adherence question within the everyday lived experiences of patients as their 
lives pertain to factors, such as family life and diagnosis, rather than just their age, 
ethnicity, or gender might be more useful. Whyte et al. (2002) present a good alternative 
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to a positivist consideration of medicines in their work on the social lives of medicines. 
Here medicines are described ‘beyond their material (chemical) properties’ as objects 
which negotiate social meaning through different actors. Describing mothers’ medication 
of children with coughs and colds, the authors state that medicines are used to send social 
messages; to the child that they care for them, to their husbands and neighbours that they 
are not negligent mothers and to themselves that they are good mothers. Insights such as 
this present something of a dichotomy within the ontology of medicines adherence; on the 
one positivist hand, therapeutic chemical entities used to prevent disease and on the other 
constructivist hand, a social tool used to negotiate relationships. Webster et al. (2002) 
expand on this in their discussion of lay pharmacology. Here medicines are understood and 
used through a lay paradigm of understanding in relation to efficacy, side effects and 
safety. This literature supports a qualitative approach to medicines adherence. As a result, 
we are undertaking a phenomenological project using interview and focus group methods 
to elicit data and draw on constructivist frameworks in theorizing patients’ medicines use. 
The wider aim of the project is to inform interventions to facilitate ‘better’ medicines 
adherence – although, again, many definitions of ‘better’ adherence exist.  Although the 
subject of the project (i.e. why patients are not adhering to their medicines regimen) is one 
highly familiar to positivist healthcare practitioners, a constructivist epistemological 
approach is not. As such, as a healthcare practitioner, negotiating an epistemological 
framing for the research - developing a ‘sociological imagination’- was challenging and it is 
this process that we reflect on here.  
Developing a sociological imagination 
In the UK healthcare practitioners are largely educated within the positivist paradigm. 
Whilst medical sociology has been taught to medical and nursing students for a number of 
years, the majority of the curriculum tends to remain rooted in positivist, quantitative 
‘ways of doing’ and natural science (Muller et al., 2014). Moreover, medical sociology has 
been adopted into the pharmacy curriculum to a much lesser extent. This paradigm, which 
underpins subsequent healthcare practice, encourages research that is repeatable, 
objective and positivist. As Timmermans and Berg (2003) show, the hierarchy of research 
and evidence in science and healthcare places a higher value on data which satisfies these 
criteria. Elsewhere, Vickers et al. (1997) have also noted that qualitative case-study 
research based on a small number of participants, which is limited in its generalizability, is 
considered inferior in healthcare. Phenomenological inquiry, and indeed qualitative 
research informed by constructivist approaches more generally, largely lacks the objectivity 
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and repeatability that is valued highly within a positivist framework. As a pharmacist, a 
science-based health profession, moving to a more constructivist discipline and, thus, 
‘changing gear’ to align with the epistemological views of phenomenology was difficult, 
presenting challenges relating to identity management and ethics. 
Educating health professionals within positivist frameworks might limit the extent to which 
they can be ‘disciplinarily mobile’ and limit inter- and cross- disciplinary work.  If pharmacy, 
for example, were to work within a positivist tradition and social sciences to continue to be 
welded to highly critical constructivism, we risk reproducing the disciplinary silos that the 
interdisciplinary agenda works hard to move away from. This is not to say that we should 
work inter-disciplinarily (or engage with diverse epistemologies) just for the sake of it, but 
rather that there needs to be a real effort made to be disciplinarily flexible and mobile to 
address research questions in the most appropriate way.   
Aligning the research subject with an appropriate epistemological paradigm provided an 
excellent way to shift long-held beliefs about qualitative and quantitative research and to 
begin developing a sociological imagination to address the research question. Such 
epistemological flexibility also provides the scope for practitioners to move away from 
healthcare research consistently undertaking large quantitative studies, and to think more 
critically about a wider variety of methodological approaches to particular research 
problems. Whilst healthcare education is teaching health professionals about research 
paradigms, professional practice often cultivates positivist perspectives with many judging 
the quality of research on the number of subjects in the study; the bigger, the better. APR’s 
clinical experience as a pharmacist has been that less concern is put on what research is 
trying to find out but rather research findings and their applicability to patient care. A more 
holistic understanding of a wider variety of research methods and design was needed to 
address the research question of medicines adherence and would be useful for any 
healthcare professional entering research. Reading about the history and development of 
social research was essential, although at times the concepts seemed abstract, 
philosophical and difficult to relate to everyday practice, patients or pills. A key focus, then, 
became disentangling research and research findings from their immediate applicability to 
practice and examining the wider lifeworld in which patients’ and professionals’ beliefs and 
behaviours are formed and performed.    
Although many healthcare professionals’ educational background is peppered with 
psychology and sociology, they rarely stray from a positivist paradigm - although they may 
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wander into the realms of post-positivism on a liberal day. One truth, posited by an object 
and only revealed through the scientific method of experimentation, repetition and 
validation is how most healthcare practitioners are trained to understand the world and is 
ascribed the most value in practice.  The concept that there is more than one theory of 
knowledge can be jarring. Exploring different paradigms in an attempt to understand 
reality, and the way things are (i.e. ontology) is an area that is very rarely discussed or 
considered once healthcare professionals leave education and get into practice. For APR, 
adopting a constructivist lens changed what he understood medicines to be. By accepting a 
framework of multiple-constructed truths, how could he be sure that the evidence 
supporting the supply of medicines was ‘true’? Without being able to rely on the familiar 
confidence intervals and statistics as markers of ‘truth’, supplying and recommending the 
use of potentially lethal pharmaceuticals, suddenly, became a lot more difficult.  
Although healthcare professionals are under increased pressure, in a healthcare landscape 
characterized by increasing managerialism and target-driven working conditions (Hanlon, 
2000), an engagement with different epistemological positions can dramatically alter the 
way research outcomes are understood and applied to practice. Discovering 
constructivism, the theory that meaning and knowledge are built through subjective 
conscious perceptions of objective characteristics, can result in a fundamental shift in 
epistemological and ontological beliefs. Ferguson, when discussing phenomenology, 
describes this shift as ‘not a new way of studying reality but the consciousness of a new 
reality’ (Ferguson, 2006: 25). Taking a constructivist approach, a capsule of paracetamol, 
for example, can be understood as more than its ‘objective’ properties - it’s colour, size, 
shape, and ingredients. Instead, a constructivist approach also includes the subjective 
understandings of what the capsule, and its properties, mean to patients - a remedy, a 
choking hazard, a hassle. Dingwall and Wilson (1995) echo this and discuss the way in 
which the tablet starts as a blank canvas for patients and is inscribed with social meanings 
by practitioners through discourse and interaction – in their case, pharmacists. As a 
pharmacist, ‘inscribing social meaning’ was not something APR had identified as part of his 
everyday work. That the social constructs of an object only exist when they are perceived 
through subjective consciousness and are valuable in understanding what a medicine is, 
presented an alternative approach to evidence-based practice. That these constructs can 
only be accessed through experiences, and so qualitative research, is a far cry from the 
familiar double-blind Randomised Control Trials (RCTs) characterised as the pinnacle of 
evidence-based practice. Acknowledging that systematic reviews are used as the ‘gold 
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standard’ of science and medical knowledge in just one particular paradigm out of many, 
presented itself as something of a eureka moment.   
Epistemological flexibility 
For healthcare professionals, being flexible in the epistemological approach taken in 
research is challenging given that the majority of practice is focused on positivist 
understandings of the social world. Given this, the development of a sociological 
imagination, although difficult, may be ultimately beneficial for other healthcare 
practitioners embarking on sociological research. Based on APR’s experience of such 
epistemological flexibility and disciplinary mobility, we examine ways in which the 
challenges of epistemological flexibility can be addressed by practitioners moving into, or 
looking to incorporate, a more constructivist framework in their research.   
Returning to APR’s own experience of disciplinary mobility, constant reflection and multiple 
modes of learning helped considerably.  In particular, writing down what Wright-Mills calls 
‘fringe thoughts’ helped unfamiliar notions and theoretical frameworks develop substance, 
which then snowballed into understanding; for example understanding the vocabulary of 
epistemology and how the different paradigms are presented. Looking up the definition 
and synonyms of words helped too, as did considering what the polar opposite would be 
for the theories trying to be grasped (Wright-Mills, 1954). Put briefly, phenomenology is 
founded on the process of bracketing off and transcending pre-existing prejudices and 
biases (Moustakas, 1994). Bracketing in phenomenology involves reflecting and removing 
any pre-existing or pre-conceived ideas about a phenomenon; setting aside judgments 
about the natural world to enable the essential structures of a phenomenon to be 
understood (Creswell 2007; Moustakas 1994). Taking a transcendental phenomenological 
approach and practicing ‘bracketing’ were also employed to develop a sociological gaze. 
Bracketing out or identifying preconceived understanding of a phenomenon, and rejecting 
these assumptions, enabled me to be reflexive in the analysis of data.  
Some scholars argue that a true and complete sense of ‘epoché’, that is bracketing off 
previous beliefs and prejudices, cannot be achieved. However the practice may still be 
beneficial by identifying biases and ‘opening up’ to the idea of a different paradigm of 
knowledge. Discourse analysts and linguists may argue that one can never truly transcend 
all previous knowledge and prejudices about a given subject, if the same language is used 
to describe it (Moustakas, 1994). An example of this from the perspective of a clinician 
might be the word ‘intention’. As a pharmacist the word intention might mean a ‘plan’, 
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perhaps pertaining to a patient’s plan for discharge from hospital or pharmaceutical care 
but in the context of phenomenological research, intentionality refers to a fundamental 
process of experience. Intentionality is a corner stone of phenomenological research and 
refers to the ‘focus of attention’, describing the process where a consciousness intends 
towards an object (Crotty, 1998). Subjective processes of conscious perception (that is 
knowing, judging, remembering, desiring) are intended towards the objective 
characteristics of the object (that is its size, shape, colour). The resultant consciousness or 
experience is constructed from two sources; the subjective perception and the objective 
characteristics. Relating this back to the perspective of a positivist clinician, a single word 
can have very different meanings when it is employed in different epistemological 
frameworks. Being ‘open’ to a new paradigm of knowledge involved a degree of 
epistemological, and personal, ambiguity as the supposed certainty and superiority of RCTs 
and evidence-based medicine, which had characterised APR’s education and practice up to 
that point, was sacrificed (or at least critiqued) in favour of constructivist framings.  As 
Voltaire is often quoted, ’doubt is not a pleasant condition’ (Buckingham et al., 2011: 146); 
and certainly transferring and doubting accepted frameworks of knowledge from clinical 
practice into social science research was further complicated through the negotiation of 
multiple identities.  
Identity management in research 
The gear change from a positivist way of understanding medicines adherence to a 
constructivist approach necessitated a critical examination of the researcher’s own role 
within the project and its findings. If research is approached from a positivist perspective, 
researchers would be looking to gather objective findings, control for biases and remove 
themselves as much as possible from the research encounter to elicit an objective ‘truth’. 
However, in developing a constructivist approach to the question, researchers must 
acknowledge that they will always influence the research, as they are part of the social 
world that they are researching. For APR this was difficult to accept as he had always 
practiced, like many clinicians, in an environment where care must be standardised, 
objective, and fair. Being disciplinarily mobile and moving into the social sciences from a 
heavily positivist background, we began to critically reflect on the role of the clinician in 
research. 
This reflection on the clinicians’ role in the research process is primarily centred on 
researcher identity and, in particular, the tensions between the two disciplines, and 
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subsequent identities, which are straddled by those undertaking social science research as 
practicing healthcare professionals. The social reality we inhabit is dynamic; discourse 
changes between our friends, our colleagues, our family and our healthcare professionals, 
as Goffman and others have described in their work on role theory (Berger, 1963). 
Familiarity with this phenomenon was established through comparison with a similar 
phenomenon seen in clinical encounters, often referred to as ‘white coat syndrome’. This 
phenomenon describes the effect that a healthcare practitioner’s perceived status can 
have on interaction and, indeed, the patient’s physiological state in reality.  The white coat 
phenomenon arguably stems from the disjointed interaction between patient and 
practitioner, arising from unequal power and expertise distribution (Dingwall and and 
Pilnick, 2011). This unequal power dynamic can mirror that between participant and 
researcher. Within research, clinicians’ identity as registered and practicing healthcare 
professionals is a key issue, in that data collection and rapport with participants may 
change fundamentally if participants are aware of the clinicians’ professional role. Just as 
the identity of the clinician influences what a patient says and how they behave in clinic, 
participants can also be influenced by the researcher and adapt behaviours to meet the 
perceived expectations of the researcher. It is well documented that characteristics of the 
researcher may influence the research encounter (Savvakis and Tzanakis, 2004). A positivist 
position would attempt to limit this influence to ensure objectivity and validity and this was 
certainly APR’s initial inclination during the research design process. However, the 
constructivist position is to accept this influence as a rich source of data and manage it 
openly (Ansdell and Pavlicevic, 2001). To refer back to our current study investigating 
patients’ lived experiences of taking medicines as they are prescribed, the role of the 
researcher is critical in ensuring that the data captured is a representation of the everyday 
lived experiences of participants, rather than participants’ attempts to satisfy the model of 
a ‘good patient’ to a pharmacist.  
If participants are made aware that a social researcher is also a practicing healthcare 
practitioner (in this case a clinical pharmacist), there is a risk of a particular kind of front-
stage performance (Goffman, 1959) in which participants take on the role of ‘compliant’ 
patients (Richards and Emslie, 2000). In doing so, the interaction itself may be renegotiated 
to become less of a research encounter and more of a clinical intervention. This presents a 
challenge in a wider context for researchers who are also practitioners, in deciding on their 
own presentation of self, their role within the research encounter and the social 
expectations and ethical demands of that role.  
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Presentations of the self 
This paper now turns to discuss the practical and ethical implications of presenting the self 
as clinical and non-clinical, briefly describing the ethical conflict generated from dual-
identities engendered through regulatory organisations and professional bodies that 
represent clinicians and researchers.  
Goffman’s seminal work on the presentation of the self in everyday life clearly provides a 
key theoretical point of departure (Goffman, 1959). He described the phenomenon 
whereby as humans our identities are fluid, contextual and dynamic. Presentations of the 
self include how we dress, how we speak, and our facial expressions, to name but a few, 
and represent the negotiations of expressions that we give (intentionally) and that we give 
off (unintentionally). Our expressions are in turn internalised by those around us, who, 
based on their previous exposures and assumptions, construct an impression of us. The 
impression, Goffman argued, is a manifestation of our perceived identities, on which, 
others can expect or elicit specific stereotypical behaviours or roles.  
Richards and Emslie (2000) describe this in interview interactions. They compared what 
similar cohorts of participants said in interviews with a GP (Richards) and a sociologist 
(Emslie), noting that the identity of ‘GP’ overshadows the personal characteristics of the 
interviewer, suggesting that “who respondents think you are affects what you get told” 
(Richards, 2000: 75). Perceived identities and impressions then, inform the behaviours of 
those around us, dependent on their preconceived expectations of the identities we have 
expressed. The expressions that we give then, represent the identities that we wish to 
project to those around us. This could be wearing a stethoscope and white coat to express 
clinical professionalism. The expressions that we give off may be our body language or tone 
of voice, which might, equally, express clinical professionalism and feed into the 
expressions we give off unintentionally to those around us.  In turn, those around us would 
identify us as clinical professionals and may alter the expressions they give to elicit 
responses and behaviours that they associate with the identity of a clinical professional 
(Goffman, 1959). As a pharmacist, this meant consideration of the expressions that APR 
gives or gives off and meant being aware of how he reacted or did not react to participants’ 
disclosures about medicines use or misuse during interviews.   
Presenting the self as a pharmacist-researcher 
Presenting the self as a pharmacist has the potential to remove the distance from the 
participants’ usual healthcare structures that a non-clinical researcher might have. In 
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presenting the self as a practitioner, participants may locate the researcher as an actor 
within ‘the system’. Although many patient advocate groups increasingly focus on 
addressing the imbalance of power, knowledge and resulting communication barrier 
between healthcare professionals and patients, Dingwall and Pilnick (2011) have recently 
suggested that this imbalance of power persists. When researchers, then, present 
themselves as practitioners, there is a risk that this imbalance would translate to research 
encounters outside of the clinical space. This would change the context of the data 
collection process, potentially engendering more of a paternalistic relationship in which 
patients may feel accountable to the researchers as a representative of the healthcare 
system. Effectively this would negate the advantage of qualitative research as conducted 
by a social scientist that is not part of the healthcare system. If the researcher sits inside of 
the usual healthcare structures and professions, participants may more carefully manage 
their own identity to present themselves as a ‘good patient’. Similarly, the context of the 
interaction may shift from research to clinical intervention. 
Presenting the self as a practitioner also carries risks of inadvertently altering participants’ 
behaviour after the research encounter. In this case, participants may feel the need to 
change the way they take their medication after the research as a result of their medicines 
use behaviours becoming problematised because they are the topic of study. In other 
words, because participants have been asked by a practitioner to discuss their medicines 
use, this may indicate to participants that there is something wrong, or at least worth 
studying, about their medicines use which may lead them to altering their behaviours. The 
risk that participants will change their medicine-taking behaviour due to influence from the 
research is potentially reduced if participants are unaware the researcher has a clinical 
background. There is an additional challenge for clinical researchers in maintaining this 
neutral presentation of self, which is not to slip into their role as a clinician and start to 
proffer healthcare intervention or advice. For a pharmacist, this may manifest itself as 
recognising prescription medicine misuse and giving the participant advice about how to 
use their prescription medicine.   If participants are to be unaware the researcher has a 
clinical background, researchers should ensure their body language, facial expressions and 
tone-of-voice are consistently neutral in response to what the patient discloses in line with 
their given off non-clinical identity. 
Palmeieri and Stern (2009) discuss the role of honesty in the professional-patient 
relationship, citing themes of shame and protection as justification for accepted untruths in 
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the clinical setting. A clear demonstration of presentation of self in everyday life occurs 
when patients present themselves by saying something that is not necessarily true to 
obtain services or medication or in this case, tell a pharmacist what they want to hear 
(Palmieri and Stern, 2009). Identifying the researcher as a part of the healthcare structure 
has implications on the nature of the data that is collected, arguably making it more about 
what participants thinks the researcher wants to hear, and patient-professional interaction.   
Presenting the self as a researcher only 
On the other hand, presenting the self as a non-clinical researcher, having distance 
between the researcher and the researched, could be justified as being important to 
optimise data collection and minimize researchers influencing participants’ usual 
healthcare or service use. Presenting the self as a researcher-only has negative 
consequences in that clinicians lose their healthcare expert status and right to offer the 
participant advice about their medication. This initially does not seem like a significant loss, 
after all, the clinician is only ‘giving up’ this status during study encounters. Indeed 
considering methodological frameworks, philosophies and the actual method of conducting 
an interview, the Vancouver School of Doing Phenomenology stressed the importance of 
‘not losing awareness of context and self as a researcher’ (Halldorsdottir, 2000). In this the 
school is advocating a demarcated awareness of the self as a researcher and the self as a 
clinician. The ‘suppression’ of the clinical identity, however, presents a conflict if a 
participant discloses a particular issue during a study encounter that the expert status of a 
clinician could help resolve. For example if a participant disclosed that they were taking two 
medicines which carry a high risk of drug-drug interaction and negative effects, as a 
clinician and pharmacist, it would be socially acceptable and appropriate to recommend 
withholding one of the medicines to avoid patient harm. In an encounter where the self is 
presented as a non-clinical researcher, would it be socially appropriate to alter the patient’s 
pharmaceutical regimen? A researcher who is not also a clinician would not be expected, or 
might not have the necessary expertise, to offer prescription advice. Could clinicians 
presenting themselves as non-clinical researchers potentially be giving up an ability to 
reduce harm? In a situation when a patient discloses a danger to themselves through an 
inappropriate use of medicines, pharmacist or clinician status could be useful in preventing 
harm to the patient in a way which social researcher status may not. As well as being a 
practical and methodological dilemma, this also presents an ethical issue. 
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A question of ethics 
Whilst Richards and Emslie (2000) show the presentation of self can impact data collection, 
ethical tensions can also prove problematic. In the context of a pharmacist conducting 
social science research, there are two sets of, often competing, ethical considerations to be 
followed simultaneously. On the one hand, the customary social science standards 
formalised in the British Sociological Association’s Ethics Standards and on the other hand, 
the General Pharmaceutical Council Ethical Standards set out by the pharmacy regulatory 
body.  
Clinicians conducting research will have expertise of, what they see as, poor healthcare 
behaviours and participants may disclose these during the research encounter. As a 
clinician there is an expectation that we will intervene to improve the participant’s health 
behaviours, in the interest of the patient’s wider healthcare outcome. This is mandated in 
the ethical standards of the regulatory body with the General Pharmaceutical Council 
(GPhC) Ethical Standard 1.7, stating that pharmacists should ‘be satisfied that patients or 
their carers know how to use their medicines’. This obligation to intervene in medicines 
misuse directly contradicts the norms of social research in which focuses on understanding 
every day and normal behaviours even when those might be considered deviant or 
‘incorrect’.   
Registered pharmacists are therefore statutorily obliged to work with patients until they 
are clinically satisfied that the patient knows how to use their medicine correctly. Such 
intervention, however, would shift the nature of the encounter from research to clinical 
involvement, from elicitation to intervention. The British Sociological Association’s Ethical 
Statement 25 speaks of caution of participants forgetting they are being studied in relation 
to consent. If the interview is re-negotiated into a clinical intervention, rather than 
elicitation, we risk the patient forgetting they are being studied and breaching sociological 
ethical standards. Additional ethical frameworks and opinions, such as the professional 
pharmacy body the Royal Pharmaceutical Society, the NHS Research Ethics Committee and 
institutional level ethics committees, might add further contention.  
Avoiding contention in ethics committee negotiations  
Operating within these conflicting ethical and professional frameworks presented several 
problems – delaying the institutional ethics approval process. This is reminiscent of the NHS 
ethics process, and indeed ethics process in the US and Canada, in which social researchers 
are forced to fit the square peg of constructivist, qualitative research into the round hole of 
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positivist, quantitative clinical research (van Teijlingen, 2006, Murphy and and Dingwall, 
2007, Dingwall, 2008). Members of the ethics committee focused on APR’s obligations to 
influence medicines use if he became aware of a medicines use issue. Disclosure of 
medicines use issues to pharmacists carries social, as well as professional and legal, 
expectations that medicines use issues would be resolved or referred to a general 
practitioner (GP). In clinical pharmacy practice, the relationship between the ‘expert’ 
pharmacist and their patient allows for medicines issues to be resolved directly through 
expert-novice advice-giving however in a research setting, a social or qualitative researcher 
may not have the necessary expertise to identify problems with prescribing or the 
necessary expert-novice power imbalance to give advice or to refer to a relevant authority. 
The social expectation there, then, is directed away from influencing the participant’s usual 
healthcare and directed towards limiting the influence the research has on the participants’ 
usual healthcare. However when the researcher has registrant status, healthcare expertise 
and professional obligations, researchers and members of the ethics committee must be 
able to negotiate a truce between identifying potentially risky behaviour patterns, which 
regulatory bodies would usually expect clinicians to directly address, and not influencing 
the participant’s usual healthcare as per conventional sociological research. 
Final thoughts 
On reflection, many of the issues presented can be considered through positivist and 
constructivist perspectives. In a positivist gaze, a clinician will always be a clinician 
regardless of their environmental context or presented self and so would always have their 
regulatory and ethical responsibilities as a clinician. In a constructivist paradigm however, 
the clinician’s identity is relative to the role within the encounter and the self that they 
present (Goffman, 1959). In a research encounter their identity, responsibility and 
expectations would then be as a non-clinical social science researcher, and this could be 
argued to negate any medico-legal obligations. There are clear epistemic, methodological 
and ethical tensions between the identities of researcher and clinician when attempting to 
conduct qualitative, social science research.  
As highlighted by Banton (2005), social research is influenced by the researcher’s personal 
traits and characteristics; with objectivity in the social sciences only achieved through 
interaction with other researchers. As Finlay (2002) suggests, clinical researchers could be 
encouraged ‘to tell ‘confessional tales’ about dilemmas and decision-making in the 
research process’. Interacting with other researchers can be reflective in nature; drawing 
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on the experiences of different researchers. Consequently there could be a call for 
clinicians conducting qualitative research, to reflect and develop a discourse to use in the 
field, which incorporates both their identity as a clinician and their desire for brutally 
honest data.  Equally a Bourdieuian analysis of inequality in cultural, or disciplinary, capital 
may be needed to address tensions between clinicians and social scientists, to deliver 
insights into this issue.     
A functionalist analysis of ethical committees, institutions and frameworks may reveal that 
although manifestly these mechanism aim to deliver safe and ethical research, latently they 
produce a sub-culture of clinical researchers who merely ‘jump through the hoops’ of 
bureaucracy without thinking ethically about their research. Regulatory bodies, such as the 
General Pharmaceutical Council and professional bodies such as the British Sociological 
Association, are in a position to open a dialogue to negotiate ethical practices of pharmacy 
registrants conducting sociological, qualitative research. The same is also true of other 
practitioners undertaking social science research who are potentially subject to similar 
epistemological and ethical dilemmas. Open dialogue between regulatory and professional 
bodies and, indeed, between researchers themselves might refocus the continued debate 
around research ethics in qualitative healthcare research. 
Conclusion 
In conclusion, the identity of many clinicians will be first and foremost as a clinician, but the 
process of ethics approval, reflection, and review can lead to a realisation that first and 
foremost, we are just human beings. Developing a sociological gaze, moving away from the 
quantitative objectivity of a natural science-based health profession such as pharmacy into 
the realms of largely qualitative social research can be, and has been, a difficult transition 
and by no means can it be completed easily – if it ever can be completed. Our position, for 
the time being at least, is that clinicians are just as capable to give sociology a voice as 
anyone, if they can negotiate their position within the research encounter successfully.   
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